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WE ARE NOW in the third decade of the HIV/AIDS epidemic and although HIV prevention efforts have grown substantially over time and we have made 
important progress, major unmet needs remain.  HIV continues to pose a significant 
threat to Americans’ health and well-being, with African Americans and men who have 
sex with men (MSM) of all races most severely affected.  While African Americans 
account for 3 percent of the population, they account for nearly half of HIV diagnoses 
in 2005 (49% in 33 states with longstanding confidential name-based reporting) and 
nearly half of the people estimated to be living with HIV (47%).   MSM also account for 
half of new HIV diagnoses in 2005 (49% in the 33 states with confidential name-based 
reporting) and nearly half of people estimated to be living with HIV (45%).
 Reducing the toll of HIV among these groups requires a collaborative and 
intensive effort by government, partners, and the private and public sectors.  The 
Centers for Disease Control and Prevention (CDC) is intensifying its own efforts 
to address the epidemic among African Americans and MSM.  Targeted initiatives 
are underway, new HIV testing recommendations have been published, and new 
partnerships with community leaders have been established. CDC will continue to 
direct the majority of its resources to strategies, programs, and research for groups 
disproportionately affected by the epidemic and is working to expand the use of proven 
interventions and develop new approaches for reaching these populations.   
 There is no simple solution for eliminating HIV in the U.S.   A complex set of 
historical, structural, environmental, and cultural factors – including racism,  
discrimination, poverty, denial, stigma, homophobia, and limited access to health 
care present significant challenges and further complicate efforts to comprehensively 
address the HIV/AIDS epidemic among disproportionately affected populations such as 
MSM and communities of color.  Addressing these factors can have an important impact 
on the HIV epidemic.
	 CDC’s	HIV	Prevention	Strategic	Plan	Through	2005	(2001	Plan)	has served as 
a valuable guide for CDC action.  CDC has used the 2001	Plan to identify needs for 
new and expanded prevention programs and initiatives, establish priorities, and direct 
and target resources.  Importantly, the 2001	Plan established a vision not only for CDC, 
but for the nation as a whole.  It set forth an overarching public health goal of cutting 
new HIV infections in half—providing a vision of what could be accomplished with 






the full implementation of the activities outlined.  While the 2001	Plan was never fully 
implemented and progress did not accelerate at the desired rate through 005, CDC 
remains committed to the aspirational goal of major reductions in HIV infection.  CDC 
will therefore work with a range of partners to update the 2001	Plan and its overarching 
goals and develop a new long-range plan to guide the nation through 00.
 In the interim, CDC has developed the HIV	Prevention	Strategic	Plan:		
Extended	Through	2010	(Extended	Plan) to guide the agency’s efforts for the next 
3 years and to define a realistic, short-term goal at a time when challenges have 
increased and resources for prevention are not commensurate with prevention needs.  
Since 00, HIV diagnoses and risk behaviors have increased among MSM; syphilis 
rates have increased nationally; and more people are living with HIV than ever before 
– many of whom are unaware of their infection – which increases the potential for  
continued HIV transmission.  While prevention needs have actually  increased, 
treatment advances have unfortunately contributed to a sense of complacency about 
the seriousness of HIV/AIDS.  An extended strategic plan to address these challenges 
is essential.  The short-term goal and milestones in this Extended	Plan were endorsed 
by the CDC /HRSA Advisory Committee on HIV and STD Prevention and Treatment 
(CHAC).  
 This Extended	Plan maintains the focus on core prevention priorities expressed 
in the 2001	Plan: reducing the number of new infections, increasing knowledge of HIV 
status, and promoting linkages to care, treatment, and prevention services.  In addition, 
new objectives have been added to make urgent priorities more explicit, including: 
preventing new HIV infections among MSM and African Americans; addressing stigma 
and discrimination; promoting the use of rapid HIV tests; addressing the role of acute 
infection in HIV transmission; and increasing routine HIV testing in medical settings.
 CDC is dedicated to helping people live longer, healthier lives by preventing new 
HIV infections and protecting the health of those already infected.  While continuing to 
challenge us as a nation, CDC believes the short-term goal and milestones outlined in 
this Extended	Plan can be achieved through the implementation of refined and targeted 
approaches.   
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Centers for Disease Control and Prevention  
HIV Prevention Strategic Plan: 
Extended Through 2010
Introduction
This plan extends the HIV	Prevention	Strategic	Plan	Through	2005	(2001	Plan) published by the Centers for Disease Control and Prevention (CDC) in January 
00.  The short-term goal, milestones, and accompanying objectives are based on 
general and specific recommendations from the CDC and HRSA Advisory Committee 
on HIV and STD Prevention and Treatment (CHAC), formerly known as the Advisory 
Committee for HIV and STD Prevention.  The HIV	Prevention	Strategic	Plan:	Extended	
Through	2010	(	Extended	Plan), which will serve as CDC’s strategic guide for HIV 
prevention through 00, includes a short-term goal of reducing new HIV infections 
by 5 percent per year or at least 0 percent by the end of 00.  To achieve this goal, 
the Extended	Plan	includes an expanded set of objectives and performance indicators 
that make priorities more explicit and ensure that key issues are effectively addressed.  
Twelve new objectives have been added, 20 existing objectives have been modified, 
and one objective was deleted (4 objectives total, compared to 7 in the 2001	Plan).  
The Extended	Plan also incorporates 7 additional performance indicators (5 total, 
compared to  previously).
Background of the CDC HIV Prevention Strategic Plan, 
2001-2005
The development of the original five-year strategic plan involved more than 100 experts from inside and outside the government: experts in behavioral science, 
medicine, and the other disciplines required to address the HIV epidemic, including 
community-based HIV prevention providers, state and local health departments, 
members of infected and affected communities.  These experts examined a situation 
analysis of the current epidemic, as well as a response analysis of CDC’s current 
activities.  They then divided into workgroups to develop prioritized objectives and 
strategies to address each of the goals.  The goals included rank-ordered objectives 
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and strategies.  The process for developing the 2001	Plan covered a two-year period 
that began in CDC in November 1998.  The first meeting with the external participants 
was held in February 000.  Between February and April 000, the workgroups held 
five face-to-face meetings and had 16 telephone conference calls to develop and 
refine their goals and to establish objectives and strategies to achieve the goals.  In 
April 000, CDC held meetings with each workgroup to evaluate their draft work plans.  
Gaps, omissions, overlaps, and ambiguities were identified and discussed.  In June 
000, the draft strategic plan was presented to the Advisory Committee for HIV and 
STD Prevention (ACHSP).  The plan was revised based on comments received from 
the ACHSP, external partners, and internal CDC review.  In December 000, the revised 
plan received endorsement from the ACHSP and was published in January 00.  The 
2001	Plan established a vision for the nation regarding what could be accomplished 
with a significantly expanded investment in HIV prevention.  
CDC Activities to Implement the 2001-2005 HIV 
Prevention Strategic Plan
While the 2001	Plan was never fully implemented and HIV prevention resources in the United States declined slightly through 005, the 2001	Plan has been a 
valuable tool for directing efforts at CDC.  Each fiscal year, the Division of HIV/AIDS 
Prevention (DHAP) in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention holds a retreat to review and discuss the plan’s goals and objectives.  DHAP 
agrees on ten priority objectives that guide funding for new projects with a particular 
focus on populations and risk groups disproportionately affected by HIV/AIDS.  
 Although progress has not accelerated at the desired rate, there has been 
significant progress and movement in HIV prevention and hope for the future.  Many 
people – both infected and uninfected – are being reached by prevention programs and 
engaging in safer behaviors:
• One of the most obvious achievements in HIV prevention is the dramatic decline 
in mother-to-child HIV transmission.  While there were ,650 documented cases of 
mother-to-child transmission in 99, today there are estimated to be fewer than 50 
cases each year.  
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• There have been declines in risk behavior among youth.  From 99-005, the 
proportion of youth who reported engaging in sexual intercourse decreased from 
54 percent to 47 percent.  During the same time period, the proportion of youth who 
reported using condoms increased from 46 percent to 63 percent.  
• In September 006, CDC published “Revised	Recommendations	for	HIV	Testing	
of		Adults,	Adolescents	and	Pregnant	Women	in	Health-Care	Settings” to make 
voluntary HIV testing a routine part of medical care for Americans aged 3-64.  These 
Revised	Recommendations	are a major step forward in reducing HIV acquisition and 
transmission and allowing people to know their HIV status.  
• Rapid HIV testing technology, combined with innovative approaches, is showing 
promising results.  Several rapid testing demonstration projects funded by CDC as 
part of the 003 initiative, “Advancing HIV Prevention: New Strategies for a Changing 
Epidemic,” report increased numbers of tests and increased proportions of persons 
receiving their test results, and a high percentage of persons knowing their HIV 
infection.  This is a sign of significant progress in increasing Americans’ knowledge of 
their HIV status.    
• There has been a strong commitment among men who have sex with men (MSM) to 
address threats to HIV prevention, such as methamphetamine use.  
• Studies repeatedly show that the majority of HIV-infected persons take steps to 
protect partners and prevent HIV transmission, once they know they are infected.  
       In addition, the focus on eliminating racial and ethnic disparities in new HIV 
infection rates has led CDC to better target prevention approaches.  For example, 
through the Minority AIDS Initiative (MAI) CDC has continued to directly fund minority- 
serving community-based organizations (CBOs) for HIV prevention in communities of 
color.  MAI funding has greatly enhanced CDC’s ability to provide resources directly to 
CBOs located in and serving minority communities, and has enhanced CDC’s ability to 
provide a range of services to disproportionately affected racial and ethnic communities. 
   CDC also realigned prevention programs that focus on persons at highest risk for 
transmitting HIV; conducted applied research to identify and evaluate evidence-based 
prevention interventions that have been shown to reduce risk behaviors; supported 
dissemination of effective interventions; implemented population-based behavioral 
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surveillance and an HIV incidence surveillance system to supplement HIV/AIDS case 
surveillance; established strong linkages for prevention and quality medical care 
services; promoted rapid HIV testing in both clinical and non-clinical settings; and 
launched new efforts to enhance prevention services for persons living with HIV and 
to develop new strategies to diagnose HIV infection.  Most recently, CDC directed $45 
million of 007 agency funds to expand access to HIV testing among disproportionately 
affected populations, particularly African-Americans.
CHAC Strategic Plan Workgroup 
 
At its May 005 meeting, the CHAC asked CDC to identify the reasons for not achieving the overarching goal of the 2001	Plan (reduce new HIV infections in 
the United States by 50% by 2005).  While several factors were identified, the primary 
reason cited was the lack of expanded funding on a national level to fully implement the 
activities outlined in the 2001	Plan.  The resources required to implement the 2001	Plan 
were estimated at the time of publication to be an additional $300 million annually. 
 At the same meeting, the CHAC also expressed a strong interest in updating the 
2001	Plan, unanimously passed a motion to form a CHAC Strategic Plan Workgroup to 
facilitate updating the 2001	Plan, and unanimously passed a motion to extend the plan 
through 008 (and later extended it through 00).  
 The CHAC focused its review on the four domestic goals of the original 2001	
Plan.  Goal 5, “Assisting in reducing HIV transmission and improving HIV/AIDS care 
and support in partnership with resource-constrained countries” was not included since 
the President launched the President’s Emergency Plan for AIDS Relief (PEPFAR).   
There is a separate set of PEPFAR goals and measures and CDC is assisting the U.S. 
government in achieving PEPFAR goals.       
 The CHAC Strategic Plan Workgroup was comprised of 30 individuals 
from health departments, universities, affected communities, advocates, partner 
organizations, and members of the CHAC (Appendix ).  The Workgroup was tasked 
with the following responsibilities:
) Provide advice to CDC on ways to update the 2001	Plan to guide the agency and 
its federal partners in formulating new strategies, activities, and directions to reduce 
HIV infection in the United States.
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) Develop recommendations for HIV prevention programs, surveillance, and research 
that can reduce HIV incidence based on current resources and the best available 
science.
3) Review the 2001	Plan to identify limitations or flaws in previous HIV prevention 
activities, missed opportunities in establishing priorities, and actions to advance the 
plan in the future.  
4) Determine whether the overarching goal to reduce new HIV infections in the United 
States by 50% is feasible and realistic, based on available resources.
 The Workgroup held two meetings: October 4-5, 005 and May 4-5, 006.  
Additional communications occurred through conference calls, emails, and intermittent 
mailings.  The Workgroup also received in-depth information about CDC’s current 
activities related to the domestic goals and objectives of the 2001	Plan and data on the 
 performance indicators, as well as samples of relevant articles and reports on HIV 
prevention activities for review and consideration (Appendix ).
 Updating the 2001	Plan was a two-year process and incorporated input from 
a diverse set of stakeholders.  In July 006, the CHAC issued a draft report of the 
Workgroup activities and recommendations to CDC (Appendix 3).
 At its November 006 meeting, the CHAC reviewed and discussed preliminary 
findings and recommendations of the CHAC Strategic Plan Workgroup.  Further, the 
CHAC recommended that the 2001	Plan be extended for five years to 2010 (Appendix 
4) and suggested that CDC develop accountable, realistic, reasonable, attainable, and 
measurable indicators to monitor progress of the Strategic Plan. 
 At its May 007 meeting in Atlanta, Georgia, the CHAC recommended that the 
plan begin in 007 and end in 00.  The CHAC also made other recommendations that 
are reflected in this document.  
CDC Response to CHAC Recommendations and  
Major Considerations of the Plan




CDC identified a short-term goal through 2010 and chose to call the four original domestic goals short-term milestones in this Extended	Plan.  CDC modified 
short-term milestones -3 and extended all four milestones to 00.  The Workgroup 
recommended deleting the original Goal 4, “By 005, strengthen the capacity 
nationwide to monitor the epidemic, develop and implement effective HIV prevention 
interventions and evaluate prevention programs.”  CDC, however, retained that goal 
(as short-term milestone 4) because the ability to measure progress toward the overall 
short-term goal and other milestones articulated in the Extended	Plan rely on the 
ongoing capacity to perform surveillance and evaluation activities.  
 To revise the milestones, CDC reviewed and analyzed information from several 
resources including: trends in HIV diagnoses, behavioral surveillance data; data on 
risk behavior among people living with HIV; proportion of people at risk for HIV; reach 
of HIV prevention interventions; and implementation of the “Revised HIV Testing 
Recommendations for Adults, Adolescents, and Pregnant Women in Health-Care 
Settings.”  
 Of the 34 new objectives recommended by the Workgroup, CDC incorporated 
more than half (12 new objectives and 13 modified objectives).  CDC did not incorporate 
the others as they were duplicative or were not within the mission of CDC.  
 Specifically, CDC added new objectives and modified existing objectives as 
follows:
•  Made more explicit the focus on African-American and MSM communities.
•  Added new objectives that 
o address advances in understanding about the importance of acute HIV infection, 
the role of incarceration in the HIV epidemic, and technical advances in HIV rapid 
testing.
o underscore the priority to increase HIV screening in medical care settings.




The Workgroup also cited lack of support for the 2001	Plan from some partner groups, and made an overarching recommendation that there be increased 
partnering with the medical community and the private sector.  
 Partnerships have always played a key role in progress toward HIV prevention 
in the United States, and both traditional and expanded partnerships will be essential 
to efforts to accelerate progress.  CDC began building public/private partnerships 
with multiple sectors in the late 980s, including efforts to engage leaders from the 
business and faith community, civic and social organizations, media and entertainment, 
philanthropy, and labor in the collective fight against HIV.  These programs have evolved 
and been built to address emerging challenges over time, with a particular emphasis on 
ensuring reach and impact among minority populations disproportionately impacted by 
HIV.   
 In recent years, CDC has had a particular focus on expanding partnerships 
necessary to implement recommendations for routine HIV testing in health-care settings 
and to accelerate progress in reducing new infections among African Americans.  The 
success of these efforts requires deepening and expanding relationships with the 
traditional medical community and with African-American leaders from all sectors of 
society.
 Since the release of the Revised HIV Testing Recommendations in 006, CDC 
has engaged in an intensive effort to assist stakeholders in preparing to implement HIV 
screening in health-care settings.  CDC has engaged community partners, grantees, 
other federal agencies, the private sector, and state and local health departments in this 
process.  Several examples include working with the Health Resources and Services 
Administration (HRSA), the National Association of Community Health Centers, the 
American Hospital Association, and a wide range of professional medical associations 
to increase the number of clinical sites that offer HIV testing as part of routine medical 
care and to develop referral and linkage procedures for HIV-infected and high-risk 
uninfected persons to additional prevention and treatment services.  CDC also is 
collaborating with the Substance Abuse and Mental Health Services Administration 
(SAMHSA) on implementation plans for HIV screening in substance abuse treatment 
programs.  

 To accelerate prevention progress in reducing infections among African 
Americans, CDC is working to both build upon existing partnerships and programs 
and make new connections with African-American leaders who have the power and 
influence to expand the reach of HIV prevention to more at-risk African Americans.   
Additionally, CDC and state and local health departments are expanding efforts 
to partner with African-American small businesses in multiple cities to reach their 
communities with HIV prevention information and links to testing services.  To further 
engage new partners in the fight against HIV and AIDS, CDC held a meeting in March 
007 to bring together a range of African-American leaders from all walks of life to 
discuss additional actions that entertainers, civic leaders, business leaders, and the  
faith community can take to intensify HIV prevention efforts for African Americans.  
Building upon these efforts will continue to be a key CDC priority to implement this 
Expanded	Plan.
Recommendations	Regarding	Stigma	and	Discrimination
The Workgroup also recommended adding a goal focused on stigma and discrimination.  CDC recognizes that interventions to reduce stigma and 
discrimination are important and need to be addressed.   While CDC did not 
include a specific goal on these issues, the Extended	Plan addresses stigma and 
discrimination in several objectives.  Given the difficulty of measuring the impact of 
stigma and discrimination on HIV transmission, CDC will also continue to investigate 
effective models for discerning behavior change associated with reducing stigma and 
discrimination.  
 CDC is also addressing stigma and discrimination through the Revised 
Recommendations for HIV Testing, which call for HIV screening in health-care settings 
for all persons aged 3-64.  By making HIV testing a routine part of medical care for 
everyone – rather than targeting certain individuals based on perceived risk behavior 
– these recommendations help to further reduce stigma and discrimination.  Research 
shows that more patients accept HIV testing when it is offered routinely to everyone.  
 Additionally, the accelerated community mobilization begun in March 007 
as part of the Heightened National Response to the HIV/AIDS Crisis among African 
Americans will work to reduce stigma by encouraging an open dialogue about HIV/AIDS 
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in places where African Americans live, work, play, and worship.  Connecting HIV/AIDS 
prevention to broader efforts to reduce stigma, discrimination, racism, homophobia, 
joblessness, sexual violence, homelessness, and substance abuse can play a key 
role in reducing the impact of HIV/AIDS among African Americans.  Together with its 
partners, CDC hopes to change the community perceptions that inhibit those at risk 
from seeking early HIV diagnosis and treatment and adopting healthy behaviors that 
prevent the spread of HIV. 
Looking Ahead:  The Future of HIV Prevention 
Strategic Planning at CDC
While advances in HIV treatment have greatly improved the lives of HIV-infected people, HIV remains a serious and fatal disease.  In 005, over 6,000 
Americans with AIDS died.  As a nation, we must continue to invest in prevention.  As 
with many other diseases, Americans tend to focus more on treating than preventing 
HIV.  For example, in FY 006, only 5 percent of the domestic HIV/AIDS budget went to 
prevention, including prevention research and programs.  While treatment and care for 
those already infected remains critical, we must intensify our collective efforts to prevent 
people from becoming infected in the first place.  The scale of our response must be 
commensurate with the challenges.  
 CDC remains committed to a strong prevention response.  However, government 
support alone will not be sufficient.  The support of the public and private sectors, as 
well as community organizations, is essential.  
 The CDC	HIV	Prevention	Strategic	Plan:	Extended	Through	2010	consists 
of a carefully considered set of short-term milestones and objectives for the nation’s 
prevention priorities that will guide CDC’s efforts for the next 3 years.  CDC does not 
anticipate a significant expansion of HIV prevention funding during that time.  This 
Extended	Plan remains rooted in the best available science and builds on important 
progress already made in recent years.  The plan refines objectives to ensure a focus 
on populations now at greatest risk and application of new technology and the latest 
science.  We believe the short-term milestones can be achieved through refined, 
targeted approaches.  These milestones challenge us to accelerate progress with 
available resources.  
4
 CDC will begin an in-depth, comprehensive, and inclusive process to develop 
a new long-range strategic plan.  That plan, when completed, will provide a blueprint 
for HIV prevention activities through 00 that is aligned with CDC’s Health Protection 
Goals and integrated with other infectious diseases such as viral hepatitis, STD, and 
TB.  As with the development of the original HIV Prevention Strategic Plan goals 
(00-005), the plan will be based on input from many sectors, including advocates 
from affected and at-risk communities, public health officials, academics, health-
care providers, and others.  CDC plans to identify the most important outcomes in 
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Short-Term Milestone 1: By 00, decrease by at least 0% the number of persons 
in the United States at high risk for acquiring or transmitting HIV infection by delivering 
targeted, sustained and evidence-based HIV prevention interventions. 
Transmission Objectives
 Among people living with HIV, increase the proportion who 
consistently engage in behaviors that reduce risk of HIV transmission. 
2 Modified Among men who have sex with men (MSM), increase the 
proportion who consistently engage in behaviors that reduce risk for 
transmission of HIV. 
3 Modified Among sexually active, HIV-infected women and HIV-infected 
sexually active heterosexual men, increase the proportion who 
consistently engage in behaviors that reduce risk for transmission of 
HIV.
4 Modified Among injection drug users (IDUs), increase the proportion who 
abstain from drug use or, for those who do not abstain, use harm 
reduction strategies to reduce risk of HIV  transmission.
5 Modified Among adolescents living with HIV, increase the proportion who 
consistently engage in behaviors that reduce risk for transmission of 
HIV, particularly among out-of-school high-risk youth.
6 New Increase the proportion of persons living with HIV who effectively 
access partner notification services.
7 New Among persons living with HIV, increase the proportion who receive 
evidence-based interventions, including mental health, substance 
abuse, and other appropriate interventions for co-morbid conditions. 
8 New Among persons with acute HIV infection, increase the proportion 
reached by appropriate HIV behavioral interventions.
9 New Increase the proportion of persons living with HIV who disclose their 
HIV infection before a risk encounter with a new partner and increase 
the proportion of persons at risk for HIV infection who disclose their 
HIV status before their first risk encounter with a new partner.
10 Modified Increase the proportion of HIV-infected pregnant women who are 
routinely tested and access prevention interventions including 
antiretroviral medication, caesarean sections (when appropriate) and 
infant formula feedings to interrupt perinatal transmission of HIV. 
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(cont) Short-Term Milestone 1: By 00, decrease by at least 0% the number of 
persons in the United States at high risk for acquiring or transmitting HIV infection by 
delivering targeted, sustained and evidence-based HIV prevention interventions. 
Acquisition Objectives
1a Modified Among men who have sex with men (MSM), increase the proportion 
who consistently engage in behaviors that reduce risk for acquisition 
of HIV.
a New Increase the number of proven effective behavioral prevention 
interventions for African Americans and other racial and ethnic groups 
disproportionately affected by HIV/AIDS.
3a New Increase the number of proven effective behavioral prevention 
interventions for MSM.
4a Modified Among at-risk sexually active women, and at-risk sexually active 
heterosexual men, increase the proportion who consistently engage 
in behaviors that reduce risk for HIV acquisition.
5a Modified Among adolescents, increase the proportion who consistently engage 
in behaviors that reduce risk for acquisition of HIV, particularly among 
out-of-school high-risk youth.
6a Modified Among injection drug users (IDUs), increase the proportion who 
abstain from drug use or, for those who do not abstain, use harm 
reduction strategies to reduce risk of HIV acquisition.
7a Increase the proportion of people at risk for HIV who are tested for 
STDs and treated appropriately
8a Modified Increase the number of and access to proven effective biomedical 
HIV prevention interventions including circumcision, vaccines, 
microbicides, and oral chemoprophylaxis.
9a Reduce the number of workers who are occupationally exposed to 
and infected with HIV.
10a Modified Continue to support the safety of blood, tissue and organ supplies in 
the United States.
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Short-term Milestone 2: By 00, through voluntary testing, increase from the current 
estimated 75% to 80% the proportion of HIV-infected people in the United States who 
know they are infected. 
Objectives
 New Increase the percentage of all ethnic/racial minorities who, if 
infected, are aware of their HIV infection, with a focus on African 
Americans.
 New Increase the percentage of all MSM who, if infected, are aware of 
their HIV infection.
3 Modified Increase the number of providers who routinely provide screening in 
health care settings (e.g., STD clinics, substance abuse treatment 
programs, family planning clinics, emergency rooms, community 
health centers), as well as voluntary counseling and testing (VCT) in 
non-clinical venues (e.g., social venues, street outreach).
4 New Increase the use of rapid testing technology that is user friendly and 
produces same day results.
5 New Increase availability of HIV screening to incarcerated persons.
6 Modified Improve access to voluntary, client-centered counseling and testing 
(VCT) in high seroprevalence communities and populations at risk, 
focusing particularly on populations with high rates of undiagnosed 
infection.
7 New Reduce structural and policy barriers to implementing routine HIV 
screening (e.g., barriers to rapid testing, counseling and consent 
requirements).
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Short-term Milestone 3:  By 00, increase from the current estimated 50% to 65% 
the proportion of newly diagnosed HIV-infected people in the United States, who are 
linked to appropriate prevention, care and treatment services.
Objectives
1 Modified Increase the proportion of persons newly diagnosed with HIV who are 
successfully linked to medical care within 3 months of learning their HIV 
infection or being re-identified as HIV-infected but out of care, including 
African Americans and other racial and ethnic groups disproportionately 
affected by HIV/AIDS.
2 Modified Increase the proportion of persons newly diagnosed with HIV who are 
successfully linked to culturally competent, science-based prevention 
services.
3 Modified Integrate prevention services, including adherence to treatment and 
partner notification services for persons diagnosed with HIV and AIDS, 
into the delivery of patient care in both public and private sectors.
4 Modified Reduce the disparities, stigma and discrimination in access to prevention 
and care services that are experienced by communities of color, women, 
and MSM.  
5 Increase the proportion of HIV care providers offering routine, periodic 
STD screening and treatment to HIV-infected clients.
6 Promote the optimal level of medical services for patients diagnosed 
with HIV to benefit individual health and reduce the likelihood of further 
transmission of HIV.
7 Increase the proportion of correctional facility detainees (incarcerated 
for at least 30 days) identified as HIV-infected who are provided HIV 
prevention, treatment and care services and who, upon release, are 
successfully linked to those services in the communities to which they 
return.
8 Increase the proportion of HIV care providers offering routine, periodic 
TB screening and treatment to HIV-infected clients.
9 Modified Increase the proportion of persons newly diagnosed with HIV (including 
pregnant women) who need substance abuse treatment services that 
are successfully linked to those services.
10 Modified Increase the proportion of persons newly diagnosed with HIV who need 
social and mental health services that are successfully linked to those 
services.
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Short-term Milestone 4:  By 00, strengthen the capacity nationwide to monitor the 
epidemic, develop and implement effective HIV prevention interventions and evaluate 
prevention programs.
Objectives
1 Modified Improve the capacity to measure incidence of new infections; track the 
prevalence of disease and its complications; monitor the transmission 
and prevalence of drug resistant virus; monitor behaviors, including 
behaviors that increase the risk of HIV infection (among persons who are 
HIV-uninfected) and behaviors that increase the risk of HIV transmission 
and the risk of disease progression (for persons who are living with HIV); 
and provide locally relevant data for community planning. 
 Increase the number of evidence-based interventions and the proportion 
of prevention providers funded by CDC who successfully provide 
demonstrably effective HIV prevention interventions.
3 Support realistic and feasible evaluation efforts to ensure the delivery of 
interventions at the highest possible quality.  
0
HIV Prevention Strategic Plan Performance Indicators
In February 2002, CDC defined 11 measurable performance indicators (noted in Appendix 3) to monitor the progress toward implementing the overarching and four 
domestic goals and objectives of the 2001	Plan.  The indicators were selected based on 
the appropriateness of the measure for the specific goal or objective of the 2001	Plan, 
practicality of the measure, and the current and future availability of HIV data.  These 
were the same indicators CDC used for other required reporting including Government 
Performance and Results Act (GPRA), Office of Management and Budget Program 
Assessment Rating Tool (PART), and the Healthy People 00.
 To appropriately address the focus on African Americans and MSM in the objec-
tives of the Extended	Plan, CDC reviewed the original  performance indicators in-
cluded the 2001	Plan to determine if some indicators needed to be modified or retained 
or if new ones needed to be added.  CDC also added incidence measures for MSM, 
African Americans, and Hispanics based on a motion from the CHAC on May 8, 007.  
Currently, there are 5 performance indicators.  Of this number, 7 are new indicators, 
six are modified, and two were unchanged.  Since 2002, CDC has developed new data 
collection systems and has also included process indicators to measure the impact of 
prevention interventions.  The outputs of these new systems are reflected in the new 
performance indicators.  

Data Source: HIV/AIDS Reporting System (e-HARS).
 
Measure FY Target Reporting Date
Decrease the rate 








005 [Trend Data] /007
004 [Trend Data] /007
003 Baseline /007
Data Source:  Calculations of HIV incidence and prevalence, utilizing HIV/AIDS Incidence 
Surveillance System and special prevalence studies.
Short-term Goal (Indicators 1-5)
1.  Reduce the rate of HIV transmission by HIV-infected persons. (new)
2.  Decrease the number of pediatric AIDS cases. (unchanged)
Measure FY Target Result/Reporting 
Date
Decrease the 
number of pediatric 
AIDS cases, from 
the 998 base of 4 
cases. 
00 <75 cases /0
009 <75 cases /00
008 <75 cases /009
007 <00 cases /008
006 <00 cases /007
005 [Trend Data] 68
004 [Trend Data] 50
003 [Trend Data] 7
00 [Trend Data] 05
00 Baseline 

3.  Decrease the annual HIV incidence. (new)
Measure FY Target Reporting Date










Data Source: HIV/AIDS Incidence Surveillance in 34 areas.
Measure FY Target Reporting Date
Decrease the number of 










 3a.  Decrease the number of new HIV cases among MSM. (new)
Data Source: HIV/AIDS Surveillance in 33 states.
3
3c. Decrease the annual HIV incidence among Hispanics. (new)
Measure FY Target Reporting Date
Decrease the annual 










Data Source: HIV/AIDS Incidence Surveillance in 34 areas.
3b. Decrease the annual HIV incidence among African Americans. (new)
Measure FY Target Reporting Date
Decrease the annual 










Data Source: HIV/AIDS Incidence Surveillance in 34 areas.
4
4.  Reduce the black:white ratio of HIV/AIDS diagnoses.  (new)
Measure FY Target Result/Reporting Date
Reduce the black:








005 [Trend Data] 8.69:
004 [Trend Data] 9.7:
003 [Trend Data] 9.90:
00 [Trend Data] 0.3:
00 Baseline 0.94:- Data are from 33 areas with 
stable HIV reporting
Data Source: HIV/AIDS Reporting System (e-HARS).
5.  Reduce the Hispanic:white ratio of HIV/AIDS diagnoses. (new)
Measure FY Target Result/Reporting Date
Reduce the 
Hispanic: white rate 







005 [Trend Data] 3.53:
004 [Trend Data] 3.66:
003 [Trend Data] 4.05:
00 [Trend Data] 4.:
00 Baseline 4.6:- Data are from 33 areas with 
stable HIV reporting
Data Source: HIV/AIDS Reporting System (e-HARS).
5
6b.  Increase condom use among sexually active youth.  (modified)
Measure FY Target Result/Reporting 
Date
Increase condom use among 







Data Source: Youth Risk Behavioral Surveillance System (YRBSS).  The YRBSS is conducted 
in odd-numbered years so there are no data for 000 and 00, and the target is set for 009 
rather than 00.
Short-term Milestone 1 (Indicators 6-9)
6a.  Decrease the percentage of youth who have ever had sexual      
       intercourse.  (modified)
Measure FY Target Result/Reporting 
Date
Decrease the percentage of 
students in 9th through th 







Data Source: Youth Risk Behavioral Surveillance System (YRBSS).  The YRBSS is conducted 
in odd-numbered years so there are no data for 000 and 00, and the target is set for 009 
rather than 00.
6
7.  Decrease risky sexual and drug using behaviors among persons at  
     risk for transmitting HIV.  (modified)
Measure FY Target Reporting 
Date
Decrease risky sexual and drug using 






Data Source: Medical Monitoring Project.
8.  Decrease risky sexual and drug using behaviors among persons at  
     risk for acquiring HIV. (new)
Measure FY Target Result/Reporting 
Date
Decrease risky sexual and drug 
using behaviors among persons 
at risk for acquiring HIV.
00 MSM – 46% /0
009 HRH- XX /0
008 IDU- XX /00
007 MSM – 47% /009
006 Baseline HRH – /008
005 Baseline IDU – /007
004 Baseline MSM – 47%
Data Source: National HIV Behavioral Surveillance System.
7
9.  Increase the proportion of persons at risk for HIV who received HIV 
     prevention interventions. (new)  
Measure FY Target Result/Reporting 
Date
Increase the proportion of persons 
at risk for HIV who received HIV 
prevention interventions.
00 MSM - % /0
009 HRH - XX /0
008 IDU  - XX /00
007 MSM - 0% /009
006 Baseline HRH- /008
005 Baseline IDU- /007
004 Baseline MSM- 8.9%
Data Source: National HIV Behavior Surveillance System.
Short-term Milestone 2 (Indicators 10-12)
10.  Increase the proportion of HIV-infected people in the United   
      States who know they are infected. (new)
Measure FY Target Result/Reporting 
Date
Increase the proportion of HIV-
infected people in the United 




005 74.5% 6/007 
003 Baseline 74.5%
Data Source: Special studies using eHARS.
8
11.  Increase the proportion of persons with HIV-positive test results  
       from publicly funded counseling and testing sites who receive  
       their test results.  (modified)
Measure FY Target Result/Reporting 
Date
Increase the proportion of 
persons with HIV-positive test 
results from publicly funded 
counseling and testing sites 







004 [Trend data] 84%
003 [Trend data] 8%
00 [Trend data] 8%
00 Baseline 8%
Data Source: Counseling, Testing, and Referral System-Program Evaluation and Monitoring 
System.
12.  Increase the proportion of people with HIV diagnosed before  
       progression to AIDS. (unchanged)
Measure FY Target Result/Reporting Date
Increase the proportion 








005 [Trend data] 78.%
004 [Trend data] 77.9%
003 [Trend data] 78.0%
00 [Trend data] 78.%
00 Baseline 78.0% Data are from 33 




Short-term Milestone 3 -  (Indicators 13-17)
13.  Increase the percentage of HIV-infected persons in publicly funded  
       counseling and testing sites who were referred to PCRS. (new)
Measure FY Target Reporting 
Date
Increase the percentage of HIV-infected persons 
in publicly funded counseling and testing sites 
who were referred to PCRS.
00 XX% /00
008 Baseline 009
Data Source: Program Evaluation and Monitoring System.
14.  Increase the percentage of HIV-infected persons in publicly     
       funded counseling and testing sites who were referred to HIV  
       prevention services. (new)
Measure FY Target Reporting 
Date
Increase the percentage of HIV-infected 
persons in publicly funded counseling and 





Data Source: Program Evaluation and Monitoring System.
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15.  Increase the percentage of HIV-infected persons in publicly  
       funded counseling and testing sites who were referred to medical 
       care and attended their first appointment. (new)
Measure FY Target Reporting Date
Increase the percentage of HIV-infected 
persons in publicly funded counseling and 
testing sites who were referred to medical 




Data Source: Program Evaluation and Monitoring System.
16.  Increase the percentage of HIV-infected persons in medical  
       care who initiated medical care within three months of diagnosis.  
       (modified)
Measure FY Target Result
Increase the percentage of HIV-in-
fected persons in medical care who 






Data Source: Medical Monitoring Project.
17.  Increase the proportion of people at the time of HIV diagnosis  
       with a CD4 count greater than 350. (new)
Measure FY Target Result
Increase the proportion of people 
at the time of diagnosis with a CD4 







004 [Trend data] 9.9%
003 [Trend data] 8.%




Short-term Milestone 4 -  (Indicators 18-21)
18.  Increase the number of states with mature, name-based HIV  
       surveillance systems. (modified)
Measure FY Target Result/Reporting 
Date
Increase the number of 
states with mature, name-







005 [Trend data] 33
004 [Trend data] 33
003 [Trend data] 3
00 [Trend data] 9
00 Baseline 9
Data Source: HIV/AIDS Reporting System (eHARS).
19.  Increase the percentage of HIV prevention program grantees  
       using PEMS to monitor program implementation. (new)
Measure FY Target Result/Reporting 
Date
Increase the percentage of HIV 
prevention program grantees 







Data Source: Program Evaluation and Monitoring System.
3
20.  Increase the number of evidence-based prevention interventions 
       that are packaged and available for use in the field by prevention 
       program grantees. (new)
Measure FY Target Result/Reporting 
Date
Increase the number of 
evidence-based prevention 
interventions that are 
packaged and available for 






006 [Trend Data] 4
005 [Trend Data] 4
004 [Trend Data] 
003 [Trend Data] 0
00 [Trend Data] 7
00 Baseline 5
Data Source: Replicating Effective Programs (REP) Project data.
21.  Increase the number of agencies trained each year to implement  
       Diffusion of Effective Behavioral Interventions (DEBIs). (new)
Measure FY Target Result/Reporting 
Date
Increase the number 
of Agencies trained 






006 [Trend Data] 987
005 [Trend Data] ,4
004 [Trend Data] ,068
003 [Trend Data] 47
00 [Trend Data] 53
00 Baseline 0
Data Source: Diffusion of Effective Behavioral Interventions (DEBI) Tracking Database.
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DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
HEALTH RESOURCES AND SERVICES ADMINISTRATION
CDC/HRSA ADVISORY COMMITTEE ON
HIV AND STD PREVENTION AND TREATMENT
November 13-14, 2006
Washington, DC
Draft Minutes of the Meeting
The Department of Health and Human Services (HHS), Centers for Disease Control 
and Prevention (CDC), and Health Resources and Services Administration (HRSA) 
convened a meeting of the CDC/HRSA Advisory Committee on HIV and STD Prevention 
and Treatment (CHAC).  The proceedings were held at the Hotel Washington in 
Washington, DC on November 3-4, 006.
Dr. Jean McGuire and Mr. Jesse Milan, Jr., the CHAC co-Chairs, called the meeting 
to order at 8:4 a.m. on November 3, 006.  They welcomed the attendees to the 
proceedings and opened the floor for introductions.  The list of participants is appended 
to the minutes as Attachment .
Dr. McGuire and Mr. Milan informed CHAC that they sent a letter to Dr. Ronald 
Valdiserri, the former Designated Federal Official (DFO) for CDC, to formally 
acknowledge his years of dedicated service to CHAC.
Opening Session
4
Mr. Stephen Smith, Senior Advisor to the HRSA Administrator, covered the following 
areas in his report.  HRSA observed the 5th anniversary of the Ryan White 
Comprehensive AIDS Resources Emergency Act (CARE Act) during its grantee 
conference in August 006.  The conference served as a time of remembrance, renewal 
and re-commitment.  The grantees reflected on the significant amount of progress that 
has been made in treating the HIV/AIDS epidemic, such as collaborations with CDC on 
the HIV testing recommendations.  The grantees also acknowledged that these efforts 
must continue to achieve greater progress in the future.
The pending bill on reauthorization of the CARE Act reflects the Administration’s 
themes, including HIV counting, core services, better coordination among CARE Act 
Titles, and improved accountability.  These themes are consistent with the President’s 
principles of serving the neediest first and better targeting of resources.  The CARE 
Act has not been re-authorized to date, but HRSA will continue to implement the 
current law and support the reauthorization process as opportunities arise.   After the 
reauthorization bill is passed, HRSA will make diligent efforts to ensure that grantees 
have all necessary information and guidance to implement the new provisions.
HRSA is pleased that the President’s FY’07 budget request includes an additional $95 
million for new activities under the domestic HIV initiative.  The House and Senate 
marked up the President’s budget with different proposed budgets.  HRSA and all other 
federal agencies are operating under a continuing resolution through November 7, 
006.  HRSA will continue to monitor the current Congressional session on the HHS 
appropriation for FY’07, but significant changes from the President’s budget request are 
not anticipated.
HRSA is continuing its analysis of 005 CARE Act data in preparation of completing 
a final report.  Preliminary results of the data analysis showed that CARE Act-funded 
service providers served a total of 954,33 duplicated clients in 005.  Of these 
clients, >33% were women and >70% were persons of color.  The >4.06 million visits 
for healthcare services that were reported in 005 represented a % increase over 
the number of healthcare visits reported in 004.  CARE Act services currently reach 
>500,000 individuals.
HRSA will continue several ongoing activities and implement new initiatives in FY’07 
to improve its ability to deliver HIV/AIDS care.  Close collaborations with CDC on new 
HIV testing recommendations will be continued.  Funding will be allocated to support a 
number of new initiatives under the Special Projects of National Significance (SPNS) 
grant program.  Ten grants will be awarded under the SPNS jail-based initiative for 
grantees to implement and evaluate innovative methods for linking persons living with 
HIV/AIDS (PLWHA) who are incarcerated or recently released from local jails to primary 
medical care and ancillary services.
HRSA Update
4
A new SPNS grant program totaling >$6.5 million will be implemented to support 
innovative oral healthcare for PLWHA.  The SPNS Information Technology Networks of 
Care Initiative will award funds to support organizations that promote the enhancement 
and evaluation of existing electronic information network systems to serve PLWHA in 
underserved communities.  The SPNS Case Management Initiative will identify case 
management models and services that are most important for improving access to and 
retaining patients in care.
The Minority AIDS Initiative (MAI) will fund five new projects from one to multiple 
years.  The MAI activities will focus on () HIV care for women of color; () intervention 
strategies to help clinics retain patients in care; (3) an evaluation of MAI activities; (4) an 
assessment of the needs of tribal providers who serve American Indians/Alaska Natives 
in AIDS Education and Training Center (AETC) regions; and (5) a study on issues and 
barriers to increasing the capacity of health professions immigrants to provide HIV care 
in the United States.
HRSA established new resources to support its HIV/AIDS programs and activities.  The 
TARGET Center is a new web site and help desk that will provide two major services.  
A centralized source will be available for CARE Act programs to obtain technical 
assistance.  Grantees will be provided with a “virtual community” to learn about and 
share ideas.  The National Perinatal HIV Consultation and Referral Service Hotline will 
provide three major services.  Around-the-clock advice will be given on standard and 
rapid HIV testing in pregnancy.  Consultation will be offered on the use of anti-retroviral 
therapy (ART) during pregnancy, labor and delivery, and the postpartum period.  HIV-
infected pregnant women will be linked to appropriate health care.
HRSA will undertake several efforts to improve the quality of its HIV/AIDS programs 
and activities.  Client-level data and National Quality Center guidelines will be used to 
develop quality indicators for the HRSA HIV/AIDS Bureau (HAB) and HIV/AIDS care 
and services provided by grantees.  Quality training, support and technical assistance 
will be provided to HAB staff and grantees.  HRSA recently completed a quality initiative 
of AIDS Drug Assistance Program (ADAP) processes with eight Title II states.  Most 
of the eight states showed significant improvements in the quality of ADAP outcomes.  
HRSA is now exploring strategies to widely disseminate the quality improvement models 
to all states.
HRSA will continue its global HIV/AIDS activities through the President’s Emergency 
Plan for AIDS Relief (PEPFAR).  PEPFAR’s accomplishments to date include 
implementation of the HIVQUAL model in 4 hospital sites in Thailand and an 
expansion of the HIVQUAL model to Uganda, Namibia and Mozambique in FY’06.  I-
TECH implemented clinical mentoring in three new countries in 006 and is currently 
providing clinical training in 5 countries.  Training of rapid HIV testing in Namibia led to 
an increase in post-test counseling from 0% in 005 to 66% in 006.  HRSA expects 
PEPFAR to continue to be supported as a $15 billion initiative over five years.
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HRSA will continue to closely monitor Medicare Part D and the impact of the donut hole 
on clients who receive HIV/AIDS services under the CARE Act.  The “donut hole” is the 
gap in coverage when no insurance for prescription drugs would be available.  After total 
drug costs reach $,50, a patient would pay an additional $,850 out-of-pocket before 
coverage would continue under Medicare Part D.  The donut hole will not affect ~70%-
80% of Medicare beneficiaries living with HIV who qualify for low-income subsidies.  
Due to the high cost of ART, however, Medicare beneficiaries living with HIV who do not 
qualify for additional assistance would need to consider strategies to obtain lower drugs 
costs in the “catastrophic” coverage level.
HRSA informed grantees that ADAPs could assist with Medicare Part D costs and 
provide ART to clients affected by the donut hole.  HRSA also advised grantees to 
encourage Medicare beneficiaries to contact state ADAPs to explore opportunities 
for assistance with the cost of ART.  Medicare beneficiaries also have the option of 
considering Part D plans that have higher premiums, but provide partial coverage to 
compensate for or completely eliminate the donut hole.  HRSA has not yet developed 
cost estimates of the impact of the donut hole on CARE Act grantees.
HRSA grantees in Alabama, Louisiana, Mississippi and Texas are still recovering 
from the devastation of Hurricanes Katrina and Rita.  The most significant challenges 
of grantees in these states are tracking clients who were displaced, meeting CARE 
Act requirements and restrictions, and adhering to conditions of awards.  HRSA will 
continue to closely collaborate with grantees in these states to overcome these barriers.
HRSA took several actions to improve its readiness to respond to emergencies.  An 
Emergency Operations Center and “e-Room” were established to provide an electronic 
system to collect data from grantee project officers in all HRSA bureaus.  The Office 
of Commissioned Corps Affairs (OCCA) was established in May 006 to provide a 
centralized point for deployments and all other HRSA officer activities.  OCCA will 
oversee implementation of the HHS Secretary’s vision for a transformed Commissioned 
Corps to ensure that the future force is prepared to meet the nation’s public health and 
emergency needs.
Mr. Smith thanked CHAC for its vital role in improving HIV/AIDS prevention, care and 
treatment throughout the nation and the world.  He emphasized that the knowledge, 
experience and dedication of each CHAC member are invaluable to HRSA and HHS as 
future policies are established for HIV/AIDS care and treatment.  He added that HRSA 
would continue to rely on CHAC’s expertise, guidance and recommendations to inform 
this process in the future.
On behalf of CHAC, Mr. Milan thanked HRSA for developing innovative strategies 
to assist CARE Act grantees.  He was aware that legislative barriers and resource 
constraints adversely impact HRSA’s ability to administer its HIV/AIDS programs.  
Despite these challenges, however, funding for the new FY’07 projects illustrates 
HRSA’s diligent efforts and continued commitment to ensure that constituencies 
represented by CHAC are served.
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Mr. Milan also commended HRSA for playing a critical role in ensuring that CHAC’s 
voice was heard during ongoing efforts to reauthorize the CARE Act.  Most notably, 
CHAC’s proposed definitions for core medical services and other recommendations are 
being considered in current legislative drafts.
Other CHAC members joined Mr. Milan in applauding HRSA for allocating funds 
to implement and support the new FY’07 activities, particularly the MAI and SPNS 
initiatives.  However, several members expressed concerns about certain aspects of 
some of HRSA’s HIV/AIDS activities.
• HRSA’s new jail-based initiative does not reflect coordination with a similar activity 
that CDC previously conducted.  Lessons learned, experiences and important findings 
from CDC’s jail-based effort should be reviewed.
• The change in the CARE Act law will require HRSA to add HIV to the formula 
for distribution of Title I and II dollars in 007.  Clients who receive HIV/AIDS 
services  under the CARE Act in states with no name-based reporting system will 
suffer adverse impacts as a result of this change.  HSRA should provide technical 
assistance to help jurisdictions in converting to a name-based reporting system 
because some areas might require up to four years to make this transition.
• HRSA has not broadly communicated information on its new HIV/AIDS activities and 
resources.  Most notably, many providers have no knowledge of HRSA’s National 
Perinatal HIV Consultation and Referral Service Hotline.
• HRSA should made stronger efforts to assist grantees in assuring continuity of care to 
clients who would be affected by the Medicare Part D donut hole.
• HRSA has not clearly described its efforts to collect client-level data.  Most notably, 
CHAC has no knowledge of whether these data reflect capacity issues at various sites 
or if this activity is coordinated with the Centers for Medicare and Medicaid Services 
(CMS).
Mr. Smith, other HRSA staff, and Dr. Deborah Parham Hopson, the HAB Director and 
CHAC DFO for HRSA, provided additional details about HRSA’s HIV/AIDS activities in 
response to CHAC’s comments, questions and concerns.
• HRSA is currently collaborating with CDC to coordinate its new jail-based SPNS 
initiative.
• HSRA will continue to implement the 000 CARE Act legislation in the absence 
of reauthorization.  HRSA will adhere to the change in the legislation to add HIV 
to the formula for distribution of Title I and II dollars by 007.  Only HIV data from 
jurisdictions with HIV reporting systems will be used.  Only name-based data that 
have been accepted and certified by CDC will be used.  AIDS data will be accepted 
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from states that do not have name-based HIV reporting systems.  The change in the 
legislation will primarily affect the allocation of funds, but will not necessarily impact 
delivery of care to clients who receive services under the CARE Act.
• HRSA is conducting several activities in preparation for the change in the CARE 
Act legislation that must be implemented in 007.  In the absence of an FY’07 
budget and reauthorization of the CARE Act, modeling is being performed to identify 
jurisdictions that will be affected.  Communications with grantees about the change 
in the legislation were initiated in 000 and will continue.  Close collaborations with 
jurisdictions with no name-based reporting systems will continue.  Assistance will 
continue to be provided to jurisdictions that lose CARE Act dollars each year to help 
these grantees to prioritize funds and assure continued delivery of essential services 
to patients.  The House bill proposed a transition period for jurisdictions to convert 
to name-based reporting systems, but the Senate bill did not contain the same 
language.
• HRSA is identifying strategies for community health centers (CHCs) to provide 
care to persons with HIV.  HRSA is aware that many care systems are currently at 
capacity and are unable to provide care to new patients.
• HRSA recognizes that some states, territories and eligible metropolitan areas will 
receive less funds under Titles I and II in 007 compared to 006 based on the 
President’s FY’07 budget.  Even with decreased funding, however, all jurisdictions 
will be held harmless in 007 according to the law.
• HRSA is pleased that ADAP waiting lists were decreased from eight to four states:  
Alaska, Montana, South Carolina and West Virginia.  HRSA will attempt to spread 
ADAP dollars in these four states to ensure continued delivery of services to 
Medicare beneficiaries living with HIV who would be impacted by the donut hole.  
However, many patients who are on ADAP waiting lists still receive medication 
through established relationships between ADAPs and Pharmacy Assistance 
Programs.
• HRSA took action on formal motions that CHAC passed during previous meetings.  
The HHS Secretary provided Congress with HRSA’s data runs for consideration 
in developing draft proposals of the CARE Act reauthorization.  HRSA convened 
several consultations with grantees on the severity of need index and is now 
identifying a more quantitative strategy to analyze these data under Title I 
supplemental dollars.
• HRSA will use its established mailing lists of AETCs, CHCs, grantees, special 
interest groups and other organizations to broadly disseminate information on its 
HIV/AIDS activities and resources.  Articles about HRSA’s National Perinatal HIV 
Consultation and Referral Service Hotline were recently published in peer-reviewed 
journals targeted to obstetricians/gynecologists and family practitioners.
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• HRSA is conducting several activities to assess the capacity of grantees to report 
client-level data.  At the next meeting, HRSA will provide CHAC with an overview of 
its ongoing efforts to collect client-level data from grantees.
Dr. Kevin Fenton, Director of the CDC National Center for HIV, Hepatitis, STD and TB 
Prevention (NCHHSTP) [proposed], reported that similar to HRSA, CDC has also taken 
several actions to assist jurisdictions in converting to name-based reporting systems.  
Since 999, states and local jurisdictions have been strongly encouraged to undertake 
this effort.  Specific guidance and technical assistance have been provided to states and 
local jurisdictions, including methods to implement name-based reporting and strategies 
to assure data quality.
Legislative reviews were performed to assist states and local jurisdictions in examining 
barriers to converting to name-based reporting systems.  New approaches are now 
being explored for CDC to more rapidly complete the data certification process.  
However, CDC is currently facing two major barriers to its ongoing role in providing 
assistance to states and local jurisdictions that still have not made the transition to a 
name-based reporting system:  () addressing the backlog of HIV/AIDS cases reported 
over the past 5 years and () capturing new diagnosed HIV/AIDS cases.
Mr. Milan concluded the session by asking CHAC to provide him or Dr. McGuire with 
suggestions on resource needs for HIV/AIDS treatment and care for FY’07 and beyond 
that should be recommended to HRSA or the HHS Secretary.  He confirmed that any 
suggestions proposed by the members would be presented and considered as potential 
formal motions during CHAC’s review of its business items on the following day.
Dr. Fenton covered the following areas in his report.  Several reasons served as the 
basis for CDC to revise and release its HIV testing recommendations for healthcare 
settings in September 006.  Many HIV-infected persons access health care, but are not 
tested for HIV until symptoms are present.  Effective treatment is available.  Awareness 
of HIV infection leads to substantial reductions in high-risk sexual behavior.  High levels 
of knowledge about HIV result in a decreased need for pre-test counseling.  A great deal 
of experience with HIV testing is available, including rapid tests.  Existing evidence is 
inconclusive about the benefits of prevention from typical counseling for persons who 
test negative
Key language from CDC’s revised HIV testing recommendations is highlighted as 
follows.  For adults and adolescents, routine and voluntary HIV screening should be 
provided to all persons 3-64 years of age in healthcare settings.  Screening should 
not be based on risk.  HIV screening of persons with known risk should be repeated at 
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least annually.  Opt-out HIV screening should be offered with an opportunity for persons 
to ask questions and decline testing.  HIV consent should be included with general 
consent for care.
Prevention counseling in conjunction with HIV testing in healthcare settings is not 
required.  Patients who test positive for HIV should be linked to clinical care, counseling, 
support and prevention services.  HIV-negative patients who are known to be at high 
risk should be advised of the need for periodic re-testing and offered or referred to 
prevention counseling.  The recommendations are intended for all healthcare settings, 
but not for community-based organizations (CBOs) or other non-clinical settings.
Recommendations on referral to care were not changed from CDC’s previous guidance. 
For example, CDC still recommends referrals or linkages to care for all HIV-positive 
persons.  Physicians should initiate screening in low-prevalence settings.  Continued 
screening would no longer be warranted if a jurisdiction demonstrated an HIV 
prevalence of </,000.
For pregnant women, universal opt-out HIV screening should include HIV in the prenatal 
screening test panel.  Consent for prenatal care should include HIV testing.  A second 
HIV test should be offered to pregnant women in the third trimester who are known to 
be at risk for HIV or those who are in key jurisdictions or high HIV prevalence healthcare 
facilities.  Opt-out rapid HIV testing should be offered to women with an undocumented 
HIV status during labor and delivery.  ART should be initiated on the basis of a rapid HIV 
test result.  Newborns should be tested if the mother’s HIV status is unknown.
CDC will launch its new Adult Hepatitis B Vaccination (HBV) Initiative in 007.  New 
HBV recommendations will be published in the Morbidity and Mortality Weekly Report 
(MMWR) in November 006 and will call for venue-based vaccination of adults.  The 
new initiative will maximize previous accomplishments in hepatitis B elimination efforts 
in the United States and will also take advantage of new synergies that are now 
available across CDC programs as a result of the agency-wide reorganization.
Four key strategies will be highlighted in the Adult HBV Initiative:  () prevent perinatal 
HBV transmission; () implement universal infant vaccination; (3) implement catch-up 
vaccination for all children and adolescents <9 years of age; and (4) vaccinate adults 
in groups known to be at risk for HIV.  Vaccination programs played a tremendous role 
in the dramatic reduction of the incidence of acute hepatitis B in the United States from 
984-004.  However, targeted interventions are still needed because the decline in the 
incidence of hepatitis B has remained flat in certain subgroups over the past few years.
In addition to publishing the new HBV recommendations, CDC will also conduct other 
activities under the Adult HBV Initiative.  Access to free adult HBV in the United States 
will be increased.  States and local jurisdictions will be encouraged to use savings in the 
federal 37 program to purchase vaccine.  Plans will be developed to direct vaccine to 
HIV, STD and other clinics with high hepatitis B prevalence.
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Vaccination capacity will be strengthened in specific sites, jurisdictions and settings 
where HBV should be provided.  A request will be made to support local HBV 
coordinators.  Training and technical assistance will be provided to HBV providers.  
Vaccination programs will be evaluated and improved.  Approaches will be explored to 
make intensive investments over the next five years to truly eliminate hepatitis B in the 
United States.
The CDC Global AIDS Program (GAP) is continuing its participation and investment in 
global AIDS initiatives through PEPFAR.  PEPFAR represents the single largest U.S. 
government investment in global HIV/AIDS activities.  GAP is serving as a leader in 
implementing a public health evaluation strategy to collect and aggregate data across 
PEPFAR programs.  GAP is also engaged in ongoing efforts for the Department of 
State and U.S. Agency for International Development to more closely collaborate 
with countries and embassies to plan initiatives, report data, and promote one U.S. 
government investment of HIV/AIDS and other health issues in different countries in
FY’07 and thereafter.
New programmatic initiatives will be incorporated into PEPFAR in FY’07 based on 
findings from initial activities.  More emphasis will be placed on prevention for HIV-
positive persons; the relationship between HIV and alcohol; gender inequalities in terms 
of access to care and quality of services; and prevention of vertical transmission of HIV.
CDC played a major role in two developments that occurred in 006 regarding STDs.  
The Food and Drug Administration (FDA) licensed use of the quadrivalent human 
papillomavirus (HPV) vaccine in June 006 in females 9-6 years of age.  The HPV 
vaccine is effective against HPV types 6//6/8 and the prevention of cervical cancer, 
genital warts, and cervical, vaginal and vulvar pre-cancerous or dysplatic lesions.
CDC’s expertise was instrumental in the Advisory Committee on Immunization 
Practices (ACIP) making final recommendations on the HPV vaccine in June 2006.  
ACIP recommended routine use of the HPV vaccine for females - years of age; 
initiation of the vaccination series beginning at 9 years of age; and catch-up vaccination 
for females through 6 years of years.  ACIP’s statement on the HPV vaccine will 
be published in the MMWR in the first half of 2007.  Data on the efficacy of the HPV 
vaccine in males are expected to be released in 007 or 008.
CDC established several workgroups throughout the agency to continuously monitor 
the impact of the HPV vaccine through communications and evaluations of vaccine 
uptake, safety and impact.  GlaxoSmithKline is expected to apply for FDA licensure of 
its bivalent vaccine for HPV types 6/8 in 007.
CDC is continuing to provide guidance on financial issues related to the HPV vaccine.  
The catalogue price of the vaccine is $0/dose for the three-dose series.  Negotiations 
are underway to establish CDC’s contract price of $96/dose.  The Vaccines for Children 
Program will pay for the cost of the vaccine at no cost to children <9 years who 
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meet the following eligibility criteria:  Medicaid recipients, uninsured persons, Native 
Americans/Alaska Natives, or under-insured and vaccinated persons at participating 
federally qualified health centers and rural health clinics.
The Merck Patient Assistance Program can be used to pay for the cost of the HPV 
vaccine in the private sector for persons who meet the following eligibility criteria:  
persons >9 years of age, uninsured persons, and persons with an annual household 
income <00% of the federal poverty level.  Efforts are underway for Merck to receive 
signed forms from applicants and complete the approval process for payment in less 
than 0 minutes.
CDC compiled the newest evidence to update and release its STD Treatment 
Guidelines in July 006 for use as a standard protocol for STD treatment in the United 
States.  Key language from the guidelines is outlined below:
• Additional focus on appropriate screening and treatment of STDs among men who 
have sex with men (MSM).
• More emphasis on the benefits of re-screening for chlamydia and gonorrhea.
• Recommendations for partner-delivered therapy for chlamydia and gonorrhea if 
other strategies to reach partners would not be likely to succeed.
• New recommendations for treatment of chlamydia in pregnant women.
• New treatment recommendations to reduce transmission of herpes simplex virus 
type  (HSV-).
• Information on available new medications for treatment of trichomoniasis.
• An update on the HPV vaccine and its licensure.
• New evidence on the effectiveness of male latex condoms in reducing the risk of 
pelvic inflammatory disease, HSV-2, HPV and HPV-associated diseases.
• Stronger recommendations for HBV vaccination of unvaccinated adults seeking 
care in venues that provide services to high-risk adults.
• Stronger recommendations for routine HIV testing for persons seeking evaluation 
and treatment for STDs, including opt-out testing.
CDC used several venues to widely disseminate the updated STD Treatment 
Guidelines, including a publication in the August 4, 006 edition of the MMWR, 
distribution of hard copies upon request, the availability of hard copies on the CDC web 
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site, a video podcast, user-friendly pocket guides and wall charts for a broader range of 
stakeholders, and presentations at multiple professional meetings.
At the center level, NCHHSTP will conduct several activities to support its FY’07 
strategic imperatives.  To “maximize public health impact,” NCHHSTP will align staff, 
strategies, goals, investments and performance to maximize its impact on the health 
and safety of populations.  NCHHSTP established three FY’07 priorities to support 
this strategic imperative.  The elimination of TB, syphilis and perinatal HIV will be 
accelerated.  The implementation of hepatitis B, HPV and other vaccine-preventable 
STDs will be enhanced.  The incidence and consequences of HIV/AIDS, hepatitis C 
and STDs will be decreased, particularly in racial/ethnic minority groups and resource-
constrained countries.
To “ensure accountability,” NCHHSTP will sustain public trust and confidence by 
making the most efficient and effective use of investments in NCHHSTP.  NCHHSTP 
established two FY’07 priorities to support this strategic imperative.  Information about 
HIV, viral hepatitis, STD and TB prevention investments will be more easily and readily 
available to the public.  Funding investments for HIV/AIDS, viral hepatitis, STD and TB 
prevention will be published on the NCHHSTP web site.
To “strengthen public health science,” NCHHSTP will create and disseminate knowledge 
and innovations for persons to protect their health now and in the future.  NCHHSTP 
established three FY’07 priorities to support this strategic imperative.  Training will be 
provided to promote scientific excellence within NCHHSTP.  The ethical framework 
for HIV, viral hepatitis, STD and TB research will be adapted and refined.  Workforce 
development will be promoted through internal and external research funded by CDC 
and its partners.
To “provide leadership,” NCHHSTP will leverage its unique capabilities, partnerships 
and networks to improve the health system.  NCHHSTP established three FY’07 
priorities to support this strategic imperative.  NCHHSTP’s governance relationships 
and strategic priorities will be clarified and implemented.  Leadership will continue to be 
provided at both national and international levels to improve health outcomes related 
to HIV, viral hepatitis, STD and TB prevention.  Meetings will be convened with federal 
partners to enhance collaboration.
To “promote customer centricity,” NCHHSTP will market tools that persons desire 
and need to choose health.  NCHHSTP established three FY’07 priorities to support 
this strategic imperative.  Existing partnerships will be sustained and strengthened.  
New and non-traditional partnerships will be developed to enhance the prevention 
and control of HIV, viral hepatitis, STD and TB.  A communications plan that delivers 
accessible and comprehensive health messages to partners and the public will be 
developed.
To “strengthen global health efforts,” knowledge and tools developed by CDC and 
NCHHSTP will be extended to promote health protection around the world.  NCHHSTP 
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established two FY’07 priorities to support this strategic imperative.  The successful 
implementation of PEPFAR will be facilitated and supported.  Collaboration with global 
surveillance, research and program partners will be fostered for the prevention and 
control of HIV/AIDS, viral hepatitis, STD and TB globally.
NCHHSTP established two new strategic imperatives that will be implemented in 
FY’07.  For “workforce development,” NCHHSTP will facilitate and support the CDC-
wide diversity initiative, employee career development planning and cross-training 
to meet future human capital needs.  NCHHSTP established three FY’07 priorities 
to support this strategic imperative.  Collaborative efforts will be undertaken with the 
CDC Office of Diversity to disseminate information on diversity policies, actions and 
initiatives related to diversity issues and trends.  NCHHSTP managers will be educated 
on available resources to assist in recruitment and retention of a diverse workforce.  
Existing NCHHSTP resources will continue to be used to support training and career 
development.
For “surveillance and strategic information,” NCHHSTP will harmonize data collection, 
analysis and distribution.  NCHHSTP established two FY’07 priorities to support this 
strategic imperative.  A cross-divisional surveillance workgroup will be convened to 
identify opportunities to harmonize data collection.  The feasibility of producing an 
integrated annual surveillance report on HIV/AIDS, viral hepatitis STD and TB in the 
United States will be explored.
In addition to the strategic imperatives, NCHHSTP will also place strong emphasis 
on two other areas to make substantial gains over the next few years.  For “program 
collaboration and service integration,” integrated services might include HIV, STD 
and hepatitis B and C counseling and testing (C&T); partner services and referrals 
to additional prevention or care; and hepatitis A and B immunization.  Integration will 
be focused at the field or client level where the interface between the system and 
the consumer occurs.  For purposes of this strategic imperative, NCHHSTP defines 
“integration” as an opportunity that results in integrated services for clients regardless of 
the agency structure.
NCHHSTP conducted several activities in 006 to support this strategic imperative.  
Internal workgroups were formed.  The NCHHSTP Director made site visits to explore 
opportunities for program integration.  A new initiative was developed to cross-train 
project officers and program consultants.  New information technology tools were 
designed to facilitate cross-collaborations within NCHHSTP.  Efforts are underway 
to recruit and fill a new position for the NCHHSTP Associate Director for Program 
Integration.
For “health disparities,” NCHHSTP will attempt to improve the health of populations 
disproportionately affected by HIV, STDs, TB and other related diseases or conditions 
to advance toward eliminating health disparities.  Target populations for this strategic 
imperative will include racial/ethnic minority groups, women, incarcerated persons, and 
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other communities and persons disproportionately affected by infectious diseases.
 
Several NCHHSTP divisions conducted activities in 006 to support this strategic 
imperative.  The Division of Tuberculosis Elimination convened a consultation in May 
006 and launched the “Stop TB in the African American Community” web site.  The 
Division of STD Prevention (DSTDP) revised and released the “National Plan to 
Eliminate Syphilis in the United States.”  The Division of HIV/AIDS Prevention (DHAP) 
held a series of consultations and is now developing comprehensive plans to enhance 
HIV prevention among African Americans (AAs).  The need to incorporate STD, TB and 
viral hepatitis prevention strategies for AAs was emphasized during the consultations.
CDC and its partners will sponsor the 007 National HIV Prevention Conference on 
December -5, 007 in Atlanta, Georgia.  The conference is being designed to ensure 
that the needs of an evolving HIV prevention climate in the United States are met.  
Several CHAC members attended a planning meeting in October 006 to provide 
advice on the agenda, speakers, abstracts, topics and other aspects of the conference.  
Similar to previous conferences, CDC expects CHAC to be strongly represented at the 
007 National HIV Prevention Conference.
Several personnel changes occurred in NCHHSTP’s senior leadership after the 
previous CHAC meeting.  Staff were appointed to serve in acting positions for the 
NCHHSTP Deputy Director, Associate Director for Health Disparities, Associate Director 
for Science, and Associate Director for Laboratory Sciences.  NCHHSTP management 
will make every effort to fill the acting positions with permanent staff in 2007.
CHAC supported CDC’s revised HIV testing recommendations that call for routine 
testing.  However, several members expressed concerns with some aspects of the 
guidelines and made suggestions for CDC to consider in addressing these issues.
• CDC’s revised HIV testing recommendations conflict with its 2001 HIV C&T 
guidelines and language in cooperative agreements.  For example, the revised 
HIV testing guidelines advise grantees to collect an enormous amount of data and 
enter this information into the Program Evaluation and Monitoring System (PEMS).  
However, these actions cannot be taken with routine testing because information 
must be gathered directly from patients and informed consent must be obtained to 
provide HIV counseling.  This approach would result in a two-tiered system in each 
state if CDC’s revised HIV testing recommendations, 00 HIV C&T guidelines, 
language in cooperative agreements, and PEMS data requirements are not changed 
to be consistent.  CDC should resolve this dilemma as efforts are made to implement 
the revised HIV testing recommendations.
• CDC should develop HIV testing algorithms for private laboratories.
• CDC should create and disseminate printed information on HIV testing and the 
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rationale for including the test in the regular battery of tests.
•  CDC’s revised HIV testing recommendations do not acknowledge that existing laws 
requiring confirmatory tests are a major barrier to streamlining routinized testing.  
These laws also undermine linkages to care for emergency room patients and hard-
to-reach populations.  Most notably, one week is still required to obtain results of 
confirmatory HIV tests.
• CDC’s revised HIV testing recommendations do not consider rapid confirmatory 
tests that are used in other countries.  The antiquated approach of post-test 
counseling in the United States requires patients to present again to providers at a 
later time to obtain test results.  This strategy results in missed opportunities to reach 
at-risk patients and address behaviors to reduce transmission of HIV.
• CDC should make plans at this time to ensure that persons who are newly 
diagnosed with HIV as a result of the revised HIV testing guidelines are linked to 
care.
• CDC’s revised HIV testing recommendations do not federally recognize Native 
Hawaiians or provide a voice for this population.
• CDC’s revised HIV testing recommendations do not acknowledge that health 
departments serve as a major barrier to grantees providing services to the “new 
faces” of HIV, such as women in Alaska and Alaska Native women.
• CDC’s revised HIV testing recommendations do not include interventions and 
strategies specifically for small and rural areas.
Dr. Fenton and other CDC representatives provided additional details on CDC’s 
activities in response to CHAC’s specific questions, comments and concerns.
• CDC’s revised HIV testing recommendations are designed to provide greater   
opportunities for HIV testing of at-risk populations in healthcare settings.   CDC   
will publish updated guidelines for HIV testing in community settings in 007 to   
assist CBOs in streamlining and modernizing HIV testing activities.
• CDC will expand existing models and best practices in the field throughout the 
country to implement the revised HIV testing guidelines.  For example, the CDC 
Division of HIV/AIDS Prevention convened a meeting in October 006 with various 
federal, provider and medical partners to obtain input on implementing the revised 
HIV testing guidelines in terms of funding allocations, expansion of existing best 
practices and models, and provision of capacity-building and training.  Feedback 
from the partners will be captured in CDC’s implementation guidelines for the 
revised HIV testing recommendations that will be released in 007.
•  CDC’s revised HIV testing recommendations contain extremely clear guidance for 
providers to obtain consent from and accurately diagnose patients.  For example, 
providers are advised not to administer HIV testing without the knowledge and 
full consent of the patient and to only give results of the test to the patient.  Local 
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jurisdictions are also advised to identify and resolve legal barriers to HIV testing.  
Providers who do not comply with CDC’s guidance on diagnosis and confidentiality 
would be at a greater risk to be sued by patients.
• CDC’s revised HIV testing recommendations clearly identify and define “high-risk” 
populations, settings and behaviors for annual routine HIV testing, such as persons 
who present to STD clinics and drug treatment settings or individuals who report > 
sexual partners in the past year.
• CDC’s Infertility Prevention Program is a top priority in DSTDP in terms of resources 
and need.  The national reported rate of chlamydia is nearly  million cases.  
Reported cases of gonorrhea increased over the past year for the first time since 
the late 990s.  Both of these infections have enormous disparities.  The prevalence 
of chlamydia and gonorrhea in family planning clinics and other sentinel settings 
has either flattened or slightly increased.  CDC is aware that stronger actions 
need to be taken for chlamydia and gonorrhea, particularly screening in non-
public sectors and wider screening and coverage of the currently recommended 
population of sexually active women <6 years of age.
• CDC will review and update its existing HIV C&T guidance to resolve any conflicts 
with the revised HIV testing recommendations.
• CDC will closely collaborate with partners to link persons who are newly diagnosed 
with HIV as a result of the revised HIV testing recommendations to care.  The 
recommendations strongly emphasize, cite solid articles and describe CDC’s 
demonstration projects on the importance of linkages to care.  CDC will use 
newly-diagnosed HIV-positive persons as a mechanism to advocate for more HIV 
prevention funding.
• CDC will hold a meeting on the following day with PEMS stakeholders in an effort 
to reach agreement on a C&T data collection form.  CDC and the stakeholders will 
also explore the possibility of developing a shorter form for STD clinics for opt-out 
purposes.  A third form will be considered as well for settings not funded by CDC to 
collect minimal data on testing.
• CDC has prioritized and is currently taking actions to develop new HIV testing 
algorithms in 2007.  CDC is aware that current tests are outdated and do not reflect 
the range of new HIV tests on the market.
• CDC will review, consider and expand excellent models of practice for inclusion 
in implementation guides of the revised HIV testing guidelines.  The guidance 
on practice will cover the development of consent and testing forms, appropriate 
materials to display in waiting rooms, information to personally give to patients, 
and pre-test information in languages that would be understandable to persons 
undergoing routine HIV testing.
• CDC expects to partner with a professional organization to analyze existing laws 
and develop model language for confirmatory tests to facilitate streamlining of HIV 
testing.
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• CDC will review its STD Treatment Guidelines to ensure that this guidance does not 
conflict with previous recommendations on STD treatment.
• CDC’s domestic recommendations on HIV testing in the United States has no  
influence on the overall PEPFAR initiative.  However, CDC’s guidance might play a 
role in routine HIV testing administered by individual global partners.
Dr. McGuire noted that CHAC’s discussions on CDC’s activities are typically dominated 
by HIV/AIDS.  As a result, she thanked Dr. Fenton for including CDC’s viral hepatitis and 
STD activities in his comprehensive update.  She conveyed that this information would 
assist CHAC in providing guidance on both HIV and STD prevention and treatment.
Similar to Mr. Milan’s request during the HRSA session, Dr. McGuire also asked CHAC 
to make suggestions on CDC’s activities that should be considered as potential formal 
motions for submission to the CDC Director or HHS Secretary.  She listed four issues 
for CHAC to consider in this effort:
• The catalogue price of the HPV vaccine of $0/dose versus CDC’s proposed 
contract price of $96/dose.
• The Adult HBV Initiative, such as the actual value of catch-up vaccination for all 
children and adolescents <9 years of age; integration of hepatitis A into the Adult 
HBV Initiative; and minimal savings from the federal 37 program for states and local 
jurisdictions to purchase HBV vaccine.
• CDC’s efforts to integrate its HIV/AIDS, viral hepatitis, STD and TB prevention 
programs, particularly the need for more solid accountability, transparency and 
communications.
•  The need for CDC to develop a strategic and time-sensitive approach to monitor 
the extensive amount of effort and resources that will be devoted to implementing 
the revised HIV testing recommendations.  The need for CDC to create an effective 
process to address false-positive test results and other potential consequences of 
the revised HIV testing recommendations.
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Dr. McGuire concluded the session by confirming that CHAC would continue to discuss 
CDC’s revised HIV testing recommendations to further address concerns raised by the 
members.
Dr. George Roberts, Associate Director for Prevention Partnerships in NCHHSTP and 
co-chair of the CHAC Strategic Plan Workgroup, covered the following areas in his 
report.  From May 005-May 006, CHAC approved the establishment of the workgroup 
to review performance of the 00-005 Strategic Plan and make recommendations 
for updating the Strategic Plan during a three-year extension.  The workgroup was 
formed with two co-chairs and 30 members.  The workgroup convened two face-to-face 
meetings and presented its report to CHAC during the previous meeting.
The workgroup established several objectives to fulfill its charge.  Priority goals, 
objectives and broad strategies of the Strategic Plan would be reexamined.  Progress to 
date in reaching the goals and objectives would be discussed.  Reasons for the nation 
not achieving some of the goals would be discussed.  Gaps and necessary revisions 
in the goals and objectives would be identified.  Recommendations would be made for 
prioritizing objectives under each goal.  Strategies would be recommended to revise the 
Strategic Plan to achieve greater progress and success.
Numerous activities were conducted from July 005-May 006 for the workgroup to 
achieve the objectives.  Background materials were reviewed, such as relevant articles 
by CDC and external researchers, related plans, guidelines and technical information.  
Presentations were made on several issues, including CDC’s funding and activities for 
each goal, racial disparities, biomedical interventions and prevention effectiveness.
Strategies to increase the likelihood of reducing HIV transmission by 50% were 
presented to the workgroup from community, health department, care and policy 
perspectives.  Progress and barriers to reaching goals and objectives were reviewed.  
Recommendations were made on updating the goals and objectives.
The workgroup identified a number of barriers to achieving the goals and objectives.  
The Strategic Plan was not accompanied by a social marketing campaign to increase 
public awareness and engage stakeholders.  Endorsement of the Strategic Plan 
at national and community levels was lacking and led to minimal coordination and 
collaboration.  The scope and relevance of the Strategic Plan to other federal agencies 
were not well defined.
The Strategic Plan did not delineate macro-level and structural factors that influence 
HIV transmission.  Resources were inadequate.  Targeting of the Strategic Plan to 
MSM and communities of color was ineffective.  Effective preventive interventions were 
lacking for communities of color, particularly AAs and MSM.  HIV prevention, C&T and 
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care systems were disconnected.
Several common themes emerged from the workgroup’s discussions on updating 
the Strategic Plan.  An overarching racial/ethnic disparities goal should inform 
implementation of objectives and strategies for all goals.  A clear distinction should 
be made between goals and objectives related to PLWH and seronegative persons at 
risk of HIV infection.  Goals and objectives related to care should be better specified, 
particularly for maintaining persons in care.  Stronger language should be developed to 
emphasize the need for routine and available HIV testing in multiple settings, including 
non-healthcare facilities.
Interventions should be targeted to structural and social norms that lead to risk.  
Biomedical strategies should accompany behavioral interventions.  Interventions 
should be targeted to persons with acute HIV infection as a strategy to interrupt 
transmission during highly infectious periods.  Targeting for populations at highest risk of 
acquiring and transmitting HIV should be improved and based on incidence rather than 
prevalence.
The workgroup’s major recommendations are highlighted as follows.  To maintain the 
overarching numeric goal for reducing new infections, AAs should be prioritized at the 
highest level, within the overarching goal, and within each individual goal.  MSM should 
be prioritized within the goals as appropriate.  Racial/ethnic minority populations with a 
disproportionate burden of disease or incidence should be prioritized.
Under goal , separate prevention goals should be created for PLWH and seronegative 
persons at risk of infection.  Goals on testing and linkage to care should be updated.  A 
new goal should be added to address stigma and discrimination.  Goal 4 on surveillance 
and capacity-building should be eliminated because strategies and objectives for these 
issues should be included in all goals. 
The workgroup proposed five specific goals for the updated Strategic Plan:
• Goal :  By 008, decrease by at least Y% the number of PLWH at risk of 
transmitting HIV.
• Goal :  By 008, decrease by a least Y% the number of persons at risk of acquiring 
HIV.
• Goal 3:  Increase the percentage (from X% to Y%) of persons [of HIV-positive 
persons] in the United States who know their HIV infection status through routine 
testing in diverse settings.
• Goal 4:  By 008, increase from the current estimated ??% to ??%, the proportion 
of persons with HIV who are receiving appropriate prevention, care and treatment 
services.
• Goal 5:  Increase public awareness of HIV and reduce HIV-related stigma and 
discrimination.
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The workgroup recommended several issues that should be considered in updating all 
goals and objectives across the Strategic Plan.
• Improve all goals and objectives to achieve better targeting.  For example, testing 
efforts should be differentially targeted by prevalence and incidence.  The efficacy 
of improving interventions with the most infectious persons should be determined.  
Specificity should be increased for populations and settings where linkages to care 
would occur.
• Develop and use improved models to differentially assess efficacious and cost-
effective interventions and describe an optimal mix of interventions.  Include an 
expanded focus on system and structural interventions and necessary mobilization 
in this framework.
• Analyze resources at the objective level to allow goal targets and funding allocations 
to be adjusted and monitored over time.
• Develop a strategy regarding expanded resources for care.
• Develop a mechanism to appropriately align evaluation and capacity-building 
activities and resources in prior goal 4 across the new goals and objectives.
• Establish resources, necessary federal and other partners, and other scale-up 
models.
• Acknowledge that success of the updated Strategic Plan will depend on taking 
different approaches, clearly defining a road map, and implementing a detailed 
mobilization strategy.
• Monitor and annually report on progress of the goals.
To guide the discussion, Dr. McGuire and Mr. Milan informed CHAC that CDC needs 
specific guidance to take next steps on the updated Strategic Plan.  For example, CHAC 
should consider whether the originally proposed three-year extension should be 
expanded for an additional two years for a five-year updated Strategic Plan.  CHAC 
should identify solid strategies for CDC to allocate HIV prevention resources.  CDC 
should not be placed in a position of attempting to achieve the updated Strategic Plan 
goals in the current environment of inadequate resources.
CHAC applauded CDC’s efforts to support the workgroup’s charge of updating the 
Strategic Plan.  Most notably, CDC provided data and a wealth of expertise to assist the 
workgroup in making recommendations.  Several CHAC members made suggestions 
for CDC to consider in finalizing the updated Strategic Plan.
• A strong disclaimer should be included in the Strategic Plan to emphasize that the 
goals cannot be achieved without adequate resources.  The language should also 
note that insufficient funding was the major cause of the failure to reach the previous 
Strategic Plan goal of reducing HIV transmission by 50%.
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• CDC should leverage resources with federal partners and other sectors over time to 
develop a National Plan for HIV Prevention, Treatment and Care.
• CDC should take advantage of existing opportunities to pilot HIV prevention 
initiatives in collaboration with federal partners.  For example, 5% of Substance 
Abuse and Mental Health Service Administration (SAMHSA) block grants is set aside 
for HIV/AIDS in key states, but this option should be expanded and available to all 
states.  The 5% set-aside in SAMHSA block grants is not restricted in terms of pre-
/post-test counseling and wraparound services.  Due to current and future budget 
cuts, communities must be able to take advantage of HIV/AIDS dollars from sources 
other than CDC.
• The Strategic Plan should not be extended for an additional two years at this 
time due to current uncertainties, such as the upcoming implementation of CDC’s 
revised HIV testing recommendations, existing flaws in PEMS and severe budget 
constraints.
• CDC should sponsor another workgroup meeting to identify and discuss other 
priority populations for HIV prevention, such as AA heterosexual men, AA women, 
youth, Hispanics and Alaska Natives.  Prioritization of MSM and AAs in the Strategic 
Plan could be misinterpreted to mean that HIV is only a problem in these two 
populations.
• CDC should develop accountable, realistic, reasonable, attainable and measurable 
indicators to monitor progress of the Strategic Plan.
Dr. Robert Janssen, Director of DHAP, clarified that DHAP has not yet formally 
responded to the workgroup’s recommendations on the updated Strategic Plan because 
internal discussions are still underway.  However, he described several actions DHAP is 
considering to finalize the updated Strategic Plan.
DHAP intends to target resources to HIV testing of AAs and MSM if funds are allocated 
in the FY’07 appropriation for the President’s rapid HIV testing initiative.  DHAP is 
currently obtaining input from external partners on its heightened response to the HIV 
epidemic in the AA community.  DHAP expects to release a concrete plan from this effort 
in early 2007.  The guidance will reflect feedback DHAP gathered from its previous 
consultations and other activities to address the HIV epidemic in the AA community.  
DHAP will develop new strategies and use existing methods to sustain previous 
mobilization efforts in the AA community.
DHAP’s senior leadership will convene a budget and strategic planning retreat on 
November 8, 006 that will include a review of all Strategic Plan objectives and 
identification of the top ten priorities across all goals.  In preparation of the retreat, 
DHAP developed and added new objectives to the Strategic Plan goals that are 
consistent with the workgroup’s recommendations.
DHAP is collaborating with and obtaining input from both internal and external partners 
to develop a model for allocating resources and analyzing the impact of the HIV 
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epidemic.  DHAP expects to review results of the model in January or February 007.  
The data will assist DHAP in determining whether existing HIV prevention interventions 
are appropriate or if new models should be developed focusing on cost-effectiveness, 
the efficacy of interventions and the impact of the HIV epidemic.
DHAP incorporated stigma into each objective to address the workgroup’s new goal on 
this issue.  CDC’s revised HIV testing guidelines also address stigma by recommending 
universal screening instead of testing on the basis of risk factors.
DHAP will develop performance indicators to monitor progress on the Strategic Plan.  
DHAP expects to create annual targets for national HIV incidence and will develop other 
annual measures after CDC’s existing monitoring systems are refined.
Dr. Janssen concluded his comments by expressing strong support of the workgroup’s 
proposed recommendation for an additional two-year extension for a five-year updated 
Strategic Plan.
Panel Presentations on Issues Impacting  
the Strategic Plan
Ms. Jennifer Kates, Vice President and Director of HIV Policy at the Kaiser Family 
Foundation and a Strategic Plan Workgroup member, described issues that would 
affect the Strategic Plan.  Of the total FY’06 federal budget of $.6 trillion, $. billion 
or <% was devoted to HIV/AIDS prevention, care, treatment and research.  Although 
this amount represented a small percentage of the total FY’06 federal budget, federal 
funding for HIV/ AIDS dramatically increased from $0 in 98 to $.8 billion in the 
President’s FY’07 budget request.
In FY’06, 55% of the federal HIV/AIDS budget was mandatory as a result of Medicaid, 
Medicare, Supplemental Security Income, Social Security Death Index, and Federal 
Employees Health Benefits programs.  The remaining 45% of the federal HIV/AIDS 
budget was discretionary as a result of annual Congressional appropriations for 
the CARE Act and HIV/AIDS research, global, housing and prevention programs.  
Discretionary funding decreased from 98-006 because more persons are now living 
with HIV and are eligible for mandatory care and income assistance programs.  For 
example, 50% of federal funding for HIV/AIDS was allocated to research in FY’8, while 
58% was allocated to care and treatment and only 4% was allocated to prevention in 
FY’06.
Federal agencies are the primary recipients of domestic HIV prevention funding with 
the majority of these dollars allocated to CDC.  Of $869 million in federal funding for 
domestic HIV prevention in FY’06, CDC received $79 million or 83%.  CDC distributes 
these funds to states, cities, CBOs and other programs.  Other recipients of HIV 
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prevention funds include other federal agencies, state and local governments and 
private-sector groups.
CDC’s federal funding for domestic HIV prevention increased from $0 in FY’8 to $79 
million in FY’06 based on nominal dollars.  However, the FY’06 amount is nearly the 
same as FY’92 dollars based on inflation.  The President’s budget requests for domestic 
HIV prevention increased from $87 million in FY’05 to $956 million in FY’07.  Of the 
President’s FY’07 budget request of $956 million for domestic HIV prevention, $808 
million or 85% would be allocated to CDC, including a $93 million proposed increase.
In FY’05, CDC/DHAP distributed $374.6 million or 59% of its total $633.8 million 
budget to state and local health departments.  DHAP allocated the remainder of the 
budget to capacity-building, intramural programs, directly funded CBOs, research, 
program evaluation and interagency agreements.  DHAP’s HIV prevention funds to 
the top ten states in FY’05 ranged from ~$77.3 million to New York to ~$5.8 million to 
Massachusetts.
CDC’s HIV prevention budget is an important factor that CHAC must consider in 
providing guidance on the updated Strategic Plan.  For example, CDC’s revised HIV 
testing guidelines for routine screening are targeted to persons 3-64 years of age.  
According to the most recent U.S. Census estimates, ~00 million persons account for 
this population in the United States.  Of this population, ~. million are HIV-positive.  
Of this population, ~50,000 are HIV-positive and do not know their status.  CDC’s 
resources are targeted to reaching this population, informing these persons of their 
status, and making linkages to care.
Of ~. million HIV-positive persons in the United States, 5% are undiagnosed, 
5% are diagnosed and not in care, and 50% are in care.  PLWHA had the following 
insurance coverage based on 996 data:  3% with private insurance, 9% with 
Medicaid, 3% with Medicaid/Medicare, 6% with Medicare, and 0% uninsured.  More 
recent data collected in 00 from 7 HIV clinics throughout the country showed 
a change in insurance coverage of PLWHA:  34% with Medicaid, 6% with private 
insurance, 3% with Medicaid, 4% with Medicaid/Medicare, and 8% uninsured.
Data collected from 5 states from 994-000 showed that private insurance accounted 
for 33% of PLWHA at the time of diagnosis, Medicaid accounted for %, other public or 
government programs accounted for 9%, and no insurance accounted for 7%.  Data 
collected in 004 from 35 areas showed that 6% of AIDS diagnoses were made > 
months after HIV diagnoses.
Data collected in 00 on HIV testing by facility and diagnosis showed that hospitals, 
emergency rooms and community clinics diagnosed most HIV-positive patients.  Data 
collected in 003 on PLWHA by awareness of serostatus showed that undiagnosed 
persons were more likely to be AA and Hispanic based on race/ethnicity and MSM and 
heterosexual based on transmission.
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Ms. Kates summarized key points for CHAC to consider in providing further guidance to 
CDC on implementation of the updated Strategic Plan.  The Strategic Plan and revised 
HIV testing recommendations target two populations:  all persons 3-64 years of age for 
routine screening and a subset or <% of the population that is estimated to be HIV-
positive and undiagnosed.  The undiagnosed population is more likely to be uninsured 
persons of color, rely on public assistance, infected through sexual contact, and present 
to emergency rooms and community clinics.
Linkages to the care system will be critical in implementing the updated Strategic Plan 
and revised HIV testing recommendations because ~50% of diagnosed persons have 
no access to care and 39% are diagnosed late.  ADAP waiting lists; other barriers to 
the care system; and resources from federal, state and local systems will need to be 
addressed to implement the Strategic Plan.
Dr. David Holtgrave, of Johns Hopkins Bloomberg School of Public Health, provided 
additional data on issues that will affect the Strategic Plan.  Since the mid-980s, 
successful HIV prevention programs have led to a decrease in the number of new 
infections in the United States from 60,000/year to ~40,000/year.  The investment in 
HIV prevention also resulted in societal cost-savings.  Modeling has been performed 
to estimate the number of new infections that would have occurred each year without 
HIV prevention programs.  The scenarios projected that ~.5 million infections were 
prevented in the United States from 985-000.
The rate of HIV transmission from PLWH to seronegative partners dramatically 
decreased from ~00% in the early stage of the epidemic to 4% in 990.  These data 
showed that at least 96% of PLWH were not transmitting HIV in a given year.  HIV 
transmission rates are estimated to be 8.8%-0.8% in persons who are unaware of their 
HIV seropositivity and .7%-.4% in persons who are aware of their HIV seropositivity.  
C&T play a major role in the significant differences in HIV transmission rates between 
the two groups.  A paper that is in press showed a strong relationship between 
resources and HIV incidence after 985.
The overarching national goal in the 00 Strategic Plan was to reduce the number 
of new HIV infections in the United States from an estimated 40,000 to 0,000 per 
year by 005 with a particular focus on eliminating racial/ethnic disparities in new HIV 
infections.  The November 8, 005 edition of the MMWR contained an article on HIV/
AIDS diagnoses collected from 33 states with name-based reporting systems from 
00-004.  Over the four-year period, 57,5 diagnoses were made in the 33 states.  
These data suggested that HIV incidence in the United States was well over 40,000/
year in the United States in 005.
Sub-goal  in the 00 Strategic Plan was by 005, to decrease by at least 50% 
the number of persons in the United States at high risk for acquiring or transmitting 
HIV infection by delivering targeted, sustained and evidence-based HIV prevention 
interventions.  Progress on this goal is uncertain due to unclear language and the lack 
of national sexual behavior data.  However, a published study showed that HIV-positive 
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persons reduced risk behaviors by 68% after learning of their HIV seropositive.  Other 
data showed that ~.7%-.9% of the general U.S. population were at heightened risk 
of HIV due to sexual transmission, drug use risk behaviors or a current STD.
Sub-goal  in the 00 Strategic Plan was by 005, to increase from the current 
estimated 70% to 95% the proportion of HIV-infected persons in the United States who 
know they are infected through voluntary C&T.  The lack of progress on this goal was 
demonstrated by CDC’s estimate of a 73%-76% awareness level of HIV in 005.
Sub-goal 3 in the 00 Strategic Plan was by 005, to increase from the current 
estimated 50% to 80% the proportion of HIV-infected persons in the United States who 
are linked to appropriate care and treatment services.  The lack of progress on this goal 
was demonstrated by a 004 Institute of Medicine report that estimated only 49.7% of 
persons in need of highly-active ART actually received therapy.
For the updated Strategic Plan, the national goal should be maintained to reduce new 
HIV infections in the United States to 0,000/year or less by 00 and place particular 
emphasis on racial/ethnic health disparities.  However, the goal should be expanded 
to monitor progress with annual report cards on the national investment; develop 
process measures for policy implementation, reduce barriers and service delivery; 
and assess annual outcomes.  The goal will continue to be important because 5-6.3 
million persons are seronegative, but have behavioral risks for HIV infection.  CDC has 
estimated that ~. million PLWH are in the United States.  Of this population, ~5% are 
unaware of their status.
A meta-analysis showed that after PLWH obtain C&T, ~6% will still continue to engage 
in risk behaviors.  Based on these data, several sub-goals should be considered for the 
updated Strategic Plan.  Risk behaviors should be decreased and serostatus awareness 
should be promoted.  Care and treatment should be available to all persons who need 
these services.
Information should be more widely disseminated to the general public to combat stigma 
of HIV.  CDC should partner with the National Institutes of Health (NIH) to invest in 
and conduct research on new interventions to decrease stigma.  Serostatus-specific 
HIV prevention efforts should be targeted to HIV-positive persons; recently tested HIV-
negative persons who are at continued behavioral risk of infection; persons who are 
unaware of their HIV status; and the general population.
A paper that is in press analyzed the potential impact of HIV seropositivity awareness 
on HIV incidence via C&T.  The data showed that prevented HIV infections could be 
achieved by lowering the transmission rate from 9% to %.  An analysis that is currently 
under review for publication examined the costs and consequences of four HIV testing 
scenarios.  The analysis showed that if HIV screening rates were increased to 5% 
in the target population, ~65 million persons would need to be tested and ~56,000 
seropositive persons would be reached.  Total program costs of this effort were 
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estimated at ~$864 million.  The gross cost per avoided infection was estimated at 
$37,49.  To provide care and treatment for newly-diagnosed persons, ~$96.3 million 
would need to be set aside in the first year.  Overall, the analysis demonstrated that ~$1 
billion would be needed to support a new Strategic Plan.
Dr. Holtgrave summarized several issues for CHAC to consider in providing additional 
guidance to CDC on implementing the Strategic Plan.  C&T and serostatus awareness 
are important interventions, but are not sufficient to achieve an “HIV disease 
elimination” program.  As a result, HIV prevention interventions should be designed to 
include individual, dyad, family, group, community and structural levels, such as laws, 
policies, environments and social determinants.  HIV prevention interventions should 
also focus on sexual, perinatal and parenteral transmission, including interventions for 
small groups, communities and housing.  Structural interventions should be designed 
to strengthen social capital at the community level to impact STDs, AIDS and teen 
pregnancies.
HIV prevention programs have changed the course of the epidemic in the United States, 
but additional progress must be made to further reduce the number of new infections.  
Previous efforts should be scaled-up to conduct activities in the future and allocate 
resources for these initiatives.  HIV prevention programs have decreased incidence, 
but flat funding of these activities must be addressed.  Targeted HIV C&T might have 
substantially more public health benefits than opt-out testing at the same cost.
Additional promotion of serostatus awareness via C&T might decrease the national 
annual incidence of 40,000 new HIV infections to 5,000-30,000 for a true HIV disease 
elimination program in the United States.  However, serostatus awareness will play 
a minimal role in further reductions in incidence.  A multi-component, multi-level and 
comprehensive National Plan for HIV Prevention, Treatment and Care for the United 
States is urgently needed as soon as possible.  The new national plan should be 
supported by substantial resources to provide high-quality HIV care and treatment to 
persons newly diagnosed with HIV through C&T campaigns.
To guide the discussion, Dr. McGuire and Mr. Milan emphasized the importance of 
CHAC providing guidance on models and resources for implementation of the updated 
Strategic Plan and the need to develop a new National Plan for HIV Prevention, 
Treatment and Care.
Several CHAC members suggested additional issues that should be considered in 
implementing the updated Strategic Plan.
• A new strategy should be developed to collect surveillance data on diseases to 
ensure these variables are clearly defined.
• Data from the HIV prevention economic models should be re-analyzed to determine 
cost-savings from HIV-positive persons who were diagnosed, received care and 
engaged in safer practices.
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• The intersection between violence and HIV should be included in structural 
interventions.
• CDC should attempt to allocate resources and take other actions at this time to 
advance toward an HIV disease elimination program.
• Quantifiable goals should be incorporated into the updated Strategic Plan to assist in 
obtaining a justified budget that is based on the science and actual numbers of HIV-
positive persons.
• CHAC should make strong recommendations for increased funding to reduce the 
number of new HIV cases.  For example, language could be included in the updated 
Strategic Plan or a companion document to emphasize that new resources will be 
needed to implement the prioritized interventions and other innovative strategies to 
further decrease the number of new HIV infections per year.
• The Strategic Plan should outline approaches to address new barriers to providing 
HIV prevention, education treatment and care in the future.  For example, the 
change in the CARE Act legislation for HIV-positive persons to be identified through 
name-based reporting systems in 007 might undermine these efforts.
Mr. Carl Schmid, of The AIDS Institute (TAI), made comments on two topics CHAC 
discussed during the meeting.  First, TAI acknowledges the importance of implementing 
a reauthorized CARE Act in 007.  A delay in implementing the new law in 008 would 
create major funding disruptions in several states and local jurisdictions.  HIV case 
counts must be included in 007 according to the legislation and some states do not 
have HIV case counts that have been accepted by CDC.
Second, TAI strongly supports CDC’s revised HIV testing recommendations that call for 
routine voluntary HIV testing in healthcare settings, but certain aspects of the guidelines 
should be addressed.  The broader HIV/AIDS community should be included in CDC’s 
implementation plans for the revised HIV testing recommendations.  Written information 
on HIV should be developed and disseminated because the guidance does not require 
prevention counseling through informed consent.  Other components that would be 
included in consent and post-test counseling processes should be widely communicated 
to constituents.
TAI is pleased that CDC’s revised HIV testing recommendations reflect its previous 
suggestions on opt-out testing, the provision of basic HIV information, and the 
distribution of materials in multiple languages.  TAI is interested in learning about the 
implementation plans for the revised HIV testing recommendations and looks forward to 
collaborating with CDC in this effort.
Public Comment Period
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Ms. Thelma King Thiel, of Hepatitis Foundation International (HFI), urged CDC and 
HRSA to target prevention, care and treatment efforts to persons <6 years of age.  
The Strategic Plan should describe primary prevention and educational interventions to 
encourage young persons to adopt healthy lifestyle behaviors and strongly recommend 
implementation of these efforts in schools.  HFI’s previous and ongoing training 
sessions, evaluations and other joint projects with diverse groups at federal, state, local 
and private levels have shown that hepatitis testing would save healthcare dollars.
Ms. King Thiel particularly thanked CDC for assisting HFI in developing and widely 
distributing school-based products.  She confirmed that HFI would continue to 
collaborate with CDC, SAMHSA, schools and other organizations to widely promote 
primary prevention among youth.
Dr. Marsha Martin, of the Washington, DC Administration for HIV Policy and Programs 
(AHPP), informed CHAC that the majority of HIV testing occurs in privately-financed 
medical settings.  However, no efforts are being made in the private sector to assist 
grantees in collecting data to manage HIV screening and coordinate care.
The HIV epidemic cannot be appropriately managed unless both public and private 
systems are included in a coordinated effort for purposes of data, care and other 
components.  For example, AHPP has no data on persons who are screened by 
healthcare maintenance organizations, student health centers and other private 
healthcare settings because CDC only requires reports of HIV-positive results from 
private facilities.
Dr. Martin urged CDC and HRSA to make stronger efforts to assist grantees in 
integrating data from both public and private sources.  She provided CHAC with 
background materials on AHPP’s campaign that was launched to routinize HIV 
screening.
With no further discussion or business brought before CHAC, Mr. Milan recessed the 
meeting at 4:40 p.m. on November 006.
Dr. McGuire reconvened the CHAC meeting at 8:3 a.m. on November 4, 006 and 
yielded the floor to the first presenter.
Dr. Howell Wechsler, Director of the CDC Division of Adolescent and School 
Health (DASH), provided an update on CDC’s adolescent sexual and reproductive 
health activities.  Of all high school students in the United States, 47% are sexually 
experienced.  Persons 5-4 years of age account for nearly 50% or 9. million of all 
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new STDs acquired each year.  Based on data from 33 states with confidential name-
based HIV infection reporting systems, an estimated 4,84 HIV cases occur annually 
among persons 5-4 years of age.  Persons 5-9 years of age account for 83,000 of 
all pregnancies that occur each year.
Recent trends in STD, HIV and teen pregnancies are summarized as follows.  Since 
the early 990s, the percent of sexually active youth has decreased and the use of 
condoms and contraception has increased among sexually active youth.  Improved 
screening has led to increased rates of some STDs.  Pregnancy rates have decreased 
overall, but smaller reductions were seen in ethnic/minority youth.  Most recent data 
suggest that rates are not continuing to decrease and have remained level in most 
states.
Racial/ethnic populations are disproportionately affected by these trends.  The rate of 
sexual intercourse is 68% among AA high school students compared to 5% among 
Hispanics and 43% among whites.  AA adolescents represent 70% of all HIV/AIDS 
cases among persons 3-9 years of age.  Data from 004 showed that Hispanics 
accounted for ~83% of teen births compared to 6% among AAs and ~7% among 
whites.  The 47% decline in teen birth rates among AAs was the largest compared to 
whites and Hispanics.
CDC recently published a paper on the percentage of high school students who ever 
had sexual intercourse by race/ethnicity from 99-005.  The data showed a dramatic 
reduction in AA students who had sexual intercourse through the 990s, but the 
decrease has stopped since 00.  The slight reduction in sexual intercourse among 
Hispanic adolescents was not statistically significant.
DASH, DHAP, DSTDP and the CDC Division of Reproductive Health formed an 
internal Workgroup on Adolescent Sexual and Reproductive Health (WASRH) which 
developed a report on CDC activities in this area.  The four divisions allocated a total of 
$77.3 million to conduct 9 different youth projects in three categories:  () research 
on adolescent sexual and reproductive health; () direct services for HIV, STD and 
pregnancy prevention; and (3) training, technical assistance and capacity-building 
programs for adolescent sexual and reproductive health.
For the research category, the four divisions have conducted studies on sexual risk 
behaviors, pregnancy, STDs and HIV.  The projects were designed as observational, 
surveillance, intervention or primary prevention studies in various units and settings, 
such as individual, group, family or community units and clinic, community, school or 
juvenile justice settings.  A three-phased activity was conducted to identify, package 
and disseminate evidence-based interventions.  Collaborations were established with 
national organizations and state teen pregnancy coalitions to assist local groups in 
selecting, adapting and implementing science-based programs.
For the direct services category, the four divisions provided STD screening and 
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treatment, HIV C&T, training for peer-based education and support, social marketing 
campaigns, prevention education, behavioral interventions, infrastructure development, 
surveillance and program evaluation.  Funding was awarded to ten CBOs to offer 
prevention programs to young MSM of color.
Of the populations served across sites, ~50%-80% were < years of age.  At least 
0% of youth were included in 35 state and local health departments that were funded 
to provide program services.  Seven CDC programs targeted or provided services to 
HIV-infected youth or youth at high risk for HIV, such as MSM, female sex workers, 
homeless youth and youth in juvenile justice systems.  CDC supported comprehensive 
STD prevention systems through its Infertility Prevention Program, 50 state health 
departments and seven local health departments.
For the capacity-building assistance category, the four divisions provided information, 
technical assistance, training and technology for persons and organizations to improve 
service delivery and effectiveness.  These services were targeted to education agencies 
at state, territorial and local levels, national NGOs, state teen pregnancy coalitions, Title 
X regional training centers and CBOs.  The capacity-building activities were designed 
for utilization of science-based approaches to promote adolescent reproductive health, 
consumer outreach, recruitment, training, leadership development and strategic 
planning.
Dr. Wechsler concluded his update by responding to CHAC’s request during the 
previous meeting for more information on CDC’s adolescent sexual and reproductive 
health activities.  The Health Education Curriculum Analysis Tool (HECAT) was 
developed to provide evidence-based guidance to schools on selecting curricula that 
would most likely be effective in improving the health of young persons.  HECAT has 
been undergoing the HHS clearance process for more than one year.
DASH provided input on a document that was developed by the Office of Population 
Affairs on a scientific process for abstinence-only grantees to plan abstinence programs 
with a more rigorous approach.  This document has been undergoing the federal 
clearance process for .5 years.  Two evidence-based interventions developed by 
DHAP are still undergoing the HHS clearance process.
Dr. Wechsler also pointed out that materials were distributed to CHAC.  One handout 
described individual projects and funding amounts for 7 national non-governmental 
organizations that were awarded to support HIV prevention for youth over the next five 
years.  Another handout described additional HIV projects conducted by other grantees.  
Overall, Dr. Wechsler was pleased that CDC’s current activities are eliminating silos and 
barriers to streamlining services for young persons.
Dr. Jose Morales, of HRSA, described HRSA’s services for adolescents living with 
HIV/ AIDS.  HRSA is an access agency with programs that are designed to provide 
care to persons with HIV, ensure the quality of care, include secondary prevention and 
decrease transmission.  Under Title IV of the CARE Act, HRSA implements 7 programs 
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specifically for youth living with HIV/AIDS and provides services to this population 
on the basis of gender, race/ethnicity and exposure.  HRSA’s total budget for the 7 
youth programs is ~$4 million.  Demographics of clients in Title IV programs are % 
transgender with an equal balance between males and males, 65% AA, 0% Hispanic, 
34% with heterosexual contact, 6% MSM, and 4% perinatal.
HRSA’s Title IV programs on sexual and reproductive health foadolescents are 
guided by the following strategies.  Additional morbidity should be limited with annual 
gynecological tests and PAP smears for young female adolescents.  Appropriate routine 
testing of STDs should be administered to young female adolescents.  Mother-to-child 
transmission should be prevented with ART.  Early prenatal care should be available to 
improve health.  ART should be provided to neonates.  HRSA’s Title IV programs are 
required to link to Title X programs and include family planning services through either 
referrals or onsite pregnancy tests.
HRSA takes several actions to monitor the quality of care of Title IV programs for 
adolescents.  Close communication and coordination are maintained with grantees 
through regular contact with project officers, compliance site visits and technical 
assistance.  Under the National Quality Center, grantees can use the HIVQUAL method 
and other quality processes to focus on annual syphilis testing, Pap smears and 
other testing for other STDs.  HRSA’s focus on quality in 007 will assist providers in 
improving efforts to obtain Pap tests.
HRSA established several criteria to determine the success of its Title IV programs 
for youth.  Activities should be client-centered to meet the needs of clients from both 
developmental and geographical perspectives.  Interventions should be designed to be 
client-driven, non-judgmental and caring.  Services and systems should be integrated 
to serve different types of youth, including gay, lesbian, bisexual, transgender, 
heterosexual and street youth.  Referrals should be incorporated into programs to 
decrease the loss of clients.  Collaborative efforts should be undertaken with testing 
sites to reduce the time between discovery of HIV infection and entry into care.
Peers should be used for case finding, C&T and speaking to youth.  Youth should be 
trained and employed for outreach, education and C&T.  Youth should be educated to 
deliver education in schools and other community settings.  Case finding should be 
performed in high-risk situations and should be consistent in reaching these areas.  
Multiple strategies should be implemented to reiterate consistent messages.  The role 
of peers should be obvious and identifiable.  Appropriate services should be offered to 
establish trust with potential clients.
HRSA is currently funding eight demonstration projects under the SPNS initiative 
targeting young MSM of color.  The projects are focusing on outreach, care and 
prevention for young HIV-infected men 3-4 years of age.  Three key objectives were 
established for the projects.  Innovative outreach strategies would be supported to 
assist HIV-infected persons learn their status.  HIV-infected persons would be linked 
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with primary care services that are appropriate for youth.  Transmission of HIV infection 
would be prevented among target clients.  The grantees are now completing the 
third year of the five-year funding cycle of the young MSM of color initiative and have 
established a web site with strategies, project summaries and other information to 
monitor progress and resources.
AETCs are using a variety of tools to educate providers on offering education, 
training and other services for adolescents living with HIV/AIDS.  For example, the 
Pennsylvania/Mid-Atlantic AETC developed a series of reference tools on case finding, 
primary and secondary prevention for adolescents, clinical risk assessment and 
screening.  HRSA will continue its close collaborations with CDC to ensure that project 
officers in the two agencies coordinate prevention, care and treatment efforts with 
the same grantee.  The partnership has served as a valuable mechanism for HRSA 
and CDC project officers to communicate on a regular basis, share information and 
maximize resources.
Dr. Morales confirmed that HRSA will continue to develop innovative strategies to 
address challenges in its Title IV programs for adolescents.  The most effective C&T 
models will be identified to find and retain infected youth in care.  Assistance will be 
provided to transition youth to adult care systems to ensure continuity of care and other 
services.
Mr. Shepherd Smith, of The Institute for Youth Development, described strategies to 
incorporate public health principles into HIV/AIDS prevention for youth.  The primary 
predictor of an individual acquiring HIV or another STD is the number of lifetime sexual 
partners.  The age of sexual debut plays a significant role in the number of lifetime 
sexual partners.  Two studies showed tremendous differences between adolescents 
with sexual debut at <4 years of age versus those with sexual debut at >7 years of 
age.  The risk of acquiring an STD was 30-fold higher and the risk of having >6 sexual 
partners by 0 years of age was 7.5-fold higher with early sexual debut compared to 
delayed sexual debut.  The results were similar between sexually active males and 
females.
A study showed that the median age at sexual debut was 4.5 years among HIV-
positive females compared to 5.5 years among HIV-negative females.  The median 
number of lifetime partners, acquisition of any STD and rates of unprotected vaginal sex 
were higher in HIV-positive females, but regular condom usage was the same between 
the two groups.
A study showed that forced or unwanted sex among female teens was higher at earlier 
ages.  A study was conducted with students in grades 9- who reported having >4 
sexual partners during their lifetime.  The findings showed that this population is at 
highest risk, but have the lowest usage of condoms on a regular basis.  By race/
ethnicity and gender, young AA males were found to be at highest risk compared to 
Hispanics, whites and females.
7
Findings from all of these studies emphasize the need to better articulate the benefits 
of delayed sexual debut and a reduction in sexual partners.  Activities targeted to youth 
do not clearly communicate the following messages:  “more risk with more sexual 
partners;” “less risk with fewer sexual partners,” and “virtually no risk with one lifetime 
uninfected partner.”  Youth programs also do not specifically target messages to young 
males about forced or unwanted sex with females.
Several factors have a positive influence on youth.  Data show that parents, particularly 
those with high monitoring of their children, are the primary influence on delayed sexual 
debut.  Youth who eat dinner with their parents >5 times per week are less likely to 
use alcohol, tobacco or marijuana compared to youth who infrequently eat dinner with 
parents 0- times per week.  Shared family meals facilitate accountability, bonding and 
communication.  Youth who develop refusal skills regarding sexual activity are less likely 
to attempt suicide or engage in other risky behaviors.
A study showed that youth were extremely challenged by achieving perfect use of 
contraception because the subjects chose intimacy rather than correct usage.  In a 
study with males who were taught about condom use during college, 60% did not 
discuss condom use with partners before sex; 43% put condoms on after starting sex; 
4% wanted to use condoms, but had none available; 40% did not leave space at the 
tip of the penis; 3% lost erections in association with condom use; 30% placed the 
condom on upside down; and 5% removed the condom before ending sex.
Mr. Smith pointed out that several conclusions can be reached based on data from the 
youth studies.  One lifetime partner should be a universal goal and mentioned often 
in HIV prevention messages.  Emphasis should be placed on limiting the number of 
partners.  All youth should be encouraged to delay sexual debut.  More attention and 
resources should be directed toward gay, AA and Hispanic youth.  Specific programs 
should be developed to reduce the number of partners in these populations.
More education should be provided to parents about their responsibility to the sexual 
health of their children.  More support should be offered to after-school programs.  
NCHHSTP should closely collaborate with DASH to develop more youth programs.  
For example, DASH has developed strong relationships with numerous youth-serving 
organizations, while NCHHSTP has the science base and expertise in HIV/AIDS 
and STDs.  DASH’s organizational network and NCHHSTP’s knowledge should be 
combined to jointly provide HIV and STD education to adolescents.
Dr. David Wiley, Professor of Health Education at Texas State University, described 
several efforts schools can undertake to end the conspiracy of silence regarding HIV 
and STD prevention and treatment for youth.  Data were collected and evaluated on 
the characteristics of effective curriculum-based programs.  The focus on behavior 
should be specific and narrow, such as delaying sex or using condoms.  Theoretical 
approaches with demonstrated efficacy in influencing other risky health-related 
behaviors should be replicated.
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Clear messages should be communicated about sex and protection against STDs or 
pregnancy.  Basic rather than detailed information should be provided.  Peer pressure 
should be addressed.  Communication skills should be taught.  Interactive activities 
should be incorporated.  The age, sexual experience and culture of young persons in 
the program should be reflected.  Programs should last at least >14 hours.  Leaders 
should be carefully selected and trained.
In terms of laws for sexuality and STD/HIV education in U.S. schools, the District 
of Columbia and 9 states require sexuality education, while 3 states do not have 
this requirement.  The District of Columbia and 36 states require STD and HIV/
AIDS education, while 5 states do not have this requirement.  The content of these 
requirements varies among states, such as a full-fledged curriculum approved by the 
state, local rather than state control of the law, guest presenters speaking to a class, 
or distribution of materials to students.  Title V grantees must adhere to eight federal 
mandates of an abstinence educational or motivational program.
Federal funding for abstinence-only sexuality education progressively increased over 
the years with Texas serving as the largest recipient in 005.  Texas has no approved 
curriculum for sexuality education, but a textbook was developed for this purpose.  
However, the textbook does not mention contraception and uses “scare tactics” about 
the possibility of being prosecuted for rape or sex with a minor.
Texas spends >$9 billion each year to address teen pregnancies and the consequences 
of unintended births.  In 004 alone, these costs included $65 million for public health 
care, $83 million for child welfare, $6 for incarceration of youth of teen mothers, and 
$349 million for lost tax revenues.  Taxpayers in Texas spent $5. billion to support 
>745,000 teen births between 99-004.
Dr. Wiley encouraged all states to consider available options to improve HIV and STD 
prevention and treatment programs for youth.  For example, existing state mandates 
should be reviewed to determine if federal funding can be more flexible to discuss all 
sexual options with youth.
The Florida, Kansas and South Carolina Departments of Education convene “Finding 
Common Ground Summits” with supplemental abstinence funding from CDC.  Staff from 
abstinence-only, planned parenthood, comprehensive and family programs attend the 
summits in an effort to identify areas where agreement can be reached at the local level, 
such as sharing resources at health fairs and presenting packets of materials to school 
districts from all programs.
Cadre members are trained and team-building activities are conducted to develop 
more effective youth programs.  Action planning summits are held six months later and 
activities are followed at the state level.  The summits have been extremely successful 
in convening staff from various programs with diverse perspectives to communicate, 
collaborate and cooperate in HIV and STD prevention and treatment programs for 
youth.  Efforts are underway to replicate the summits in more states.
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HECAT provides evidence-based guidance to schools on designing, selecting and 
evaluating appropriate curricula for youth.  However, HECAT is still undergoing the HHS 
clearance process and cannot be distributed to schools at this time.  CHAC should 
make a strong recommendation to the HHS Secretary to expedite the clearance process 
for immediate dissemination of HECAT to schools.
A stronger focus should be placed on developing and distributing culturally-appropriate 
materials to underserved populations, particularly AA and Hispanic youth.  School board 
members, administrators and teachers should be trained and informed about solid 
data that show linkages between student health outcomes and academic achievement.  
Assistance should be provided to schools on developing policies for HIV, human 
sexuality education and testing.  Schools should be supported with advocacy and skills 
on managing controversies related to HIV and STD prevention and treatment programs 
for youth.
Several CHAC members made suggestions for CDC and HRSA to consider in refining 
national strategies to prevent and treat HIV and STD infection in youth.
• More emphasis should be placed on involuntary sexual debut through force, 
domestic violence or other types of abuse in the home.  Appropriate messages on 
this issue should be developed and delivered beginning at the first-grade level.
• A clear distinction should be made between “functional” and “dysfunctional” families.  
For example, youth who eat dinner with their parents >5 times per week could 
be just as likely to engage in risky behaviors as those who share meals with their 
parents on a more infrequent basis.
• Stronger efforts should be made to engage the media in youth initiatives because 
the vast majority of advertisements and entertainment programs promote sex.
• Parents should be educated about the critical importance of serving as true role 
models.  For example, adolescents will be less likely to follow parental advice if 
parents have multiple sex partners, give birth to children out of wedlock, and engage 
in the same risky behaviors as youth.
• HRSA should include pregnancy prevention and hepatitis B and HPV vaccination in 
its strategies to limit additional morbidity of STDs among youth.
• HRSA should reconsider its focus on annual syphilis testing because this infection 
has a larger impact on older adults than youth.  Emphasis should be placed on the 
ongoing chlamydia epidemic because this infection primarily affects persons <0 
years of age.
• Copies of articles should be distributed and references should be provided for 
studies that are used to support youth programs.  Inaccurate data will continue 
to serve as a barrier to effective implementation of HIV and STD prevention and 
treatment initiatives for youth.  For example, a study cited in one of the panel 
presentations on infection rates with HIV prevention tools was flawed in several 
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areas.  The study showed that condoms resulted in an 80% infection rate of HIV 
after a decade of use.  However, no data from any other source have shown that 
condoms led to even an 8% infection rate per year.  Oral acyclovir and vaccines 
were described as HIV prevention tools in the study, but no data have been 
published in this area.  The study referred to a decade of female condom use, but 
efficacy data have not been collected in this area for the past ten years.  No solid 
data were provided to support the statement that 75% of persons were infected after 
a decade of life with no knowledge of the population or discordant couples.
• More emphasis should be placed on reaching high-risk youth in the non-general 
population.  For example, curriculum- or school-based programs would not be 
effective for AA and Hispanic youth, high school dropouts, homeless youth with no 
family foundation or youth sex workers.
• Innovative strategies should be developed to reach youth who use the Internet for 
sex.  For example, HIV prevention and other health education materials could be 
developed and posted on the “My Space” web site, chat rooms and other Internet 
tools used by youth.
Mr. Milan informed CHAC that Dr. McGuire would no longer serve as the CHAC co-
Chair after the current meeting because her term would expire on November 30, 006.  
Dr. Temoshok raised the possibility of CHAC making a formal recommendation to 
extend Dr. McGuire’s term for an additional year due to her ongoing involvement in the 
Strategic Plan Workgroup and other CHAC activities.
Dr. Fenton clarified that this request would most likely not be honored because Dr. 
McGuire has served for two consecutive terms as a member and co-Chair.  However, he 
explained that Dr. McGuire could still be involved in CHAC’s activities as a workgroup 
member or external consultant.  The participants applauded Dr. McGuire’s diligent 
efforts, dedication and commitment during her outstanding service as the CHAC co-
chair.
Mr. Milan entertained a motion to approve the previous minutes.  A motion was properly 
placed on the floor and seconded by Drs. Leoutsakas and Garcia, respectively.  CHAC 
unanimously approved the May 7-8, 006 Meeting Minutes with no changes or 
further discussion.
Mr. Milan reviewed issues that the members raised during the meeting or suggested to 
him and Dr. McGuire off-line as CHAC’s potential formal motions or letters of advice to 
the CDC Director, HRSA Administrator or HHS Secretary.




• Strategic Plan issues:  () creation of a coordinated National HIV Strategic Plan with 
cross-sector and cross-agency resources; () a related or separate Strategic Plan 
for AAs; (3) an additional two-year extension for a five-year Strategic Plan, including 
annual targets, resource requirements and strategies for AAs; and (4) development 
of models for resources needed for each year of the Strategic Plan.
• Issues related to CDC’s revised HIV testing recommendations:  () projections of 
newly-diagnosed HIV cases identified through the new HIV testing initiatives; (2) 
implementation in both public and private sectors; (3) standardized language or 
best practices for HIV testing consent forms; and (4) development of HIV testing 
algorithms for private laboratories.
• Refined projections by HRSA on the current number of PLWH affected by the 
Medicare Part D donut hole and strategies to ensure continued HIV care for these 
clients.
• Completion of the HHS clearance process for HECAT.
• STD issues:  () consistent messages to implement CDC’s STD Treatment 
Guidelines; and () future activities and resources by DASH and DSTDP to reduce 
the number of STD infections in the United States.
• Inadequate funding of the CDC Division of Viral Hepatitis and the need for more 
resources for hepatitis prevention, C&T and vaccine distribution.
• Response by HRSA, CMS and NIH on treatment and care for newly-diagnosed HIV-
positive persons.
• Development of medical protocols by HRSA and CMS for HIV and STD testing and 
treatment.
• CDC’s approaches to resolve problems with PEMS data elements.
• Specific language in the reauthorized CARE Act to allow for a transition period for 
states that have not converted to name-based reporting systems.
• Recognition of HRSA’s outstanding efforts during a time with no reauthorization of 
the CARE Act.
CHAC extensively discussed the issues Mr. Milan proposed as potential formal motions 
or letters of advice to the agencies.  The deliberations resulted in CHAC making ten 
formal motions to the CDC Director, HRSA Administrator or HHS Secretary.  All ten 
of the formal motions were properly placed on the floor and seconded by voting 
members and unanimously approved by CHAC.
. CHAC recommends that the HHS Secretary seek supplemental funding in the 
FY’07 budget to meet current program needs for domestic HIV, STD and hepatitis 
prevention, treatment and care.
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. CHAC recommends that the HHS Secretary request FY’08 and FY’09 budget levels 
for domestic HIV, STD and hepatitis prevention, treatment and care which move 
beyond historic flat funding levels and provide significant new resources to meet 
program and domestic needs.
3. CHAC recommends that CDC revise the draft HIV Prevention Strategic Plan 
with the following changes.  The first two bullets under the “summary of 
recommendations” on page 5 should be deleted.  The third bullet should be 
modified with the following language:  “Prioritize racial, ethnic and sexual minority 
populations as well as demographic groups with disproportionate burden of 
disease/incidence where funding prioritization is linked to the degree of burden/
incidence.  On the basis of current epidemiology, highest priority in implementation 
of the Strategic Plan should be given to high-risk AAs and MSM within the goals as 
appropriate.”
4. CHAC recommends that CDC extend the Strategic Plan to 00 and include annual 
indicators of progress.
5. CHAC recommends that the HHS Secretary take the following actions:  () The 
HHS Secretary should initiate the development of a multi-sectoral National Plan 
for HIV Prevention, Treatment and Care that addresses activities of all sectors 
and includes all relevant federal agencies.  () The HHS Secretary should provide 
CHAC with a status report on progress in developing the National Plan by the next 
CHAC meeting.  (3) The HHS Secretary should request that the President support 
and impanel a committee to develop the National Plan.  (4) The HHS Secretary 
should meet with CHAC or its co-Chairs on the development of the National Plan.
6. CHAC recommends that CDC develop projections for the number of newly 
identified HIV-positive persons who might be identified through its new HIV testing 
initiatives.  CHAC further recommends that CDC develop models for financial 
resources needed to successfully implement the updated HIV Prevention Strategic 
Plan.
7. CHAC recommends that HRSA continue to refine its estimates of the number of 
HIV-positive persons who would be impacted by the Medicare Part D donut hole.  
CHAC further recommends that HRSA develop strategies to support and maintain 
health coverage for these individuals.
8. CHAC recommends that the HHS Secretary expedite final clearance of the HECAT 
curriculum for STDs among youth because this evidence-based guidance is a 
critical need in the field.
9. CHAC recommends that CDC develop projections and models of needed resources 
for promoting national control of HPV, genital herpes, chlamydia, gonorrhea and 
syphilis.
0. CHAC recommends that the co-Chairs draft a letter to the HHS Secretary with the 
formal motions approved during the meeting and a delineation of percent increases 
for the funding requests.
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In addition to approving the ten formal motions, CHAC also took actions to address 
other issues.  CHAC agreed that CDC would complete the development of the goals, 
objectives and targets in the Strategic Plan.  CDC would finalize and distribute the 
Strategic Plan to each CHAC member no later than March 3, 007 in preparation of a 
discussion of the document during the May 007 meeting.
CHAC identified several items to be placed on the next meeting agenda:
• Progress report by DSTDP on CHAC’s formal motion to promote national control of 
HPV, genital herpes, chlamydia, gonorrhea and syphilis.
• Presentation by CDC and HRSA on prevention strategies with the Internet, text 
messaging and other technologies that could be used to reach young MSM of color 
and other high-risk populations.
• Presentation by CDC and HRSA on HIV prevention, care and treatment targeted to 
Native Americans, Alaska Natives and Native Hawaiians.
• Update by HRSA on the CARE Act.
• Presentation by an HHS representative on the HHS department-wide strategic plan 
and its relationship to HIV and STDs.
• Overview by CDC on its approaches to generate, collect and utilize surveillance 
data, particularly information gathered on MSM.
• Progress report by CDC on the ongoing development of laboratory algorithms for 
HIV testing and confirmation in the context of rapid HIV tests.
Ms. Shay Welch emphasized the critical need for federal agencies to gather HIV data 
in Indian Country.  Existing systems do not collect or report HIV data in Indian Country 
despite the disproportionate and alarming rate of HIV infection.  Education and other 
HIV activities targeted to Indian Country are limited.  Tribes have government-to-
government relationships and are not captured in federal data sets.  American Indians 
are frequently misclassified in reporting systems.  The HIV epidemic is causing a 
reduction in the overall Indian population.  
Ms. Welch urged CHAC, HHS, CDC, HRSA and the Indian Health Service to serve as 
voices for indigenous people and consult with Indian Country.  For example, CHAC and 
the federal agencies could convene a workgroup of American Indians to obtain feedback 




Mr. Milan announced that the current proceedings would be the final CHAC meeting 
in the 5th year of HIV/AIDS.  He thanked the members for their continued support, 
dedication and commitment to PLWHA in the United States.  He was extremely proud 
that the passion, expertise, advocacy and knowledge of the CHAC members have 
significantly contributed to improving the quality of life of PLWHA.  Mr. Milan looked 
forward to continuing to participate in CHAC’s efforts to end the HIV epidemic through 
prevention and provide service to persons in most need.
The next CHAC meeting would be held on May 7-8, 007 in Atlanta, Georgia.  With no 
further discussion or business brought before CHAC, Mr. Milan adjourned the meeting 
at : p.m. on November 4, 006.
I hereby certify that to the best of my knowledge, the foregoing Minutes of the 
proceedings are accurate and complete.
___________________                  ___________________________________
Date                    Jean Flatly McGuire, Ph.D., Co-Chair
                    CDC/HRSA Advisory Committee on
                    HIV and STD Prevention and Treatment
___________________                  ___________________________________
Date                              Jesse Milan, Jr., JD, Co-Chair
                              CDC/HRSA Advisory Committee on
                    HIV and STD Prevention and Treatment
Closing Session
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CDC HIV Prevention Strategic Plan Through 2005
Highlights of CDC Activities that Address  
the Goals and Objectives
Goal 1- “By 2005, decrease by at least 50% the number of persons 
in the United States at high risk for acquiring or transmitting HIV 
infection by delivering targeted, sustained and evidence-based  
HIV prevention interventions.”
CDC has currently implemented three indicators to monitor the progress towards 
achieving Goal 1.  The first indicator is “the percentage of students in 9th through 12th 
grade who report that they have never had sexual intercourse; or, if they have had 
sexual intercourse, not in the past month; or, who have had sexual intercourse in the 
past 3 months and used a condom.”  The most recent data for this indicator from 003 
showed that 87.5% of 9-th graders had never had sexual intercourse; .3% had sex, 
but not in the past month, and .3% had sex in the past 3 months but used a condom.
The second indicator is “among persons diagnosed with HIV infection for > months 
and interviewed in the Supplement to HIV/AIDS Surveillance (SHAS) project, the 
percentage who did not use a condom at last vaginal/anal sex when the status of the 
partner was unknown.”   The most recent data for this indicator from 004 showed 
3.4% of HIV-infected persons did not use a condom at last sex with their partner of 
unknown status.
The third indicator is “among persons diagnosed with HIV infection > months and 
interviewed in SHAS, the percent of injection drug users (IDUs) who shared a needle 
or syringe with someone in the past  months.”  The most recent data for this indicator 
from 004 showed that 7% of HIV-infected persons shared needles.
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Performance Indicators (5, 6, & 7) for Goal 1 with baseline 
data, performance progress data, and projected targets
Indicator 5:  The percentage of students in 9th through th grade who report they 
have never had sexual intercourse; or, if they have had sexual intercourse, not in the 





*YRBSS is conducted in odd numbered years so there are no data for 000 and 00, and the target is 
set for 009 rather than 00.




86.% of 9th-th graders had never had sexual 
intercourse (.% had sex, but not in past month 
and 9.% had sex in the past 3 months, but used a 
condom)
Year 003 (performance): 87.5% of 9th-th graders had never  had sexual 
intercourse (.3% had sex, but not in the past 
month, and .3% had sex in the past 3 months, but 
used a condom)
Year 005 target:  88%
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Indicator 6:  Among the persons diagnosed with HIV infection for > months and 
interviewed in SHAS,* the percentage who did not use a condom at last vaginal/anal 
sex when the status of the partner was unknown.
Baseline	data,	performance	progress	data,	and	projected	targets:
Year 00 (baseline): .3% did not use a condom at last vaginal/anal sex 
with a partner whose HIV status was negative or 
unknown  
Year 00 (performance): 3.9%
Year 003 (performance): 7%
Year 004 (performance): 3.4%
 Year 005 target: 0% 
Year 00 target: 8%
Data source: CDC. Supplement to HIV/AIDS Surveillance (SHAS) Project
_____________________________________
* The Supplement to HIV/AIDS Surveillance (SHAS) project is conducted in the following states: 
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Kansas, Maryland, 
Michigan, Minnesota, New Jersey, New Mexico, South Carolina, Texas, and Washington; and the 
following cities: Houston and Philadelphia. CDC summarizes data from SHAS project and examines 
the representativeness of these data. This indicator will not be available after 004 because CDC will 
discontinue this project in mid-004.  To replace SHAS, CDC is developing a more representative 
surveillance system for the entire HIV-infected population in the United States in mid-004.
 
Indicator 7:  Among persons diagnosed with HIV infection for > months and 
interviewed in SHAS,* the percent of injection drug users (IDUs) who shared a needle 
or syringe with someone in the past  months.




Year 005 target: 3%
Year 00 target: %
Data source: CDC. Supplement to HIV/AIDS Surveillance (SHAS) Project
____________________________________
*The Supplement to HIV/AIDS Surveillance (SHAS) project is conducted in the following states: 
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Kansas, Maryland, 
Michigan, Minnesota, New Jersey, New Mexico, South Carolina, Texas, and Washington; and the 
following cities: Houston and Philadelphia. CDC summarizes data from SHAS project and examines 
the representativeness of these data. This indicator will not be available after 004 because CDC will 
discontinue this project in mid-004. To replace SHAS, CDC is developing a surveillance system for the 
entire HIV-infected population in the United States.
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Supplemental Activities
In addition to the three performance indicators, CDC has implemented programs and 
activities that focus on decreasing the numbers of persons at high risk for acquiring or 
transmitting HIV infection, specifically relating to Objectives 1, 2, and 4 of Goal 1.
CDC’s HIV/AIDS surveillance system is the nation’s key source of information used 
to track the epidemic.  Surveillance activities provide demographic, laboratory, 
clinical, and behavioral risk data that are used to identify populations at greatest risk 
for HIV infection.  In 00, CDC began implementation of a national, population-
based incidence surveillance system to provide estimates of HIV incidence using a 
testing technology known as STARHS (Serologic Testing Algorithm for Recent HIV 
Seroconversion).  STARHS is a way of analyzing HIV-positive blood samples to 
determine if an HIV infection is recent. To date, 34 areas that cover approximately 90% 
of the epidemic in the United States have been funded for HIV incidence surveillance.   
CDC expects to have incidence data available in 006.  This new national system for 
measuring the rate of new HIV infections in the United States is expected to provide 
the clearest picture yet of the magnitude of the domestic HIV epidemic, as well as aid 
CDC in more effectively targeting HIV prevention efforts to promote decreases in the 
incidence of new HIV infections.  
CDC has also implemented the National Behavioral Surveillance System (NHBS) to 
learn more about risk behaviors among groups of persons at high risk for HIV infection, 
trends in these behaviors over time, and exposure to and use of HIV prevention 
services.  As of 004, CDC has funded 5 Metropolitan Statistical Areas (MSAs) 
to implement behavioral surveillance for three groups at highest risk for acquiring 
HIV infection: men who have sex with men (MSM), injection drug users (IDUs), and 
heterosexuals practicing high-risk sexual behaviors.  These groups will be surveyed 
every 3 years so that trends in risk behaviors can be monitored and effective HIV 
prevention programs can be developed and implemented that encourage the adoption 
of behaviors that place these groups at lower risk for HIV infection or transmission.
In an effort to assure that scientifically sound interventions are available to prevention 
service providers, planners, and others who request science-based interventions, 
CDC has conducted a systematic literature review of HIV prevention interventions that 
have been formally evaluated and shown to reduce the risk of HIV transmission.  The 
results of this review are compiled in the Compendium	of	HIV	Prevention	Interventions	
with	Evidence	of	Effectiveness	(Compendium).  The Compendium provides up-to-date 
information about interventions with evidence of reducing sex-and/or drug-related risks, 
and the rate of HIV/STD infections.  These interventions have been effective with a 
variety of populations, e.g., clinic patients, heterosexual men and women, high-risk 
youth, incarcerated populations, IDUs, and MSM.
The Diffusion of Effective Behavioral Interventions (DEBI) project is an additional activity 
that brings evidence-based prevention interventions to the field.  The DEBI project 
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involves development and distribution of intervention resource materials, training on the 
interventions, and technical assistance and other capacity building strategies around the 
interventions.  Currently, CDC has diffused 4 evidence-based prevention interventions 
to health department and community-based organization (CBO) partners though 
regional DEBI trainings.  From January 003 through November 005, 5 regional 
DEBI trainings have occurred.  More than 500 CBOs and 39 local or state health 
departments have participated in these trainings and approximately 5000 individuals 
have been trained on one or more of the DEBIs.
CDC’s Advancing HIV Prevention (AHP) initiative, launched in April 003, expanded and 
strengthened prevention efforts by adding new prevention strategies based on proven 
public health approaches that have been used successfully in preventing other 
infectious diseases.  The four AHP strategies are:
• Make HIV testing a routine part of medical care
• Implement new models for diagnosing HIV infections outside medical settings
• Prevent new infections by working with persons diagnosed with HIV and their 
partners
• Further decrease perinatal HIV transmission
In support of the AHP initiative, CDC provided funding for seven -year demonstration 
projects to health departments, CBOs, and primary care providers to test the feasibility 
of the four AHP strategies and provide detailed information that could be used to 
implement the strategies widely.   
Objective 1: Among people living with HIV, increase the proportion who 
consistently engage in behaviors that reduce risk for HIV transmission or 
acquisition.
Two AHP demonstration projects focused on implementing new models of diagnosing 
HIV infection outside medical care settings and preventing new infections by working 
with persons diagnosed with HIV and their partners.  The first project, “Incorporating HIV 
Prevention into Medical Care Settings,” used an intervention called Positive S.T.E.P.S 
(Striving to Engage People) to explore the effects of clinic-based repeated, brief 
prevention counseling on patient behaviors and sexually transmitted diseases (STDs).  
The project was implemented in HIV outpatient clinics.  It provided an opportunity to 
reach large numbers of HIV-infected individuals who visit the clinic on a regular basis, to 
implement safer-sex and needle-sharing intervention, to integrate the intervention with 
routine clinical care, and to involve nurses and physicians in the intervention.  Because 
some individuals, after testing positive for HIV, fail to change risky behaviors, ongoing, 
brief prevention counseling is a cost-effective measure that can be incorporated into 
routine care for HIV-infected individuals.  
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CDC supported six sites in implementing the 2003	Incorporating	HIV	Prevention	into	
Medical	Care	Settings	Guidelines—recommendations developed by CDC, the Health 
Resources and Services Administration, the National Institutes of Health, and the HIV 
Medicine Association (HIVMA) of the Infectious Diseases Society of America, to help 
health care providers incorporate HIV prevention into the medical care of people with 
HIV.   The six sites assessed the impact of the guidelines on reported risk behaviors, 
STD rates, tailored risk reduction counseling, and referrals.  As of August 005, 09 
persons had enrolled in the program, the intervention had been delivered to all patients 
attending the clinics, and the clinics were conducting 6- and -month follow-up 
assessments.  
The second AHP demonstration project, “Prevention Case Management for People 
Living with HIV/AIDS,” was a client-centered HIV prevention activity that combined 
HIV risk-reduction counseling and traditional case management to provide intensive, 
on-going, individualized prevention counseling and support.  Nine CBOs were funded 
in Maryland, Massachusetts, Michigan, Missouri, California, Pennsylvania, New York, 
and Washington, D.C., to provide specialized assistance through prevention case 
management, to HIV-infected persons with multiple and complex HIV risk-reduction 
needs.  Through this project, CDC’s aim was to monitor risk reduction behavior change 
of HIV-infected persons by providing individualized, multiple-session HIV reduction 
counseling to prevent the transmission or acquisition of HIV, assess risks of other 
sexually transmitted infections, and ensure appropriate diagnosis and adequate 
treatment.  
In 005 and 006, CDC published in its Morbidity	and	Mortality	Weekly	Report 
preliminary findings from a study of MSM in the National HIV Behavioral Surveillance 
System (NHBS), results of a meta-analysis study of high-sexual behavior in persons 
aware and unaware of their serostatus, and results of a second meta-analysis of HIV 
prevention interventions for people living with HIV.  
Data from NHBS on HIV prevalence and unrecognized HIV infection among MSM in five 
cities found an overall HIV prevalence rate of 5%.  Rates varied by race/ethnicity and 
rates were highest among African-American MSM (46%), followed by white MSM (%), 
and Hispanic MSM (7%).  Among the HIV-infected MSM, 48% were unaware that they 
were infected with HIV.
Data from a meta-analysis of high-risk sexual behavior in persons aware and unaware 
that they were infected with HIV found that the prevalence of high-risk sexual behavior 
was reduced substantially after people became aware they were infected with HIV.  
Overall, the prevalence of unprotected anal or vaginal intercourse with any partner was 
an average of about 50% lower in persons aware of their status compared to those 
who were not and 68% lower with HIV-negative partners.  A second meta-analysis of 
HIV prevention interventions for people living with HIV showed that interventions with 
HIV-infected persons led to significant reductions in unprotected sex and acquisition 
of STDs.  These recent data show that high levels of unrecognized HIV infection exist 
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in some sub-populations, that persons substantially reduce HIV risk behaviors once 
they become aware of their HIV infection and that effective prevention intervention can 
further reduce HIV risk behaviors among persons living with HIV. 
Objective 2: Among men who have sex with men (MSM), increase the proportion 
who consistently engage in behaviors that reduce risk for HIV acquisition or 
transmission.
Three of the 14 DEBI interventions are specifically targeted to MSM:  Many Men, Many 
Voices; Mpowerment; and Popular Opinion Leader (POL).  In response to an outbreak 
of HIV among males attending colleges in the Research Triangle area of North Carolina, 
the North Carolina Department of Health implemented the Men’s Health Initiative 
to adapt and test the effectiveness of the POL intervention as a prevention strategy 
focusing on primarily African-American men who have sex with men and women 
(MSM/W), 8-30 years of age in three geographic areas and one college campus in 
North Carolina.  The intervention was previously tested among primarily white gay men 
and African-American women living in subsidized housing.  The goal of the POL is to 
identify, train and enlist the help of key opinion leaders to help change social norms 
through engaging in risk reduction conversations with friends.  The reported outcomes 
of the North Carolina Men’s Health Initiative using POL showed that a total of 64 POLs 
(5% of the target population) were trained for the intervention, 6 in the community 
and 38 on campus; 30 conversations were held by POLs, 8 by community POLS 
and 480 by campus POLs; and eight booster sessions and four reunions were held.   
The North Carolina Department of Health heralded the POL as a successful intervention 
for the targeted population claiming that it created a safe, non-sexual environment 
for African-American MSM/W that did not exist previously, promoted sexual wellness 
for African-American men regardless of their sexual orientation, and created new 
community advocates and empowered POLs to do more for the community.
Objective 3: Among adolescents increase the proportion who consistently engage 
in behaviors that reduce risk for HIV acquisition or transmission.
The Youth Risk Behavior Surveillance System (YRBSS) is a key tool used by CDC to 
monitor adolescent HIV risk behaviors.   From 99-003, YRBSS data showed that the 
proportion of high school students who have ever had sex, showed a significant decline 
from 54.% to 46.7%.  During the same time period, the percentage of high school 
students who had their first sexual intercourse before age 13 also declined significantly, 
from 0.% to 7.4%, and the percentage of students who had four or more lifetime sex 
partners also declined significantly, from 18.7% to 14.4%.  Finally, the percentage of 
students who used a condom during their last sexual intercourse increased significantly, 
from 46.% in 99 to 63% in 003.  The YRBSS data are collected every other year 
and allow CDC to monitor sexual activity among high school students and risk behavior 
mechanisms to reduce the acquisition and transmission of HIV in this population.
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One of CDC’s 4 DEBI interventions, “Street Smart: Reducing HIV Risk among 
Runaway and Homeless Youths,” is specifically targeted toward adolescents.  Street 
Smart is a multi-session, skills-building program designed to help groups of runaway 
youth reduce unprotected sex, number of sex partners, and substance use.  
Objective 4- Among injecting drug users (IDUs), increase the proportion who 
abstain from drug use or, for those who do not abstain, use harm reduction 
strategies to reduce risk for HIV acquisition or transmission.
In November 005, CDC released the most recent HIV/AIDS surveillance data from the 
33 states with longstanding confidential name-based HIV surveillance systems.  
One of the notable findings in the data is a decline in HIV/AIDS diagnoses among IDUs 
from 00-004.  During this 3-year period, there was an estimated annual percentage 
decline of 3.9% per year among IDUs, suggesting that prevention activities targeted 
toward this group are contributing to reduced HIV transmission rates.
One DEBI intervention targeted to female sex partners of male IDUs, MSM who 
do not self-identify as gay, and other populations at risk is “Community PROMISE: 
Peers Reaching Out and Modeling Intervention Strategies.” This is a community-
level intervention that promotes progress toward consistent HIV prevention through 
community mobilization and distribution of small-media materials and risk-reduction 
supplies.
Goal 2: “By 2005, through voluntary counseling and testing,  
increase from the current estimated 70% to 95% the proportion of  
HIV-infected people in the United States who know they are infected.”
CDC has currently implemented two indicators to monitor progress towards achieving 
Goal 2.  The first indicator is “the percentage of HIV-positive test results from publicly-
funded counseling and testing sites with post-test counseling sessions.” The most 
recent data for this indicator from 003 show that 7% had post-test counseling 
sessions.  The second indicator is “the percentage of HIV cases diagnosed before 
progression to AIDS.”  The most recent data for this indicator from 004 show that 78% 
of persons were diagnosed with HIV before progression to AIDS.
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Performance Indicators (8 & 9) for Goal 2 with baseline data, 
performance progress data, and projected targets
Indicator 8:  The percentage of HIV-positive test results from publicly-funded 
counseling and testing sites with post-test counseling sessions.
Baseline	data,	performance	progress	data,	and	projected	targets:
Year 000 (baseline): 69.3% 
Year 00 (performance): 7.3% 
Year 00 (performance): 7%
Year 003 (performance): 7%
Year 004: Data not yet available
Year 005 target: 75% 
Year 00 target: 80%
Data source: CDC. HIV Counseling and Testing System (CTS)
Indicator 9: The percentage of HIV cases diagnosed before progression to AIDS.
Baseline	data,	performance	progress	data,	and	projected	targets:*
Year 000 (baseline): 76% 
Year 00 (performance): 77%  
Year 00 (performance): 77% 
Year 003 (performance): 78%
Year 004 : 78%
Year 005 target: 79% 
Year 00 target: 85%
Data source: CDC. HIV/AIDS Reporting System
_____________________________________
* The baseline estimate of 70% for Goal  was based on modeling methods that yield broad-based 
estimates that cannot measure year-to-year changes with confidence. As a surrogate indicator for which 
year-to-year changes are available, we use persons who already have AIDS at the time they are initially 
diagnosed with HIV. Trends in the percentage of HIV cases that are diagnosed before AIDS should 
parallel the trends in the proportion of HIV-infected persons who know their serostatus, and therefore, 
this is a useful indicator of progress toward Goal . Similar to Goal , the data are only currently 
available from the 30 states with longstanding confidential HIV reporting.
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Supplemental Activities
In addition to the two indicators, CDC has implemented programs and activities that 
focus on increasing the proportion of HIV-infected people who know they are infected.
In the United States, CDC estimates ,039,000-,85,000 persons are infected with 
HIV, and that 5% (approximately 50,000) are not aware of their infections and  risk 
for transmitting HIV.   As part of the AHP initiative, identifying persons with undiagnosed 
HIV infection and linking them to medical care and prevention services is a national 
priority.  
Objective 1: Increase the motivation of at-risk individuals to know their infection 
status and decrease real and perceived barriers to HIV testing.
One of CDC’s most promising AHP demonstration projects is the Social Networks.  
CDC funded nine CBOs to implement a social networks approach to reach high-risk 
individuals with HIV counseling, testing, and referral services.  The project involved 
training HIV-infected and high-risk individuals in communities of color to reach out 
through their social, sexual, and drug-using networks and encourage their peers who 
may be at risk to be tested.  Preliminary data from October 3, 003-September 4, 
2004 indicated that of newly identified positives, prevalence rates were highest among 
MSM (6%), MSM/IDU (5%), and transgender individuals (0%).  The recruiters most 
effective at identifying undiagnosed HIV infections were MSM (5%) and transgender 
(0%), suggesting that transgender and MSM networks might be more likely to include 
persons with undiagnosed HIV infection.  Additionally, 8% of network associates 
tested were at high risk (had unprotected sex in the past year, exchanged sex for drugs 
or money, had  an STD, or shared drug injection equipment).  Preliminary findings 
published in the June 4, 005 MMWR showed that 33 recruiters in seven cities 
referred 84 high-risk individuals for counseling and testing.  Of those, 46 were newly 
diagnosed as HIV positive, representing a prevalence of 5.7 percent—almost six times 
that typically seen in publicly funded HIV counseling and testing sites.  
This Social Networks demonstration project has proven to be a viable strategy for 
reaching and providing counseling, testing, and referral services to persons with 
undiagnosed HIV infection and an efficient and effective route to access HIV-infected 
persons or those at very high risk for HIV.  CDC believes that the Social Networks 
Project can enhance counseling, testing and referral programs (targeted testing), 
partner, counseling and referral services, and aid in priority setting for interventions 
and target populations, such as undiagnosed HIV infections among MSM of color and 
African-American women.  At the September 005, Executive meeting of the National 
Alliance of State and Territorial AIDS Directors, CDC provided plans to operationalize 
the social networks project for implementation in the states.  CDC issued a “Dear 
Colleague” letter to partners in September 005, and is in the process of developing a 
social networks toolkit and project information that will be available on the CDC Web 
site, as well as Grantee Procedural Guidance and a training curriculum that includes 
technical assistance for grantees targeting MSM and women of color.
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Objective 3: Increase the number of providers who routinely provide voluntary, 
client-centered counseling and testing (VCT) in health care settings (e.g., STD 
clinics, substance abuse treatment programs, family planning clinics, emergency 
rooms, community health centers), as well as in non-clinical venues (e.g., social 
venues, public assistance programs, street outreach).
CDC is currently revising recommendations for HIV testing of adults, adolescents and 
pregnant women in health care settings.  These will update previous recommendations 
with the intended purpose of increasing routine, voluntary HIV screening of patients 
in health care settings.  Further, CDC expects the new recommendations will result in 
substantial increases in HIV testing and increases in the proportion of persons who 
know their HIV status.  Key elements of these recommendations include: ) Routine, 
voluntary HIV screening in all health care settings, (cost-benefit analyses have shown 
the routine HIV screening is cost-effective at HIV seroprevalence rates as low <0.%); 
) Normalization of HIV testing -- meaning that HIV testing should be incorporated into 
the routine medical screening panel at that facility; 3) Incorporation of informed consent 
for the HIV test into the facilities’ general medical consent process with an “opt-out” 
approach, whereby the patient can specifically decline the HIV test if so desired; 4) 
Strong encouragement of prevention counseling in settings where risk behaviors are 
routinely ascertained (e.g., STD clinics), but counseling does not have to be linked to 
routine screening in health care settings.
Objective 4: Increase the percentage of people who know their results after 
testing.
One AHP demonstration project focused on the use of rapid HIV testing among high-risk 
populations in nonclinical settings.  The “Routine Rapid HIV Testing of Inmates in Short-
Stay Correctional Facilities,” was targeted to persons entering the correctional system.  
High rates of HIV and STDs have been documented among this group of people, and 
currently, only a fraction of jails routinely test for HIV on entry.  People incarcerated 
for less than 30 days are unlikely to receive traditional HIV counseling and testing, 
and, if they do, they may be released before their test results from traditional testing 
are available.  Routine rapid testing would facilitate initial testing, delivery of results, 
confirmatory testing, and appropriate referral to care, treatment, and prevention services 
within the facility or in the community.  CDC funded state health departments in Florida, 
Louisiana, New York, and Wisconsin to assess the feasibility of rapid HIV testing in 
short-stay correctional facilities.  From January 004 through March 005, 6,676 
inmates were tested and 56 (.5%) were reactive.
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Goal 3: “By 2005, increase from the current estimate 50% to 80% the 
proportion of HIV infected people in the United States who are linked 
to appropriate prevention, care, and treatment services.” 
CDC has currently implemented one indicator to monitor the progress toward achieving 
Goal 3: “the percentage of HIV/AIDS cases in care within three months of diagnosis.”  
The most recent data for this indicator from 004 show that 85.% of persons were in 
care within three months of diagnosis.
Performance Indicator (10) for Goal 3 with baseline data, performance 
progress data, and projected targets
Indicator 10:  Percentage of HIV/AIDS cases in care within three months of diagnosis.
Year 00 (baseline): 78.8% 
Year 00 (performance): 79.%  
Year 003 (performance): 80.4% 
Year 004 (performance): 85.%
Year 005 target: 8% 
Year 00 target: 85% 
Data	source:	CDC.	Supplement	to	HIV/AIDS	Surveillance	(SHAS)	Project.
_____________________________________
*The SHAS project is conducted in the following states: Arizona, California, Colorado, Connecticut, 
Delaware, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Minnesota, New Jersey, New Mexico, 
South Carolina, Texas, and Washington; and the following cities: Houston and Philadelphia. CDC 
summarizes data from SHAS project and examines the representativeness of these data. This indicator 
will not be available after 004 because CDC will discontinue this project in mid-004. To replace SHAS, 
CDC is developing a surveillance system for the entire HIV-infected population in the United States.
Supplemental Activities
Objective 1:  Reduce disparities in access to prevention and care services 
experienced by communities of color, women, and special needs populations.
Since Fiscal Year 999, CDC has implemented over 70 HIV prevention projects targeted 
to high-risk racial and ethnic minority populations supported through the Minority AIDS 
Initiative (MAI).  CDC receives direct MAI appropriations from Congress and additional 
MAI resources from the Discretionary Fund of the Secretary of the Department of 
Health and Human Services.   Funds are awarded through cooperative agreements 
to state and local health departments; national, regional, and local organizations; 
CBOs, (including faith-based organizations); and universities, to specifically target HIV 
prevention to communities of color which are disproportionately affected by the HIV/
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AIDS epidemic.  MAI has greatly enhanced CDC’s ability to provide direct funding to 
CBOs and has allowed CDC to allocate significant resources to communities of color 
and high-risk populations, such as gay men of color, and to MSAs with the highest 
number of AIDS cases in racial and ethnic minorities.  MAI funding e nhances HIV 
program efforts in three categories:  ) technical assistance and infrastructure support; 
) increasing access to prevention and care; and 3) building strong community linkages. 
In 005, CDC implemented the “Translation/Adaptation of Science-Based Interventions 
for Communities of Color, Women, Substance Abusers, IDUs, and other High Risk 
Groups” project.   The aim of this MAI project is to translate proven HIV prevention 
interventions identified in the CDC	Procedural	Guidance	for	Selected	Strategies	and	
Interventions	for	Community-Based	Organizations, for culturally appropriate use in 
different at-risk communities.  Using the Guidance, funded grantees will conduct 
formative research to assess the match between the intervention, the target population, 
and the organization.  The organization will then adapt and tailor the selected 
intervention and pre-test materials with members of the target population.  The adapted 
and tailored intervention or components will be pilot-tested and a logic model detailing 
intervention activities will be developed.  CDC expects to use the results of this project 
in future program guidance and training for directly-funded CBOs on how to adapt and 
tailor interventions shown to be effective in research settings for use among at risk 
populations.  Further, this project will enhance the way that proven interventions are 
used in the community by giving CBOs the tools they need to adapt effective science-
based programs into practical strategies for use in at risk communities.   
A second MAI project is the “Evaluation of Innovative HIV Prevention Interventions for 
IDUs and High Risk Minority Populations.”  The purpose of this project is to identify and 
evaluate innovative HIV prevention interventions for injection drug users and high-risk 
minority populations that have been developed by CBOs with substantial input from 
served communities.  These programs have exhibited an ability to reduce HIV risk 
behaviors although they have not undergone formal outcome evaluations.   Through this 
project, CBOs will examine the effectiveness of their interventions in reducing sexual 
risk behaviors (including sexual abstinence), increasing HIV testing, and changing 
knowledge and attitudes regarding HIV risk.  Those programs proving effective may 
then be disseminated through CDC’s DEBI project.  
CDC also supports intramural training for minority researchers through the Research 
Fellowships on HIV Prevention in Communities of Color Program and extramural 
training through the Minority HIV/AIDS Research Initiative (MARI).  The goal of the 
Research Fellowship is to recruit, mentor, train, and retain investigators with expertise 
in conducting public health research. The project is specifically designed for minority 
post-doctoral fellows and aims to increase the quality and quantity of research to reduce 
HIV infection in communities of color most heavily impacted by HIV, and to increase the 
overall number of minority racial and ethnic investigators within CDC.
The goals of the MARI are to conduct HIV epidemiologic and prevention research 
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of direct public health importance to communities of color (namely African-American 
and Hispanic) that have been deeply affected by the HIV epidemic, and to build HIV  
prevention research capacity in communities in which little research of this type has 
been conducted.  Currently, 3 junior investigators at  sites are participating in 
MARI.  This prevention research capacity building project aims to serve as a catalyst 
for improved HIV prevention efforts in communities of color, ultimately helping to reduce 
disparities in services experienced by these groups. 
Objective 4:  Promote the optimal level of medical services for patients diagnosed 
with HIV to benefit individual health and reduce the likelihood of further transmis-
sion of HIV. 
CDC has funded several activities which enhance the level of medical services for 
HIV-infected persons.  One was the AHP demonstration project, “Prevention Case 
Management (PCM) for Persons Living with HIV/AIDS.”   In November 005, CDC 
officially changed the name of PCM to comprehensive risk counseling and services 
(CRCS).  CRCS is a client-centered HIV prevention activity that combines HIV risk 
reduction counseling and traditional case management to provide intensive, on-
going, individualized prevention counseling and support.  CDC funded nine CBOs in 
Maryland, Massachusetts, Michigan, Missouri, California, Pennsylvania, New York, and 
Washington, D.C., to provide specialized CRCS to HIV-infected persons with multiple 
and complex HIV risk reduction needs.  As of January 006, 480 persons have been 
enrolled in the CRCS; of these 66% were African American and 4% were Hispanic.  
The primary referrals provided through this program were for housing assistance, drug 
counseling and treatment, mental health services, Ryan White case management, and 
psychosocial support groups.   
Objective 5: Increase the proportion of persons diagnosed with HIV who are suc-
cessfully linked to medical care no later than 3 months after learning their HIV 
status or re-identified as being HIV infected but out of care. 
In an effort to enhance the proportion of HIV-infected people who are linked to HIV care 
in a timely manner, CDC has funded the Antiretroviral Treatment Access Studies (AR-
TAS) I & II.  Both studies examine the impact of linkage case management on getting 
HIV-infected persons into care.  In the linkage case management approach, a person 
who has recently received an HIV diagnosis is assigned a linkage case manager to en-
sure that he or she accesses HIV primary care.  Results from the ARTAS I study show 
that when individuals with a recent HIV diagnosis meet with a linkage case manager up 
to 5 times in a 3-month period, they have a greater chance of being linked to care.   To 
further test these results, the ARTAS II demonstration project was implemented to com-
pare rates of linkage (to HIV care providers) before and after instituting the linkage case 
management.   These findings will enhance the understanding about how well linkage 
case management works in typical HIV program settings.  The primary objective of this 
demonstration project is to reach a 75% rate of HIV care use associated with linkage 
0
case management after six months of follow up.   The 0 collaborating sites for ARTAS 
II include five local or state health departments and five CBOs, each with at least one 
ARTAS II linkage case manager.  As of August 005, 37 HIV-infected persons had 
been enrolled. 
To further improve linkage of HIV-infected persons into appropriate care and treatment, 
in 005 CDC implemented the MAI project, “Characterizing HIV Diagnosed Persons that 
are Not in Care.”  Through this project, quantitative and qualitative data are being col-
lected about those persons infected with HIV who are not receiving care; quality of care 
and severity of need for care; and barriers to receiving care, prevention and support 
services at the local level.  This data will provide a means of evaluating new prevention 
initiatives that focus on the provision of prevention services and linkage to care for per-
sons living with HIV.   Further, this project will provide supplemental surveillance data to 
characterize persons who have a diagnosis of HIV infection and who are not receiving 
care.  This information will be critical in understanding the additional burden on health 
care delivery systems when persons are successfully linked into care.  As an enhanced 
surveillance activity it will also provide an opportunity to evaluate existing methods of 
laboratory reporting for HIV.
0
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During its May 005 meeting, CHAC stressed the need to identify reasons for not 
achieving the overarching goal (i.e., to reduce new HIV infections in the U.S. by 50% by 
005, with a focus on eliminating racial/ethnic disparities) of the national HIV Prevention 
Strategic Plan.  The CHAC also expressed a strong interest in updating the Plan and, 
therefore, unanimously passed a motion to form a Work Group to facilitate this effort.  
At that time, the CHAC decided to restrict the focus of its review and proposed update 
of the Plan to four of the five goals established in 2001.  “Global HIV” was not to be 
included because other agencies have developed international activities since that time 
to address this goal. The CHAC recommended that CDC not develop a new Plan at this 
point.  Instead, the Work Group was tasked with the following responsibilities:
. Provide advice on ways to update the existing Plan to guide CDC and its federal 
partners in formulating new strategies, activities, and directions to reduce HIV 
infection in the United States.  
. Develop recommendations for HIV prevention programs, surveillance and research 
that can reduce HIV incidence based on current resources and the best available 
science.
3. Review the existing Plan to identify limitations or flaws in previous HIV prevention 
activities, missed opportunities in establishing priorities, and actions to advance the 
Plan in the future.
4. Determine whether the overarching goal to reduce new HIV infections in the United 
States by 50% is feasible and realistic based on available resources.
A small committee (of ten people), comprised of CHAC members, CDC staff, and 
external partners, was formed in July, 005 to () identify work group members who 
would have responsibility for developing recommendations, () develop a process for 
gathering input from the work group, and (3) plan a face-to-face meeting for deliberating 
about recommendations that would be submitted to the CHAC. The committee was 
chaired by CHAC co-chair, Dr. Jean McGuire.  CDC appointed Dr. George Roberts to 
serve as its co-chair.  After several conference calls, the committee identified more than 
30 individuals to join the previously identified members of the committee to serve as the 
HIV Prevention Strategic Plan Work Group (see Appendix A for a list of participants).
The Work Group met face-to-face twice:  first on October 24-25, 2005; and then on 
May 4-5, 006.  Additional communications occurred during conference calls, e-mails, 
and intermittent mailings.  The Workgroup received information about CDC’s current 
activities relating to the Strategic Plan, as well as samples of relevant articles and 
reports for their review and consideration.  The following report provides a synthesis of 




Overall Benefits of the National HIV Prevention Strategic Plan
The Plan has served as a tremendously valuable tool for CDC.  CDC uses the Plan as 
a living document to link HIV prevention programs, activities, and budget allocations 
to specific goals and objectives.  CDC also uses the Plan as a guide in identifying new 
and expanded programs and initiatives, establishing priorities, directing and targeting 
resources, and ensuring that objectives are appropriately weighted and prioritized.  CDC 
holds an annual retreat for senior staff to review and discuss activities and resources 
related to all 7 objectives under the Plan goals.  The top ten objectives are also 
prioritized during the retreat to guide funding and program activities with a particular 
focus on populations and risk groups.
The Plan has had positive impacts on CDC programs.  Because of the Plan’s goals, 
the focus on persons at highest risk of transmitting HIV and becoming infected was 
enhanced.  Prevention services were prioritized for persons living with HIV. CDC 
used the Advancing HIV Prevention initiative to develop new strategies to diagnose 
HIV infection.  Strong linkages were established for prevention and quality medical 
care services. Rapid testing was promoted in both clinical and non-clinical settings.  
Behavioral interventions are now more effective and evidence-based through 
the Prevention Research Synthesis (PRS) and Diffusion of Effective Behavioral 
Interventions (DEBI) projects. 
CDC developed six national surveillance systems to monitor the complete pathway of 
HIV in the areas of behaviors, incidence, HIV cases, prevalence, morbidity, and AIDS 
cases and deaths.  In addition, CDC developed the Program Evaluation and Monitoring 
System (PEMS) to better monitor and evaluate HIV prevention programs that are 
implemented by community-based organizations (CBOs) and health departments.  
PEMS assists CDC in identifying what services are provided, the populations receiving 
services, behavioral and service utilization outcomes reported by clients, the reach of 
programs to target populations, and the relationship between exposure to services and 
changes in behavioral outcomes.
The Plan’s focus on eliminating racial and ethnic disparities in rates of HIV infections 
has led to better targeting of prevention approaches. CDC has directly funded minority 
and minority service community-based organizations for HIV prevention in communities 
of color since FY’99.  From 00-006, CDC awarded funds to 658 minority CBOs; 
state, local, surveillance, research and evaluation activities; minority fellowship 
programs; and communications, partnerships and policy development projects to 
increase HIV prevention in communities of color.  CDC also formed an internal work 
group to address the disproportionate impact of HIV/AIDS among African Americans, 
focusing on assessing current activities and identifying unfilled gaps.  This effort resulted 
in CDC convening three consultations in 005-006 with African Americans, African 
American MSM, and faith-based organizations.  CDC is developing a comprehensive 
action plan to address the ongoing HIV/AIDS crisis in African American communities.
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Barriers to Reaching the Plan’s Goals
The Work Group identified a number of factors that hindered progress toward achieving 
the Plan’s goals and objectives. The following list includes barriers related to leadership, 
resources, policies, and levels of intervention:
• Insufficient leadership and strategic partnering
o Absence of national leadership / sense of urgency to market the Plan
o Lack of community / broad-based buy-in for the Plan
o Lack of partnership coordination & collaborative action
•  The scope of the Plan was too narrow to include all of the potential partners 
needed to bring about prevention
• Inadequate interconnection w / other federal partners (SAMSHA, etc.)
•  Inadequate resources
o Flat funding during the period of the Plan
o Impact of intervening emergencies such as the 9/ disaster
o Reduced and diverted resources among community-based organizations
o Lack of adequate investments in communities of color
o Lack of access to services for highest risk populations such as MSM, youth, and 
women
• Obstructive federal policies / practices
o Prohibitions against funding needle exchange
o OMB/GAO program reviews of organizations serving gay populations
o Shifting policies / distorted information on abstinence and condom use 
o Blocked release of compendium, adolescent health curriculum etc
o Leadership gaps / capacity issues at CDC
• Inadequate framework & interventions
o Neglect of macro & structural factors that facilitate HIV transmission
o Insufficient targeting of interventions to highest risk groups
o HIV exceptionalism (treating HIV differently from other diseases)
o HIV-related stigma
o Disconnect between prevention messages and counseling and testing strategies
o No national social marketing campaign
o Inadequate capacity building to deliver effective prevention services and 
interventions
• Prevention fatigue
o Prevention “fatigue and burnout” caused communities to ignore CDC’s prevention 
messages
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 Considerations for Updating the Strategic Plan
The Work Group identified a number of concerns and suggestions for updating the Plan. 
Some of the important themes that arose from these deliberations included:   
•  Develop an overarching racial/ethnic disparities goal to inform the implementation of 
objectives and strategies for all goals in the updated Plan.
• Distinguish between goals and objectives that relate to persons living with HIV and 
seronegative persons at risk of HIV infection.
•  Emphasize the importance of creating greater specificity within the Plan for goals 
and objectives related to care, particularly for maintaining persons in care.
• Write stronger language that stresses making HIV testing routine and available in 
multiple settings including and beyond health care.  
•  Address structural and social norms that lead to HIV risk, and to target these areas 
for intervention.
• A resource analysis at the objective level needs to occur in order to allow goal 
targets and funding allocations to be adjusted and monitored
• Biomedical interventions must be explicitly included, as should appropriate focus on 
interventions with acute / more highly infectious individuals 
• A mechanism for appropriately aligning the evaluation and capacity building activities 
and resources of prior Goal 4 across the new goals/objectives must be developed
• Appropriate federal partners should be identified for each objective
• Progress on goals needs to be monitored and reported annually
• There should be a strategy regarding expanded resources for care
•  Improve all goals / objectives to achieve better targeting
o Target testing efforts differentially regarding prevalence / incidence
o Determine efficacy of improving interventions w/ most  infectious people
o Increase specificity of care linkage goal 
• Success of the updated Plan will depend on taking different approaches, clearly 
defining a road map, and implementing a detailed mobilization strategy.
• Improved models for assessing differentially efficacious/cost-effective interventions 
must be developed and used to describe an optimal mix of interventions
o Expanded focus on system/structural interventions and the needed mobilization 
must be a part of this framework 
•  Scale up models including resources and needed federal and other partners must be 
established
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• A review of the current models of replication package development, dissemination, 
fidelity, effectiveness and provider/agency burden must be undertaken




• Maintain over-arching numeric goal for reducing cases
o Prioritize African Americans at the highest level (within overarching goal and 
within each goal)
o Prioritize men who have sex with men within the goals as appropriate
o Prioritize racial and ethnic minority populations with disproportionate burden of 
disease / incidence 
• Update the Goals
o Create separate prevention goals for persons living with HIV and sero-negative 
persons at risk of infection
o Update testing and linkage to care goals
o Add new goal addressing stigma and discrimination 
o Drop goal 4 (maintain the strategies across goals)
Specific Recommendations for Existing Plan’s Goals and Objectives
Proposed Goal 1: By	2008,	decrease	the	number	of	HIV	infected	persons	transmitting	
HIV.	(Percentage	decrease	to	be	determined.)
Objectives - Proprosed Revisions
.  Among persons living with HIV at behavioral risk of transmission, increase the 
proportion who receive evidence-based interventions, including mental health, 
substance abuse, and other appropriate interventions for co-morbid conditions. 
[Provide key activities for adolescents, including HIV-positive children. Adolescents 
should be included in a separate objective.]
.  Increase the proportion of persons with HIV who are routinely tested for STDs and 
appropriately treated and referred for partner notification.
3.  Among persons with acute HIV infection, increase the proportion engaged in 
appropriate HIV behavioral interventions, including partner referral.
4.  Increase the proportions of HIV-infected pregnant women who receive anti-
retroviral medication to interrupt perinatal transmission of HIV. [Suggest objective 
be expanded to ensure that “related medically necessary services and appropriate 
0
medication” are also available to HIV-infected pregnant women.]
5.  Increase the percent of HIV-positive IDUs who reduce sharing of needles and have 
access to clean needles and drug treatment.
6.  Increase the proportion of persons living with HIV who effectively access partner 
disclosure services.
7.  Increase the proportion of HIV care providers who perform risk assessment and 
provide appropriate intervention and referrals.
8.  Reduce legal, regulatory, and policy barriers to implementing effective HIV 
prevention at federal, State, and local levels. [Issue should be revised as a broad 
statement or guiding principle across the entire Plan rather than a Goal  objective.]
Proposed Goal 2:	By	2008,	decrease	the	number	of	persons	at	risk	of	acquiring	HIV.	
(Percentage	decrease	to	be	determined.)
Objectives - Proposed Revisions
.  Increase the proportion of persons at risk for HIV who have access to free condoms. 
[Expand language to “create an environment of expected condom use for women.”] 
[CDC should be advised to conduct these activities in partnership with communities 
to increase support.]
.  Increase the proportion of persons at risk for HIV who have access to evidence-
based risk prevention interventions, including mental health, substance abuse, and 
other appropriate intervention for co-morbid conditions.
3.  Increase the proportion of incarcerated and transitioning persons who have access 
to prevention services. (Define “transitioning” as persons on parole, probation, etc.) 
[Activities for adolescents who enter/exit juvenile systems should be added.]
4.  Increase the proportion of IDUs who do not share needles and have access to clean 
needles and drug treatment.
5.  Increase the proportion of in-school and out-of-school high-risk youth who have 
access to evidence-based prevention, including STD screening and treatment.
6.  Increase the proportion of healthcare providers who perform sexual, drug, and other 
risk assessments and provide appropriate interventions and referrals.
7.  Reduce legal, regulatory, and policy barriers to implementing effective HIV 
prevention at federal, State, and local levels (e.g., rapid testing restrictions, 
increased taxes on alcohol, etc.) [This issue should be revised as a broad statement 
or guiding principle across the entire Plan rather than a Goal  Objective.]
8.  Increase the proportion of HIV-negative partners and discordant “couples” who are 





Objectives - Proprosed Revisions
.  Increase the percentage of African Americans who know their HIV status
.  Increase the percentage of all ethnic / racial minorities with disproportionate burden 
of disease / incidence who know their HIV status
3.  Increase the percentage of all gay and other MSM who know their HIV status
4.  Increase the percentage of IDU, substance users, mentally ill, STD, and other co-
morbidities who know their status 
5.  Increase the opportunity for all inmates to be tested
6.  Reduce the barriers (including stigma and discrimination) and increase opportunities 
so that all providers can test routinely in clinical and non-clinical settings
7.  Increase the use of and disseminate rapid testing technology that is user friendly and 
produces same day confirmed results
8.  Increase the percentage of people who are tested (early) and during acute infections 




Objectives - Proposed Revisions
.  Increase the percentage of HIV positive African Americans who are linked to 
appropriate prevention, care, and treatment services within 3 months of diagnosis
.  Increase the percentage of all HIV positive racial / ethnic minorities with 
disproportionate burden of disease / incidence who are linked to appropriate 
prevention, care, and treatment services within 3 months of diagnosis
3.  Increase the percentage of HIV positive gay and other MSM who are linked to 
appropriate prevention, care, and treatment services within 3 months of diagnosis
4.  Increase the percentage of HIV positive IDU, substance users, mentally ill, STD and 
other co-morbidities who are linked to appropriate prevention, care, and treatment 
services within 3 months of diagnosis
5.  Increase the opportunity for all HIV positive inmates who are linked to appropriate 
prevention, care, and treatment services within 3 months of diagnosis
6.  Ensure that all HIV positive persons receive comprehensive prevention services  
that include adherence, disclosure, and sexual risk reduction in their care settings  
within 3 months of diagnosis (Monitor to assure that HIV positive persons receive  

optimal medical care for their own health)
7.   Increase the number of culturally competent science-based prevention services for  
 racial and ethnic minorities, gay men, and other MSM
8.   Monitor the extent of multi-drug resistant virus among HIV positive people to prevent 
 the potential development of bio-disparity
9.   Increase the proportion of HIV care providers, offering routine, periodic reproductive  
 services, and STD and TB screening and treatment to HIV-infected clients
0.  Increase the proportion of persons diagnosed with HIV needing substance abuse      
treatment and social and mental health services that are successfully linked to  
those services
Proposed Goal 5: Increase	public	awareness	of	HIV	and	reduce	HIV-related	stigma	
and	discrimination.
Suggestion: Awareness of the Plan should also be increased in the medical community 
and private sector to ensure that these groups partner with CDC in meeting the targets.
Final Comments and Recommendations
Several themes and recommendations were repeated throughout the deliberations of 
the Work Group.  The following comments represent a consensus feeling among the 
participants:
• The health emergency among African Americans must compel a statement about the 
priority of prevention for this group at this time.
• There is a critical need to continue to focus on MSM and the broader group of high-
risk HIV-positive persons.
• Most of the revised objectives are directed to patients; but providers, medical 
associations, and healthcare institutions should also serve as targets.  Success of 
the updated Plan will depend on taking different approaches, clearly defining a road 
map, and implementing a detailed mobilization strategy.
• CDC, HRSA, and other federal agencies should develop and deliver a unified 
message to constituents:  “Every individual in the country should be tested for HIV 
and know their status.  All HIV-positive persons should be linked to treatments, care, 
and preventions services.”  Clear delivery of this message will reduce stigma in 
certain populations and eliminate need to update the existing Plan or develop a new 
Plan with new objectives.
• CDC alone cannot address the issues in the Plan.  A national Plan should be 
developed at this time.  The Work Group should serve as the initial voice for this 
effort.
3
Recognizing that the Strategic Plan is already functioning in an extension to 008 and 
recognizing that there were many Work Group recommendations that can begin to 
inform CDC efforts even in the absence of updated goals and objectives, the CHAC 
requests that CDC report back to the CHAC at its next meeting regarding:
• How it plans to align resources and strategies to optimize impact given current levels 
of funding; how it would adjust strategies assuming the roles of other federal and 
private partners
• Given the above, how it plans to address concerns regarding scale-up, translational 
research, CBO capacity, and related cross-plan recommendations coming out of the 
Workgroup.
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Appendix B: Current Goals and Objectives of the  
National HIV Prevention Strategic Plan
Goal 1: By 005, decrease by at least 50% the number of persons in the United 
States at high risk for acquiring or transmitting HIV infection by delivering targeted, 
sustained and evidence-based HIV prevention interventions.
OBJ # Activities
 Among people living with HIV, increase the proportion who consistently 
engage in behaviors that reduce risk of HIV transmission or acquisition.
 Among men who have sex with men (MSM), increase the proportion who 
consistently engage in behaviors that reduce risk for HIV acquisition or 
transmission.
3 Among adolescents, increase the proportion who consistently engage in 
behaviors that reduce risk for HIV acquisition or transmission.
4 Among injecting drug users (IDUs), increase the proportion that abstain 
from drug use or, for those who do not abstain, use harm reduction 
strategies to reduce risk of HIV acquisition or transmission.
5 Among at-risk sexually active women (including women who have sex with 
other women), and at-risk heterosexual men, increase the proportion who 
consistently engage in behaviors that reduce risk for HIV acquisition or 
transmission.
6 Increase the proportion of people at risk for HIV who are tested for STDs 
and treated appropriately.
7 Increase the proportion of HIV-infected pregnant women who routinely 
receive HIV counseling, accept HIV testing and choose to take 
antiretroviral medication to interrupt prenatal transmission of HIV.
8 Support HIV vaccine research.
9 Reduce the number of workers who are occupationally exposed to and 
infected with HIV.
0 Continue to monitor and support the safety of blood, tissue and organ 
supplies in the United States.
0
Goal 2: By 005, through voluntary counseling and testing, increase from the current 
estimated 70% to 95% the proportion of HIV-infected people in the United States who 
know they are infected.
OBJ # Activities
 Increase the motivation of at-risk individuals to know their infection 
status and decrease real and perceived barriers to HIV testing.
 Improve access to voluntary, prevention counseling, testing and 
referral in high seroprevalence communities and populations at risk, 
focusing particularly on populations with high rates of undiagnosed 
infection.
3 Increase the number of providers who routinely offer CTR for HIV in 
health care settings (e.g., STD clinics, substance abuse treatment 
programs, family planning clinics, emergency rooms, community 
health centers), as well as in other non-clinical venues (e.g., social 
venues, public assistance programs, street outreach).

Goal 3:  By 005, increase from the current estimated 50% to 80% the proportion of 
HIV-infected people in the United States, who are linked to appropriate prevention, 
care and treatment services.
OBJ # Activities
 Reduce the disparities in access to prevention and care services that are 
experienced by communities of color, women and special-needs populations.
 Integrate prevention services, including adherence to treatment, for persons 
diagnosed with HIV and AIDS into the delivery of patient care in both public 
and private sectors.
3 Increase the proportion of persons who have been diagnosed with HIV who 
are successfully linked to culturally competent, science-based prevention 
services.
4 Promote the optimal level of medical services for patients diagnosed with 
HIV to benefit individual health and reduce the likelihood of further transmis-
sion of HIV.
5 Increase the proportion of persons diagnosed with HIV who are successfully 
linked to medical care no later than 3 months after learning their HIV status 
or re-identified as being HIV-infected but out of care.
6 Increase the proportion of correctional facility detainees (incarcerated for at 
least 30 days) identified as HIV-infected who are provided HIV prevention, 
treatment and care services and who, upon release, are successfully linked 
to those services in the communities to which they return.
7 Increase the proportion of HIV care providers offering routine, periodic STD 
screening and treatment to HIV-infected clients.
8 Increase the proportion of HIV care providers offering routine, periodic TB 
screening and treatment to HIV-infected clients.
9 Increase the proportion of persons diagnosed with HIV, including pregnant 
women, needing substance abuse treatment services that are successfully 
linked to those services.
0 Increase the proportion of persons diagnosed with HIV needing social and 
mental health services that are successfully linked to those services.

Goal 4:  Strengthen the capacity nationwide to monitor the epidemic, develop and 
implement effective HIV prevention interventions and evaluate prevention programs.
OBJ # Activities
 Develop an integrated monitoring system to measure incidence of new 
infections, track the prevalence of disease, monitor behaviors that 
increase the risk of HIV infection, and provide locally relevant data for 
community planning.
 Increase the number of evidence-based interventions and the propor-
tion of prevention providers funded by CDC who demonstrate effective-
ness in providing these interventions.
3 Continue to support realistic and feasible evaluation efforts to ensure 
the highest possible quality of service and intervention delivery.
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Appendix C: CDC’s HIV Funding
The Division of HIV/AIDS Prevention’s budget has been cut by about 0 million over the 
past several years, and was further decreased by an additional $6 million in FY 006.   
The Plan has been instrumental in determining funding priorities for these diminishing 
resources.
CDC’s total domestic HIV budget was $74 million in FY’04.  By goal, $86.8 million (or 
39%) was allocated to goal  activities. By focus area, the vast majority of resources 
were dedicated to the top five objectives for youth, HIV-positive persons, MSM, at-risk 
sexually active women and heterosexual men, and IDUs.
$00. million (or 7%) was allocated to goal  activities. Of the total funding for this 
goal, 95% was allocated to extramural activities for counseling, testing and partner 
referral services.  The $00. million was distributed evenly across the four objectives 
of increasing motivation to test, access to testing, making VCT routine, and increasing 
return of results. 
$43. million (or 6%) was allocated to goal 3 activities.  Allocations went to the top three 
priorities for reducing disparities in access to care, integrating prevention services, and 
increasing linkages to culturally-competent prevention services.
Finally, $0.8 million (or 8%) was allocated to goal 4 activities. Of the total funding 
for this goal, 45% was dedicated to surveillance, % was dedicated to technical 
assistance, % was dedicated to program evaluation, and 3% was dedicated to 
research, intervention/implementation and policy development.  By objective, the $0.8 
million was allocated in order of priority to surveillance, interventions, and evaluation 
(see Appendix G for more detailed budget information).
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Appendix D: Measuring Success in 
Achieving Plan’s Goals 
One of the ways to measure success toward attaining the goals of the Plan is to monitor 
changes in the epidemic using data provided by national surveys and surveillance 
systems.  CDC identified 12 measurable performance indicators in 2002 to monitor 
annual progress toward achieving Plan goals.  The indicators are based on quantitative 
measures for specific goals or objectives and the current and future availability of data.  
Baselines were established for 000 and performance targets were determined for 005 
and 00.  CDC designed the HIV prevention performance indicators to be consistent 
with standardized measures used for other federal activities.
Goal Indicators Outcomes
Overarching 
goal: Reduce the 
number of new 
HIV infections 
in the United 
States from an 
estimated 40,000 
to 0,000 per 




racial and ethnic 
disparities in new 
HIV infections.
. Measure the number of 
persons 3-4 years of age 
diagnosed with HIV/AIDS in 
30 areas with at least a four-
year history of implementing 
named-based reporting
. Trend in gonorrhea rates 
reported each year
3. Trend in primary and 
secondary syphilis cases 
reported each year
4.  Estimated number of new 
perinatally acquired AIDS 
cases diagnosed each year
•   Between 000-004, the 
number of people aged 3-4 
years of age diagnosed with 
HIV/AIDS increased from 
,99 to 3,465.
•   Between 000-004, the rate 
of gonorrhea declined from 
8.7 to 3.5 cases per 
00,000 population.
•   Between 000-004, 
the rates of P&S syphilis 
increased slightly from . 
to .7 cases per 00,000 
populations.
•   Between 000-004, 
the estimated number of 
perinatally-acquired AIDS 
cases declined from 4 to 
48 cases.
Summary of goal indicators and outcomes
5
Goal 1:  
By 005, decrease 
by at least 50% 
the number of 
persons in the 
United States at 









.  YRBS data monitoring % 
of 9th-th grade students 
who reported safe sexual 
behaviors defined as a) never 
having engaged in sexual 
intercourse b) not sexually 
active in past 3 months c) 
if sexually active in past 3 
months, used condom.
.  SHAH data monitoring 
condom use of persons 
diagnosed with HIV for 
> months when status of 
partner was unknown.
3.  SHAS data monitoring 
sharing of needles among 
HIV-infected IDUs diagnosed 
for > months.
•  From 999-003, % of 
students practicing safer sex 
or abstinence increased from 
85%-88%.
•  Between 00-004, % of 
condom use among HIV-
infected persons increased 
slightly from .3% to 3.4%.
•  Between 00-004, % of 
those who shared of needles 
among HIV-infected persons 
decreased from 7% to 3% in 
00, but increased to 7% in 
004.
Goal 2:  








infected people in 
the United States 
who know they are 
infected. 
. CDC’s CTS measures % of 
HIV-positive test results from 
publicly funded counseling 
and testing sites with post-
test counseling sessions.
. HIV/AIDS Monitoring System 
measures % of HIV cases 
diagnosed at least one month 
before progression to AIDS.
•  From 000-003, % of HIV-
positive test remained stable 
at 69%-7%
•  From 000-004, % of 
diagnosed HIV cases 




Goal 3:  
By 005, increase 
from the current 
estimate of 
50% to 80% the 
proportion of HIV 
infected people in 
the United States 





. SHAS monitors % of HIV/
AIDS cases in care within 3 
months of diagnosis
•  From 000-004, data 
shows % of HIV-infected who 
received medical care within 
















. Measures the number of 
states and territories with 
integrated, confidential, 
name-based HIV/AIDS case 
surveillance systems.
• January 00, 33 states and 
 territories had implemented 
HIV case surveillance 
systems
• By April 006, all states and 
territories had some form of 
HIV reporting: 43 states use 
name-based reporting, two 
use name-to-code reporting, 
and 6 use code identifiers
Goal Indicators Outcomes
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Indicators for Goal  measure abstinence, sexual intercourse and condom use among 
students in grades 9-. The indicator is designed to measure youth who have never 
had sexual intercourse, abstained from sexual intercourse in the past three months, and 
used condoms in the past three months.  Data from the Youth Risk Behavioral Survey 
(YRBS) showed a substantial increase in safer sex behaviors among adolescents from 
999-003.
Indicators also measure condom use during vaginal or anal sex among persons 
diagnosed with HIV infection for > months who did not know the HIV status of their 
partners; and the sharing of needles or syringes among persons diagnosed with HIV 
infection for > months. Data from the Supplement to HIV/AIDS Surveillance (SHAS) 
show minimal changes in the indicators from 00 to 004 because prevention activities 
targeted to PLWH are a new component of CDC’s overall HIV prevention efforts.
Indicators for Goal  measure the percentage of HIV-positive test results from publicly-
funded counseling and testing sites with post-test counseling sessions and the 
percentage of HIV cases diagnosed before progression to AIDS. The percentage of 
HIV-positive tests remained relatively stable from 69%-7% from 000-003, while the 
percentage of diagnosed HIV cases slightly increased from 76%-78% from 000-004.
The indicator for Goal 3 measures the percentage of HIV/AIDS cases in care within 
three months of diagnosis. Available data showed an increase in the indicator from 
79%-85% between 000 and 004.
The indicator for Goal 4 measures the number of state and territories with integrated, 
confidential, name-based HIV/AIDS case surveillance systems.  As of January 2001, 
33 states and two territories had implemented HIV case surveillance using the same 
confidential system as AIDS for named-based HIV case reporting.  Three states 
converted names to codes for HIV reporting.  Seven states and Puerto Rico used coded 
identifiers for HIV reporting.  Six states had no HIV reporting system at that time.  As 
of April 006, all states and territories have some form of HIV reporting:  43 states use 
name-based reporting, two use name-to-code reporting, and five and the District of 
Columbia use coded identifiers.
In summary, most of the indicators for the above goals produced stable results for 
behaviors and incidence, while CDC notes significant progress in efforts to implement 
national HIV surveillance and to link HIV-infected persons to care (see Appendix G for 
more detail about these indicators).
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Appendix E: Progress Toward Reaching the Goals of the Plan
While available data do not demonstrate success in achieving the overall goal 
of reducing HIV infections by half, there is evidence of considerable progress in 
implementing activities that meet the objectives of the national HIV Strategic Plan.   
The table that follows highlights major activities undertaken by CDC in support of 





•  Released program announcements for Serostatus Approach to Fighting 
the HIV Epidemic framework in 00 and Advancing HIV Prevention 
Initiative in 003
•  PCM demonstration project awarded funds to 9 CBOs to evaluate 
effects of PCM on HIV transmission risk behaviors and health of PLWH
•  Published report of 12 interventions that show significant reduction in     
 unprotected sex and STD acquisition in PLWH.
MSM
•  North Carolina Men’s Health Initiative developed for DEBI intervention 
targeting AA MSM
•  Researching Brothers y Hermanos study to understand risk and 
experiences of AA and Latino MSM
Youth
•  Supports dissemination of 3 interventions for at-risk, homeless, runaway, 
and HIV-positive youth.
IDUs
•  Supports dissemination of 3 interventions for IDUs
•  Conducted research on intervention trials for HIV+ and HIV- IDUs and 
safety trials of Tenofovir.
Heterosexuals
•  Supports dissemination of 4 interventions for clinic patients, female sex 
workers, female partners of IDUs, and AA women  
•  Research activities include a video-based intervention in STD clinics, 
projects for incarcerated men, and safety of a microbicide to prevention 
heterosexual HIV transmission
Summary of progress toward reaching goals
30
Goal 2 Increasing motivation to HIV testing
• Recommends annual testing for MSM and routine offering of testing to 
reduce stigma
•  Conducted social networks demonstration for HIV positive and high-risk 
persons that increased prevalence of undiagnosed HIV among peer 
referrals
• Collaborating with state partners to design comic books in English and    
Spanish with HIV-related stories to be launched in Los Angeles
•  Launched PCRS demonstration projects in 003 to offer rapid testing 
among persons who were exposed to an HIV-positive partner
Improving access to HIV testing
•  Increased rapid testing availability for non-healthcare workers and   
migrant farm workers at 0 sites from 004-006
• Distributed more than half a million OraQuick devices to 5 US    
organizations from 003-005
Increasing routine VCT in healthcare settings
•  Launched demo projects of rapid HIV screening in  clinics at 5 sites 
nationwide. 
•  Evaluating alternative procedures for pre-test counseling prior to HIV 
testing.
Increasing number of persons who return for HIV test results
•  Data collected in two cycles from 003-005 show rate of return for 
results from 9%-95.4% among persons with negative and preliminary 
positive rapid test results.




Goal 3 Reducing disparities in access to care
•  Five different data sources from the HIV/AIDS Surveillance Report show 
8%-88% of whites and AAs were prescribed antiretroviral therapy.
•  From 004-006, CDC conducted demonstration project on rapid testing 
in Historically Black Colleges and Universities. Demonstrated capacity to 
provide direct referrals to case management and care.
Integrating prevention services
• CDC and other federal agencies published guidelines incorporating HIV 
prevention into medical care of PLWH.
•  Prevention in Care social marketing campaign launched to promote 
usage of guidelines among partners, providers, and patients.
Increasing proportion of HIV-infected persons linked to prevention 
services
•  Provided funding to National Network of STD/HIV Prevention Training 
Centers and AETCs to develop extensive training for medical care pro-
viders of HIV-infected patients.
•  The training was designed to assist HIV care providers incorporate 
science-based interventions to help their patients reduce risk behaviors. 
3,400 services providers completed the training by 006.
Promoting optimal level of medical services
•  HHS guidelines for use of antiretroviral agents widely used to improve 
and optimize level of medical care
Increasing linkage to care within 3 months
•  ARTAS randomized trial showed 78% of persons with case management 




Goal 4 Monitoring the epidemic
•  Developed integrated surveillance system to measure the incidence 
of new infections, track the prevalence of disease, monitor behaviors 
that place persons at risk for HIV, and provide locally relevant data for 
community planning.  
•  Funds 34 areas to conduct population-based HIV incidence surveillance; 
plans to provide precise estimate of recent HIV seroconversions by the 
end of 006.
•  Collects NHBSS data each year from 5 metropolitan statistic areas 
throughout the United States with the largest number of AIDS cases.  
Uses these data to guide the development and implementation of 
effective behavioral interventions for high-risk populations.
Implementing effective interventions
•  Identified 14 evidence-based interventions under the DEBI program.
•  Since 004, diffused  of the 4 interventions to CBOs and health
    departments.  
Evaluating programs and interventions
•  Developed and released PEMS in 004 to 4 health departments and 7
    CBOs. 
•  Currently analyzing final data and developing dissemination plans for
    PEMS.
Goal Progress/Activities
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Appendix F: CDC Discussion of Barrier for Each Goal
Additional barriers and challenges have been recognized by CDC. These insights are 
described below in reference to each goal.
Goal 1.  Despite numerous HIV prevention activities for this goal, there are several 
challenges in further reducing HIV risk behaviors. Effective interventions for African 
American and Latino MSM, and other priority populations, do not exist or have not been 
packaged for dissemination. Intertwining epidemics of substance abuse, poor mental 
health, STDs, poverty, violence and other structural factors play a critical role in placing 
persons at risk for HIV. The effects of HIV treatment have impacted public perception 
about the severity of and susceptibility to HIV.
“Prevention burnout and fatigue” are causing some communities to ignore CDC’s 
prevention messages.  Barriers exist to scaling-up the dissemination of evidence-
based interventions and adequately meeting the demands of communities.  Resources 
have not been sufficiently allocated to specific activities and local needs of certain 
communities.  Minimal progress has been made in determining the optimal mix of 
prevention strategies to achieve the greatest impact at both national and local levels.
Goals 2 and 3.  While there are numerous HIV prevention activities for goal  of the 
Plan, there are several challenges in increasing VCT. Most HIV testing is performed 
outside of public health settings. HIV counseling and testing sites that are supported by 
CDC dollars only administer ~5% of all HIV tests in the United States. State laws impact 
the legality and feasibility of implementing rapid test programs. Reimbursement issues 
have not been resolved to date. The integration of HIV screening programs into existing 
care settings poses a number of barriers.
Similarly, there are several challenges in increasing linkages to appropriate HIV 
prevention, care and treatment services.  Traditional disparities in accessing care still 
exist among some groups (e.g., racial and ethnic minorities, MSM, injection drug users). 
Competing priorities, time constraints, and other barriers are significant issues for HIV 
care providers.  Reimbursement issues for case management are unresolved.  Activities 
to develop and sustain capacity to collect high-quality data on clinical outcomes and 
access to care are extremely difficult for health departments, providers and CBOs to 
implement.
Goal 4.  Although numerous HIV prevention activities have been implemented for 
this goal, several challenges remain related to monitoring, evaluating, and delivering 
programs. Variations in reporting policies and priorities for HIV surveillance increase 
complexity. The tension between monitoring treatment and care versus incidence has 
not been resolved to date.  The intervention portfolio and pipeline for HIV are limited 
for MSM of color and other specific populations. Efforts to adapt and tailor existing 
interventions for certain groups are extremely difficult.
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Community norms play a critical role in the content of interventions and “appropriate” 
or “acceptable” messages to deliver. Several issues related to PEMS have not been 
sufficiently addressed, such as privacy and confidentiality for non-infected persons, 
data collection versus expanded testing, and lack of capacity and resources to compile 
PEMS data.  Local needs continue to compete with federal capacity in the areas of 
scaling-up surveillance systems or interventions, and to provide assistance in the face 
of shrinking resources and restrictions on new hires and travel.
There are additional reasons why CDC has not achieved the overarching goal to reduce 
new infections by half:
. Policy limitations affect what interventions are implemented and how resources are 
directed.
2. Scientific factors such as the epidemiology and transmission dynamics of HIV in the 
United States, behavioral factors, and public “optimism” with HIV treatment.
3. Contextual factors influence HIV transmission in the United States, including gender 
inequality and other societal issues; poverty, homelessness and other socioeconomic 
issues; mental health and substance abuse; and stigma, racism and homophobia.
HIV transmission is ongoing. HIV rates and transmission among MSM, African 
Americans, and heterosexual women continue to play a critical role in the HIV epidemic. 
“Prevention fatigue” has increased the difficulty in sustaining behavioral interventions.
Better interventions have not been developed to address geographic, risk, and racial/
ethnic diversities of the HIV epidemic in the United States.  Methamphetamine use 
serves as a strong barrier to implementing behavioral interventions.  National data are 
not available on risk behaviors among out-of-school, homeless and runaway youth.  
Legislative barriers still exist in implementing new HIV testing and counseling and 
models.  Issues related to stigma have not been adequately addressed in the United 
States.
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Appendix G: CDC Report of HIV Prevention Strategic Plan 
Activities and Progress
Background and Purpose
Since the publication of the CDC HIV Prevention Strategic Plan Through 005, CDC 
has identified 10 performance indicators to measure and monitor the progress of 
the overarching national goal and four domestic goals of the Plan.  In addition, CDC 
monitors and measures its progress regarding activities to achieve the goals and 
objectives in the Plan.  CDC has realigned prevention programs; conducted research to 
identify and disseminate interventions that are scientifically effective, have been formally 
evaluated, and shown to reduce the risk of HIV transmission; implemented a national, 
population-based incidence surveillance system as a supplement to HIV and AIDS case 
surveillance activities; and launched a new initiative that supports the HIV prevention 
work of the past two decades.  
This Summary Document highlights selected activities that address the overarching 
national and four domestic goals, and presents a summary analysis of the current 
performance data for the goal indicators, and assesses the overall impact of CDC 
efforts in achieving the Plan’s goals.
 
State of the U.S. Epidemic
 Overarching National Goal: Reduce the number of new HIV infections in the    
 United States from an estimated 40,000 to 20,000 per year by the year 2005,  
 focusing particularly on eliminating racial and ethnic disparities in new HIV  
 infections. [FY 2004 Funding: $741 million]1,2  
CDC estimates that currently approximately .0 to . million people in the United 
States are infected with HIV and about a quarter, 50,000 – 300,000, are unaware they 
are HIV-infected.  CDC believes that HIV transmission from people who are unaware 
of their infection status accounts for more than half of the estimated 40,000 new HIV 
infections that occur each year.  The majority of the new HIV infections are among
 The funding amounts presented here represent amounts spent in 004 by CDC’s National Centers on 
goals  - 4 of CDC’s HIV Strategic Plan.  They exclude amounts spent on Goal 5 (to assist in reducing 
HIV transmission and improving HIV/AIDS care and support in partnership with resource-constrained 
countries) and amounts for centralized rent, utilities, and program support at CDC.  They include funding 
transferred to CDC from HHS for the Minority AIDS Initiative.
 This figure represents amounts spent in 2004 by CDC’s National Centers on goals 1-4 of CDC’s HIV 
Strategic Plan.  It excludes amounts for centralized rent, utilities and program support and includes 
funding transferred to CDC from HHS for the Minority AIDS Initiative.
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African Americans and other people of color.  Indeed, African Americans are the hardest 
hit racial and ethnic population bearing a disproportionate burden of illness and death 
from the HIV/AIDS epidemic.  Data from 004 indicate that African Americans account 
for 50% of the new HIV/AIDS cases reported in 33 states and two territories with 
confidential name-based HIV reporting, and account for 51% of the people who died 
with AIDS.  The rate of HIV/AIDS diagnoses for African-American women is 3 times the 
rate for white women; and the rate of HIV/AIDS diagnoses for African-American men is 
8 times the rate for white men.  Moreover, despite the significant declines in perinatal 
HIV transmission, a national success story, African-American children still remain at 
disproportionate risk.  In 004, 7% of infants reported as having HIV/AIDS were African 
American, and 63% of U.S. children younger than 3 years of age who had a new AIDS 
diagnosis were African American.
Summary Analysis of Performance Indicators 
CDC has implemented four indicators to monitor progress of the Overarching National 
Goal.  Indicator  examines the number of people 3-4 years of age diagnosed with 
HIV/AIDS.  Trends in HIV/AIDS diagnoses among young persons <5 years of age 
are currently our best indicator of trends in new HIV infections (incidence), because 
these persons are likely to have been infected relatively recently.  The trends in this 
indicator have increased between 000 (baseline: ,98 HIV/AIDS cases) and 004 
(performance for most current year: 3,465 HIV/AIDS cases).  This increase may be 
interpreted in one of two ways: ) there is a true increase in incidence; or ) something 
has happened that has affected our measurement of this indicator (i.e., ascertainment 
bias: for example, an increase in the proportion of new infections diagnosed). 
The group where increases are most prominent is men who have sex with men (MSM); 
trends in other risk groups appear to be stable or decreasing.  Other data, such as 
trends in sexually transmitted diseases (STDs) in MSM, and increases among MSM 
in substance use (e.g., methamphetamine use) combined with sexual risk taking 
behaviors, suggest that high risk behaviors may also be rising within this risk group. 
Indicator  explores the rate of gonorrhea cases reported each year.  Trends in 
gonorrhea rates were selected as an indicator because this STD is an important 
indicator of risk behaviors that may put individuals at risk for HIV.  This indicator may 
also be useful to monitor Goal  of the Plan.  Between 000 and 004, the rate of 
gonorrhea declined from 8.7 cases per 00,000 population to 3.5 cases per 
00,000 population.  This trend may be interpreted to mean that there has been a 
decline in true gonorrhea transmission thereby suggesting a decline in sexual risk 
behaviors.  As with HIV trends, gonorrhea rates can also be affected by changes in 
screening patterns (especially in women) and changes in reporting practices.  Trends 
in gonorrhea have been declining steadily since the 970s and have only recently 
begun to level.  Since gonorrhea is largely a disease of adolescents and young adults, 
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declines may have also been influenced by declines in risk-taking behaviors in that 
population (e.g., increases in abstinence, improved partner selection, serial monogamy) 
and increases in condom use.  As with HIV, minorities are disproportionately affected 
by gonorrhea; in 004, nearly 70% of reported gonorrhea cases were among African 
Americans.  The rate of gonorrhea was nearly 9-fold greater in African Americans, 
3-fold greater in American Indian/Alaska Natives and -fold greater in Hispanics, 
compared with whites.
Indicator 3 highlights rates of syphilis cases reported each year.  Trends in primary 
and secondary (P&S) syphilis were selected as an indicator because this STD is an 
important indicator of risk behaviors that may put individuals at risk for HIV.  Historically, 
P&S syphilis has tracked well with trends in HIV, possibly because of the similarity 
in populations and risk behaviors for acquisition.  This indicator may also be useful 
in monitoring Goal  of the Plan.  Between 000 and 004, the rate of P&S syphilis 
increased from . cases per 00,000 population to .7 cases per 00,000 population; 
when the rates are stratified by men and women, the increases are occurring in men.  
This trend may be interpreted to mean that there has been a true increase in P&S 
syphilis and high-risk sexual behaviors in men.  P&S syphilis rates can also be affected 
by changes in screening and reporting practices.  As with HIV and gonorrhea, syphilis 
disproportionately affects African Americans.  In 004, the rate of P&S syphilis was 
nearly 6-fold higher in African Americans than whites, and 4% of reported P&S syphilis 
cases were among African Americans.
Indicator 4 focuses on the number of perinatally-acquired AIDS cases diagnosed each 
year.  This indicator is a measure of effectiveness of screening pregnant women for 
HIV and implementing effective interventions to prevent mother-to-child transmission.  
Trends in new perinatally-acquired AIDS cases have been monitored since early in the 
epidemic.  As prevention of mother-to-child HIV transmission (MTCT) and treatment 
for perinatally infected infants and their mothers have improved, the number of new 
cases of perinatally-acquired AIDS has dramatically declined.  Between 000 and 004, 
the estimated number of new perinatally-acquired AIDS cases declined from 4 to 
48 cases and may be approaching the theoretical number of transmission events that 
would occur if optimal prevention strategies were applied to all pregnant HIV-infected 
women.  African American infants are disproportionately affected; in 004, 60 (7%) of 
the 84 cases of HIV/AIDS in infants born to HIV-infected mothers and reported to CDC 




Two major activities addressing the overarching goal are: the CDC Minority AIDS 
Initiative (MAI) program, and the “Advancing HIV Prevention (AHP): New Strategies for 
a Changing Epidemic,” launched in April 003.  
CDC, through the MAI program, addresses the health disparities experienced in racial 
and ethnic communities.  Since Fiscal Year (FY) 999, Congressional language has 
included MAI resources to specifically target HIV prevention services to communities 
of color through direct funding of community-based organizations (CBOs).  In FY 
005, CDC used MAI funding to make over 50 awards for distinct projects.  CDC 
provided over $33 million in MAI funds to CBOs to provide HIV prevention services, 
over $7 million to support capacity building, and approximately $0 million for 
research, evaluation, and demonstration projects.  MAI funding has greatly enhanced 
CDC’s ability to provide resources directly to CBOs located in and serving minority 
communities and enhanced our ability to provide a range of HIV prevention services to 
disproportionately affected racial and ethnic communities.   
The AHP initiative represents a multi-agency collaboration within the Department of 
Health and Human Services, allowing CDC to strengthen partnerships and create 
ones with public and private entities and federal agencies to better address national 
efforts aimed at reducing HIV transmission.  AHP has four key strategies: . incorporate 
voluntary HIV testing a routine part of medical care; . implement new models for 
diagnosing HIV infections outside medical settings; 3. prevent new infections by working 
with persons diagnosed with HIV and their partners; 4. further decrease mother-
to-child HIV transmission.   Through AHP, CDC has placed increased emphasis on 
diagnosing individuals who are unaware of their HIV-positive status, particularly high-
risk groups such as men who have sex with men (MSM), injection drug users (IDUs), 
and disproportionately affected racial and ethnic communities; and increasing access 
to quality medical care, treatment, and ongoing  prevention services for people living 
with HIV.  The initiative’s four key strategies are incorporated throughout CDC’s HIV 
prevention program funding of CBOs and state and local health departments.  In 
support of the initiative, CDC provided funding for  demonstration projects to develop 
models and demonstrate efficacy for implementing the AHP strategies to 13 health 
departments,  CBOs, and 5 sites.  
Overall Impact of the Overarching National Goal
At this point, we have no national measure of the number of new HIV infections 
(incidence) in the United States.  While the number of persons currently living with HIV 
(prevalence) has increased each year--in large part due to improvements in medical 
treatments-- indirect measures suggest that HIV incidence has been stable or has 
possibly increased from 00 through 005.  It should be noted that the 50% decline 
called for by the overarching goal was predicated upon receiving additional resources.  
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While some increases in funding were provided to CDC, and were used for prevention 
programs for high-risk racial and ethnic minority populations, these were not sufficient to 
mount a national program to reduce transmission by half.
We have been successful in lowering infections among some sub-populations and risk 
groups.  For example, perinatal HIV transmission continued to decline as indicated by 
reductions in HIV/AIDS cases among children born to HIV-infected mothers.  Increased 
testing of pregnant mothers, highly-active-antiretroviral therapy, and surgical delivery 
of infants through C-sections all contributed to the decline.  Declines in HIV and AIDS 
cases, likely indicative of declines in HIV transmission, were also seen among injection 
drug users, possibly due to changes in needle sharing practices, changes in drug using 
behavior, and access to sterile injecting equipment.
  3The funding amounts presented here represent amounts spent in 004 by CDC’s National Centers on 
goals  - 4 of CDC’s HIV Strategic Plan.  They exclude amounts spent on Goal 5 (to assist in reducing 
HIV transmission and improving HIV/AIDS care and support in partnership with resource-constrained 
countries) and amounts for centralized rent, utilities, and program support at CDC.  They include funding 
transferred to CDC from HHS for the Minority AIDS Initiative.
 Goal 1: By 2005, decrease by at least 50% the number of persons  
 in the United States at high risk for acquiring or transmitting HIV  
 infection by delivering targeted, sustained and evidence-based HIV  
 prevention interventions. [FY 2004 Funding: $286.8 million;39% of  
 total] 3 
Background 
Of the estimated number of persons living with HIV in the United States, 47% are 
African American, 34% are white, 17% are Hispanic, <1% are Asian/Pacific Islander, 
and <% are American Indian/Alaskan Native.  By mode of exposure, an estimated 45% 
of persons living with HIV are MSM, % are IDUs, 5% are both MSM and IDUs, 7% 
were exposed through heterosexual contact, and % had an undetermined exposure.
Summary Analysis of Performance Indicators  
CDC has developed three indicators (Indicators 5-7) to monitor Goal .  Indicator 5 
monitors the percentage of students in 9th through th grade who reported safer 
sexual behaviors defined as:  a) never having engaged in sexual intercourse, b) 
were not sexually active in the past 3 months, or, c) if they had sexual intercourse in 
the past 3 months, they used a condom.   Data are from CDC’s Youth Risk Behavior 
Survey (YRBS).  Trends in the sexual behaviors of adolescents may indicate how 
well messages to reduce sexual risk are being incorporated into the lives of young 
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people.   Between 999 and 003, the percentage of 9th-th graders who engaged 
in safer sexual behaviors increased from 85% to 88% (the percentage who were 
abstinent increased from 50% to 53% during this period).  These data include only youth 
attending school and may not be representative of youth not in school, who may be at 
higher risk for HIV.
Indicator 6 monitors the percentage of persons diagnosed with HIV infection for > 
months who did not use a condom at last vaginal/anal sex when the status of the 
partner was unknown.  Condom use among HIV-infected persons who have sex with 
HIV-negative persons or those whose status is unknown is an important indicator of 
ongoing risk behaviors that lead to HIV transmission.  The data for this indicator are 
from the Supplement to HIV/AIDS Surveillance (SHAS) project.   Between 00 and 
004, the percentage of HIV-infected persons interviewed in SHAS who did not use a 
condom with a partner of unknown serostatus increased slightly from .3% to 3.4%.  
The SHAS project conducted in-depth interviews with a large number HIV-infected 
persons in a selected number of cities and states; however, the sampling methods 
were not uniform in these areas (some used convenience sampling and others used 
population-based sampling).  Therefore, small year-to-year fluctuations in the data 
may be due to differences in samples of persons interviewed rather than true changes 
in behaviors.  Also, during interviews, HIV-infected persons may not provide accurate 
information about sexual activities because of fear of negative feedback or stigma.  
CDC discontinued the SHAS project in 004, and, in its place, CDC has funded the 
Morbidity Monitoring Project (MMP).  MMP will interview a population-based sample of 
HIV-infected persons in care and out of care.  This new approach should provide more 
useful data; the first data from this project should be available in 2007.
Indicator 7 is the percentage of HIV-infected IDUs (diagnosed for > months) who 
shared a needle or syringe with some in the past  months; data come from the SHAS 
project.  This indicator decreased from 7% to in 00 to 3% in 00 and increased to 
7% in 2004.  As stated above, small year-to-year fluctuations in this indicator may not 
be meaningful due to the sampling limitations of the SHAS project.   The percentage of 
persons sharing needles and works is nevertheless very low and supports the declining 
trends we are seeing in new HIV diagnoses among IDUs.
All three indicators for Goal  lack a direct measurement of who actually received 
interventions that may have had impact on changing behaviors.  CDC has developed 
the Program Evaluation and Monitoring System (PEMS) to collect the data to address 
this problem.  CDC is currently working with its partners to identify the best ways to 
implement PEMS.
Selected Activities 
To address Goal , CDC conducted the Prevention Research Synthesis project to 
identify behavioral interventions with solid scientific evidence of efficacy.  Based on the 
findings from this project,  CDC develops and provides culturally competent, evidence-
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based HIV prevention interventions for persons at risk of acquiring or transmitting 
HIV through the Replicating Effective Programs (REP) and the Diffusion of Effective 
Behavioral Interventions (DEBI) project.  These prevention interventions target specific 
racial and ethnic groups and subpopulations at high risk for HIV.  CDC funds 65 
state and local health departments, 6 directly-funded CBOs, and other partners to 
provide these interventions across the United States.  To build the capacity among 
CDC partners; the agency also provides training and materials to implement these 
interventions.  Currently, there are 4 CDC supported evidence-based prevention 
interventions that target both HIV-infected and uninfected persons.  CDC has diffused 
 of those interventions to funded grantees.  The interventions have been designed to 
exclusively target high-risk groups but are also adaptable to other groups.  For example, 
79% of directly-funded CBOs provide evidence-based prevention interventions for 
high-risk sexually active MSM and their partners; 58% of directly-funded CBOs provide 
interventions for sexually active IDUs and their partners; and 8% of directly-funded 
CBOs provide interventions serving high-risk sexually active women and their partners.  
CDC also provides DEBI trainings to individuals, state and local health departments, 
and directly and indirectly-funded CBOs.  These efforts are complemented by an 
extensive capacity building assistance (CBA) program which aims to help grantees 
effectively implement scientifically based prevention programs.  In 2004, CDC 
provided funding to 7 organizations to provide CBA in the adaptation, tailoring, and 
implementation of HIV prevention interventions for people living with HIV or AIDS, their 
serodiscordant partners, and others at very high risk of HIV infection.
In 003, CDC launched the AHP initiative.  The goal of the initiative is to reduce HIV 
transmission in the United States, particularly by expanding HIV testing and increasing 
the number of people who are aware of their infection.  AHP focuses primarily on 
populations at high risk for acquiring and transmitting HIV, such as MSM, IDUs, 
heterosexual men and women, adolescents, and persons infected with HIV; the 
majority of which are racial and ethnic minorities.  Through AHP, CDC refocused its 
prevention strategy by placing greater emphasis not only on diagnosing individuals who 
are unaware of their HIV status but also providing prevention services to HIV-infected 
persons.  CDC has also directed community planning groups across the country to 
make people living with HIV their highest priority target population.  
One key AHP strategy is to “prevent new infections by working with people diagnosed 
with HIV and their partners.”  Results from two AHP demonstration projects:  
“Prevention Case Management for Persons Living with HIV/AIDS” and “Incorporating 
HIV Prevention into Medical Settings” has led CDC to embark on a modification of 
the Comprehensive Risk Counseling and Services (CRCS), formerly referred to as 
Prevention Case Management, guidelines to better coordinate case management for 
persons living with HIV with other federal agencies.
Another key AHP strategy is to further decrease perinatal HIV transmission.  Effective 
interventions can reduce perinatal HIV transmission to less than % among HIV-infected 
pregnant women.  For this reason, CDC is striving to ensure that no child is born in the 
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United States whose HIV status (or whose mother’s HIV status) is unknown.  Reduction 
of perinatal HIV transmission is one of the nation’s most remarkable HIV prevention 
successes.  In supporting implementation of this strategy, CDC is working with partners 
to promote routine prenatal HIV testing using an “opt-out” approach (i.e., pregnant 
women are told that an HIV test will be included in the standard group of prenatal tests 
and that they may decline the test), developing guidance for using rapid tests during 
labor and delivery or immediately post partum, providing training in conducting prenatal 
testing, and monitoring the integration of routine prenatal testing into medical practice. 
Overall Impact of Goal 1 
Between 00 and 005, CDC broadened the scope of its programs to include 
prevention programs for people living with HIV and increased the focus on the 
most effective prevention interventions.  Through the AHP initiative, CDC provided 
increased funding for identifying and promoting prevention services for those living 
with HIV, particularly in the context of medical care.  CDC identified proven behavioral 
interventions for those at risk for becoming infected with HIV as well as those at risk for 
transmitting HIV and translated those into packages for use by grantees.  Thousands 
of HIV prevention service providers were trained on provision of these interventions 
beginning in 00.  CDC provided support for adapting and tailoring interventions for 
specific groups at risk for HIV and encouraged grantees to target services for those 
high-risk communities.  CDC also increased access to and provision of HIV testing, one 
of the most effective interventions for preventing HIV transmission.  People who know 
they are infected they are likely to change their behavior.  The agency continued to work 
to develop and test new interventions including antiretroviral prophylaxis through trials 
in the United States and internationally, microbicides through laboratory studies and 
animal models, and prepared international sites for large scale HIV vaccine trials.
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 Goal 2: By 2005, through voluntary counseling and testing, increase  
 from the current estimated 70% to 95% the proportion of HIV-infected  
 people in the United States who know they are infected. [FY 2004  
 Funding: $200.2 million; 27.0%  ] 4
Background
CDC is very concerned about the estimated 5% of HIV-infected persons 
(approximately 50,000-300,000) in the United States who are unaware of their 
infections and at risk for unknowingly transmitting HIV.  As part of the AHP initiative, 
identifying persons with undiagnosed HIV infection and linking them to appropriate care 
is a national priority.  With this new priority, CDC has focused many of its efforts on 
making testing a routine part of medical care and instituting new models for diagnosing 
HIV infections in non-clinical settings, with the ultimate goal of increasing the proportion 
of HIV-infected persons who know their serostatus.  
Summary Analysis of Performance Indicators  
CDC has developed two indicators (Indicators 8 and 9) to monitor progress on Goal .  
Indicator 8 is the percentage of HIV-positive tests performed in publicly-funded clinics 
that were associated with post-test counseling sessions.  Data for this indicator are from 
CDC’s Counseling and Testing System (CTS).    Between 000 and 003, the number 
of tests accompanied by post-test counseling sessions remained relatively stable at 
69% to 7%.  CTS may not be able to measure this percentage very well because of the 
difficulties many clinics have in entering post-test counseling sessions into the system, 
especially when these sessions occur long after the test was performed.  As HIV rapid 
testing is implemented more widely, individuals may increasingly be able to get their 
test results and receive post-test counseling at their initial visit, and this indicator may 
show improvement.  Within the next year, CTS will be incorporated into the Program 
Evaluation Monitoring System (PEMS) which may yield more complete and higher 
quality information.
Indicator 9 is the percentage of HIV cases diagnosed at least one calendar month 
before progression to AIDS.  The data for this indicator are from the HIV/AIDS Reporting 
System.  Between 000 and 004, the percentage of persons diagnosed before 
progression to AIDS has increased slightly from 76% to 78%; while this increase may 
not yet be statistically significant, the trend is encouraging.  The current data are only 
available for 30 states with longstanding name-based HIV reporting policies; as more 
4The funding amounts presented here represent amounts spent in 004 by CDC’s National Centers on 
goals  - 4 of CDC’s HIV Strategic Plan.  They exclude amounts spent on Goal 5 (to assist in reducing 
HIV transmission and improving HIV/AIDS care and support in partnership with resource-constrained 
countries) and amounts for centralized rent, utilities, and program support at CDC.  They include funding 
transferred to CDC from HHS for the Minority AIDS Initiative.
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states adopt name-based HIV reporting, the data will become increasing representative. 
In the past two years through the AHP initiative and other activities, CDC has focused 
resources on expanding testing into new venues, targeting existing testing programs 
toward higher risk populations, and implementing rapid testing technology into its 
programs.  CDC is also developing new guidelines for testing in medical care and non-
medical care settings.  With these efforts, it is anticipated that many more infected 
persons will be diagnosed earlier, and this indicator will show continued improvement.           
Selected Activities 
CDC currently provides nearly $00 million per year for counseling and testing activities 
to health departments and to directly funded CBOs.  Efforts to expand HIV testing in 
both clinical and non-clinical settings were central to the AHP initiative, as well as the 
promotion of the use of rapid HIV tests for quick diagnosis of one’s serostatus.  From 
003-005, CDC purchased and distributed more than 500,000 rapid HIV tests to 97 
health departments and CBOs in 36 states.  Through March 005, 64,4 persons 
were tested and 3,694 (.4%) persons tested HIV positive.  In jurisdictions that have 
implemented rapid HIV testing, the rate of receipt of test results has increased from 
60%-65% to more than 95%.  Nearly all HIV-negative persons receive their test result 
on the day of testing; all persons with reactive rapid tests receive a preliminary positive 
result, and more than 90% return to receive their confirmatory positive test result.  
In 2003, CDC funded four demonstration projects specifically designed to increase HIV 
testing rates in specific populations at high risk for HIV infection through the use of rapid 
testing.  For example, eight CBOs in seven cities were funded to implement rapid HIV 
testing in non-clinical settings such as bars and parks.  As of December 005, 5,4 
persons had been tested for HIV, and 336 had confirmed positive results (HIV- positivity 
= .3%).  Also through funding to four state health departments, routine rapid HIV 
testing of inmates in short-stay correctional facilities was conducted.  As of April 006, 
3,39 inmates had received a rapid HIV test.  Overall, more than 99% of inmates 
received their HIV test results and the overall positivity rate was 0.8% (range 0.%-
.4%).  CDC is also offering HIV testing in alternative venues and populations, such as 
Historically Black Colleges and Universities, gay pride events and minority gay pride 
events, and at sites that serve migrant and seasonal farmers, transgendered persons, 
or American Indians.   
To reach persons infected with HIV who do not have access to traditional medical 
settings, CDC funded demonstration projects for diagnosing HIV infections outside 
medical settings.  One of the most promising projects is “Using Social Network 
Strategies to Reach Persons at High Risk for HIV infection in Communities of Color.”  
Through funding to nine CBOs in seven cities, HIV-infected and high-risk individuals 
in communities of color were trained to conduct outreach through social, sexual, and 
drug-using networks and encourage their peers to be tested.  Through December, 005, 
47 recruiters participating in the project referred 3,5 persons in their networks.  Of 
these persons, 222 were HIV-infected and 179 were newly identified HIV infections.  
45
The seropositivity rate across all sites was 5.5%, approximately three times higher 
than the seropositivity rate found in publicly funded HIV test sites (.5%).  The social 
networks strategy has proven to be a viable strategy for reaching and providing CTR 
services to persons with undiagnosed HIV infection and an efficient and effective 
route to access HIV-infected persons or those at very high risk for HIV.  In 005, CDC 
formally encouraged funded grantees to implement the social networks strategy, and 
in November 005, CDC held a Social Networks grantees’ meeting to discuss and 
review their project experiences, opportunities and challenges to the broader adoption 
of the social networks model.  CDC is currently developing a social networks tool kit, 
an implementation manual, and training curriculum that includes technical assistance 
strategies to CDC grantees targeting MSM and women of color.   
To complement these efforts, CDC is currently revising and updating three important 
HIV guidance documents.  The first, “Revised Recommendations for HIV Testing of 
Adults, Adolescents, and Pregnant Women in Health Care Settings,” is expected to be 
published in mid-006.  The guidelines are being revised to recommend HIV screening 
in all health care settings of all persons aged 3-64, will recommend including HIV 
testing as part of the general consent for care, and will propose that traditional HIV 
prevention counseling is not required in conjunction with HIV testing in health care 
settings.  The second, “Revised Guidelines for HIV Counseling, Testing, and Referral 
for Non-Health Care Settings,” is expected to be published in late 007.  These 
revisions will specifically address both traditional and new models of counseling, testing, 
and referral and will be aimed at a variety of settings, such as bars, drug or alcohol 
prevention and treatment programs, CBOs, and faith-based organizations.  The third, 
“HIV Partner Counseling and Referral,” is expected to be published in early to mid 007 
and will be integrated into the agency guidelines for STD partner services. 
In the President’s 007 budget an increase of $90 million is requested for a rapid 
HIV testing initiative targeted in health care and non-clinical settings and among 
incarcerated persons and IDUs.  The intent is to reach those high-risk persons who do 
not access current testing services.  
The structure of CDC program activities convey the importance of people knowing their 
status following HIV testing.  Program announcements have measurable outcomes that 
are in alignment with performance goal(s), which include increasing the proportion of 
HIV-infected people who know they are infected, as well as increasing HIV prevention 
outreach and education efforts to high-risk populations to encourage them to know their 
HIV status.  To ensure this focus, upon the delivery of test results persons are linked to 
services through HIV Partner Counseling and Referral Services (PCRS).  
Overall Impact of Goal 2
CDC has increased emphasis on knowledge of serostatus to facilitate entry into 
effective care and prevention services and because it reduces risk behavior by nearly 
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two thirds among those who learn they are HIV-infected.  Despite over 50,000 new 
HIV diagnoses every year, and more people knowing they are living with HIV, at least 
50,000 people are unaware they are living with HIV.  CDC has increased testing 
through distribution of rapid HIV tests which have augmented receipt of positive 
test results - 84% in 004, up from 8% in 003 in publicly funded testing venues, 
encouraging use of oral fluid testing that increases testing by 30%, testing new 
strategies for outreach including recruiting people through their social networks where 
nearly 6% are found to be positive, and supporting established and proven interventions 
including PCRS. 
 Goal 3: By 2005, increase from the current estimate of 50% to 80%  
 the proportion of HIV-infected people in the United States who are  
 linked to appropriate prevention, care and treatment services. [FY  
 2004 Funding: $43.l million; 6% of total] 5
Background
For the past decade, CDC has estimated 40,000 new HIV infections occur annually in 
the United States.  One factor involved in this stable rate is the delay between receiving 
an HIV diagnosis and seeking HIV primary care.  It is estimated that of the 670,000 
adults in the United States aware of their HIV infection, about one-third fail to receive 
timely care.  This is, in part, because about 40% of those testing positive delay care 
for a year or more.  With CDC’s increased focus on ensuring that people are aware 
of their HIV status, delays in seeking care may become more problematic.  When 
people delay care, they fail to get the benefits of care, including ongoing counseling 
which leads to behavior change and reduced HIV transmission and initiation of highly 
active antiretroviral therapy which reduces HIV levels and can decrease the risk of 
transmission.  To address this issue, CDC has prioritized linking HIV-infected persons to 
appropriate prevention, care and treatment services soon after receiving an HIV positive 
test result, and has implemented various programs and activities focused on this goal 
and related objectives.  
5 The funding amounts presented here represent amounts spent in 004 by CDC’s National Centers on 
goals  - 4 of CDC’s HIV Strategic Plan.  They exclude amounts spent on Goal 5 (to assist in reducing 
HIV transmission and improving HIV/AIDS care and support in partnership with resource-constrained 
countries) and amounts for centralized rent, utilities, and program support at CDC.  They include funding 
transferred to CDC from HHS for the Minority AIDS Initiative.
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Summary Analysis of Performance Indicators  
CDC has one indicator (Indicator 0) to monitor this goal: the percentage of HIV/AIDS 
cases in care within three months of diagnosis.  The data source for this indicator is the 
SHAS interview project (described above).  Between 00 and 004, the percentage of 
HIV-infected persons interviewed in SHAS who said they received medical care within 
three months of their initial diagnosis increased from 79% to 85%.  While SHAS data 
are not fully representative due to sampling methods explained under Indicator 6 above, 
this trend is encouraging.  Most patients interviewed in the SHAS project were in care 
at the time of interview, and, therefore, SHAS may overestimate the true percentage 
of persons who received care within three months of diagnosis.  When CDC begins to 
receive data from its Morbidity Monitoring Project (MMP) in 007, it is anticipated that 
more representative data for this indicator will be available.  
Selected Activities 
The AHP initiative focused CDC’s efforts on conducting HIV prevention with the large 
population of HIV-infected persons, collaborating with other federal agencies as well as 
primary medical care providers to ensure that HIV-infected persons receive specialized 
individually tailored assistance based on their HIV risk reduction needs.  
Two AHP demonstration projects support this goal.  Through funding to six sites, 
CDC implemented the “Incorporating HIV Prevention into Medical Care Settings,” to 
assist clinicians in incorporating HIV prevention into the medical care of HIV-infected 
individuals; while assessing their impact on patient-reported risk behaviors, STD rates, 
tailored risk-reduction counseling, and referrals.  As of August 005, ,086 patients have 
been screened; ,09 were enrolled in a measurement cohort, and all patients attending 
the clinics were given the Positive Striving to Engage People (S.T.E.P.S) intervention.  
A second project, “Prevention Case Management for People Living with HIVAIDS,” 
provided funding to nine CBOs in seven states and Washington, D.C. to provide 
specialized Comprehensive Risk Counseling and Services to HIV-infected persons 
with multiple and complex HIV risk reduction needs.  As of January 006, 480 persons 
have been enrolled in this program; of these 66% were African-American and 4% 
were Hispanic.  The primary referrals provided through this program were for housing 
assistance, drug counseling and treatment, mental health services, Ryan White CARE 
Act (RWCA) case management, and psychosocial support groups.  
A third demonstration project focusing on linkage to prevention, care and treatment 
for HIV-infected individuals is the “Antiretroviral Treatment and Access Studies II” 
(ARTAS II) that is based on the significant findings of the ARTAS I clinical trial of 
linking newly diagnosed HIV-infected persons to care.  The ARTAS I trial revealed a 
31% improvement in the first use of HIV clinic care after six months of follow-up for 
case management clients compared to standard one-time referrals, and also found a 
37% improvement in the use of HIV clinical care twice after  months of follow-up in 
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the case management group compared to the standard one-time referrals.  In 004, 
CDC provided funding to 0 sites for the ARTAS II study.  The goal of this project is 
to determine whether a 75% rate of linkage to care can be attained in non-research 
settings.  As of August 005, 8 persons living with HIV had been approached and 
screened for participation, and 37 participants have been enrolled.
To monitor the quality of services for HIV-infected persons, CDC, in collaboration with 
the Health Resources and Services Administration (HRSA) and the National Institutes 
of Health (NIH), developed the Morbidity Monitoring Project (MMP), a nationally 
representative, population-based surveillance system to assess clinical outcomes, 
behaviors, and the quality of HIV care.  Data are being collected from a national 
probability sample of HIV-infected persons receiving care in the United States, and 
describes the clinical and virologic status of recruited patients, the HIV care and 
support services, as well as quality of services being received and the prevalence and 
occurrence of co-morbidities related to HIV disease.  In 004, CDC provided funds to 0 
states and six cities to collect information in facilities across the United States.  Data for 
planning, evaluation, monitoring, and allocation of resources will be available in 007.  
Through the Diffusion of Effective Behavioral Interventions (DEBI) project, seven of the 
4 interventions are designed to meet the prevention needs of people living with HIV 
and to teach prevention providers at the community level how to recruit individuals into 
prevention with positive interventions or build the capacity to teach medical clinicians 
how to provide appropriate prevention messages to their HIV-infected patients.  The 
interventions with a special emphasis on recruitments include: Healthy Relationships, 
Holistic Health Recovery, and Partnership for Health.  
Finally, CDC has augmented efforts to work with HRSA realizing that increases in HIV 
diagnoses will result in increases in need for treatment and care services.  CDC and 
HRSA have established an ongoing collaboration to ensure that prevention, care and 
treatment services are well coordinated among their grantees.   For example, CDC 
and HRSA are working together with the National Association of Community Health 
Centers (NACHA) to promote HIV testing as part of routine medical care.  CDC is also 
working with HRSA to develop uniform HIV testing policies for grantees; strategies to 
link newly diagnosed persons to care and treatment services; re-entry procedures to 
link HIV-infected individuals to HIV prevention and treatment services in the community; 
training of providers; and procedures to provide HIV/STD prevention services for high-
risk uninfected persons either on-site or through referral mechanisms to CDC supported 
programs in the community.  
Overall Impact of Goal 3    
Referral to clinical and prevention services is routinely provided to clients through 
CDC funded testing programs.  In addition, CDC, in collaboration with federal, state, 
and community partners has implemented a number of discrete activities to increase 
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the proportion of HIV-infected people who are linked to appropriate prevention, care, 
and treatment services and to provide prevention services to those living with HIV.  
These activities include development of guidelines, funding demonstration projects, 
translation of proven behavioral interventions for people living with HIV, and research 
and surveillance projects. 
CDC has developed new guidelines for Comprehensive Risk Counseling and Services 
(CRCS) which links high-risk HIV-positive and -negative individuals to appropriate 
services as well as provides risk-reduction services.  In a project with nine CBOs, 
480 persons were enrolled and clients have been linked to housing assistance, drug 
counseling and treatment, mental health services, RWCA case management and 
psychosocial support groups. 
CDC, in collaboration with HRSA, NIH, and the Infectious Diseases Society of America 
(IDSA), published guidelines for “Incorporating HIV Prevention into Medical Care.”  In 
an AHP demonstration project, over ,000 HIV-infected patients were enrolled in a 
project incorporating the STEPs intervention.  Several health departments were funded 
to implement medical staff provided interventions for people living with HIV including 
Partnerships for Health and Sisters Informing Sisters on Topics about AIDS (SISTA).  
In addition, CDC has funded a project to teach physicians how to provide appropriate 
prevention messages to their HIV-infected patients.  CDC developed the “Antiretroviral 
Treatment and Access Studies I and II” and showed that a linkage case manager 
can significantly increase linkage to care and adherence to antiretroviral therapies; a 
demonstration project is ongoing.  
To improve care for pregnant women and to reduce perinatal transmission, CDC is 
evaluating Perinatal Prevention Case Management and is evaluating interventions for 
adherence to antiretroviral therapies among children perinatally infected with HIV. 
To monitor quality of care, CDC has been conducting the Hospital Outpatient Study 
collecting data on 8,000 patients in 0 HIV-specialty clinics across the United States.  
CDC recently launched the population-based MMP that will assess quality of care and 
risk behaviors among those in care. MMP will also be the basis for a study to identify 
those not in care and look at factors to explain their lack of care and how to link them to 
care and prevention services. 
Overall, CDC’s major roles in Goal 3 are linking people tested in agency programs to 
appropriate services, improve prevention services for people in care, and monitor the 
quality of their care and their risk behavior.  However, as previously indicated, SHAS 
data (our current indicator) are not fully representative of the population of interest.   
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 Goal 4: By 2005, strengthen the capacity nationwide to monitor  
 the epidemic, develop and implement effective HIV prevention  
 interventions and evaluate prevention programs. [FY 2004 Funding:  
 $210.8 million; 28% of total] 6
Background
CDC’s HIV/AIDS surveillance system is the nation’s key source of information used to 
track the epidemic. CDC funds HIV/AIDS surveillance in 65 areas to monitor the number 
and characteristics of persons who have been diagnosed with HIV and trends in the 
incidence of HIV-related morbidity and mortality.  
In July 005, CDC formally recommended that all states and territories adopt 
confidential name-based surveillance systems to report HIV infections. CDC policy is 
to accept HIV infection and AIDS case surveillance data only from areas conducting 
confidential name-based HIV reporting because this reporting has been shown to 
routinely achieve high levels of accuracy and reliability.  As of April 006, 43 states and 
5 territories have adopted confidential, name-based HIV reporting.  
Summary Analysis of Performance Indicators 
For Goal 4, CDC has one performance indicator (Indicator ): the number of states 
and territories with integrated, confidential, name-based HIV/AIDS case surveillance 
systems for adults and adolescents.  Prior to the advent of highly effective HIV 
therapies, data on AIDS (which has been reported through name-based systems since 
the beginning of the epidemic) was reasonably adequate to monitor the epidemic; 
however, as the proportion of HIV-infected persons progressing to AIDS has declined, 
it is increasingly important to have information on the larger population of HIV-infected 
persons who have not yet developed AIDS.   Data from the HIV/AIDS case surveillance 
system are used as the basis for the fair allocation of both prevention and care 
resources by multiple federal agencies.  In states with confidential, name-based HIV 
reporting, the state and local health departments retain the names of persons in their 
case registries to assist them in follow-up of epidemiologically important cases and 
de-duplication of cases from multiple jurisdictions; names are not sent to the federal 
government.  This is the same method as that used for AIDS cases.   In 000, there 
were 3 states and  territories with name-based HIV/AIDS case surveillance systems.  
By 006, these numbers increased to 43 states and 5 territories.   The remaining states 
6The funding amounts presented here represent amounts spent in 004 by CDC’s National Centers on 
goals  - 4 of CDC’s HIV Strategic Plan.  They exclude amounts spent on Goal 5 (to assist in reducing 
HIV transmission and improving HIV/AIDS care and support in partnership with resource-constrained 
countries) and amounts for centralized rent, utilities, and program support at CDC.  They include funding 
transferred to CDC from HHS for the Minority AIDS Initiative.
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use non-name-based systems with coded identifiers.  These have not been shown to 
allow adequate de-duplication of cases, and they are much more costly because of the 
extensive follow-up needed to confirm codes.  At all levels of government where name-
based data are held, elaborate security and confidentiality procedures have been put 
into place to protect the confidentiality of individuals. It is hoped that a uniform national 
HIV/AIDS case surveillance system will be implemented by the end of the decade.  An 
important impetus for states to move to name-based reporting has been the Ryan White 
CARE Act, which requires the use of HIV data to make resource allocations for HIV/
AIDS care and treatment.
Selected Activities
CDC currently funds a total of 34 areas to conduct a population-based incidence 
surveillance system using the Serologic Testing Algorithm for Recent HIV 
Seroconversion (STARHS).  STARHS is a way of analyzing HIV-positive blood samples 
to determine whether an HIV infection is recent or has been long-standing.  The system 
is expected to provide the clearest picture yet of the magnitude of the domestic HIV 
epidemic, as well as aid CDC in more effectively targeting HIV prevention efforts to 
promote decreases in the incidence of new HIV infections.  Date on estimates of 
incidence are expected in mid-006.
In addition to assessing infection and disease trends, CDC conducts the ongoing 
National HIV Behavioral Surveillance (NHBS) system to monitor risk behaviors, testing, 
and use of prevention services among three groups of persons at risk for HIV infection:  
MSM, IDUs, and high-risk heterosexual adults.  Data are collected from one group 
per year in 5 metropolitan statistical areas across the United States.  Data collection 
began for MSM in 004; for IDUs in 005; and for high-risk heterosexuals in 006.   The 
information collected in NHBS will be used to develop and implement effective HIV 
prevention programs for these high-risk groups.  
In conjunction with tracking disease trends and monitoring risk behaviors, the provision 
of locally relevant data for community planning is an integral component of this goal.  
In 004, CDC funded four organizations under the new CBA program to provide 
assistance and training to state and local health departments and HIV prevention 
community planning groups to assure high-quality incidence, prevalence and behavioral 
profile reporting.  Through this program, organizations are required to provide CBA to 
help community planning groups understand surveillance data, particularly how to apply 
locally relevant information to community planning activities.  
The DEBI project is CDC’s primary means of disseminating scientifically proven, 
evidence-based interventions to funded grantees.  Over the past 3 years, CDC has 
diffused  of the 4 interventions to CBOs and health departments, and provided 74 
DEBI trainings to ,55 CBOs; 400 county, city, state, and territorial health departments; 
and 5,36 individuals.  
5
In 004, CDC responded to the need for more accurate and timely data for monitoring 
HIV prevention programs by designing and implementing the Program Evaluation and 
Monitoring System (PEMS).  PEMS is a national data reporting system that aims to 
strengthen the capacity to monitor and evaluate CDC-funded HIV prevention programs 
supported or delivered by health departments and CBOs.  PEMS is being rolled out 
and developed in phases.  It was first released in late 2004 to 42 health departments 
and 7 CBOs with the goal of improving reporting capabilities between the CDC, health 
departments, and CBOs.  The system includes a standardized set of HIV prevention 
data variables to measure and track prevention processes and outcomes, such as HIV 
counseling and testing results, client risk factors for HIV transmission, service utilization, 
and detailed risk behaviors.  Also to monitor the implementation of quality evidence-
based behavioral programs and interventions, data from PEMS will include detailed 
information on the program services as intended and actually delivered to clients.  
This information will enable CDC and funded-grantees to demonstrate successful 
programs as well as modify program activities to improve service delivery and achieve 
programmatic goals. 
Overall Impact of Goal 4
From 00 through 005, CDC revamped its surveillance system, its CBA program, 
and program evaluation system.  CDC has argued for the implementation of name-
based HIV reporting and 43 states and 5 territories now have name-based HIV reporting 
systems.  CDC has implemented a national surveillance system to estimate HIV 
incidence with the first estimates expected in 2006.  A national behavioral surveillance 
system in 5 MSAs has been implemented with a focus on MSM, IDUs, and high-risk 
heterosexuals.  CDC is also implementing a population based system for monitoring 
quality of care and risk behaviors of those living with HIV. 
With the development of prevention packages of proven behavioral interventions, 
CDC has revamped its CBA program.  There is a greater focus on using such proven 
interventions and thus a need for training.  Over 5,000 individuals have been trained on 
how to provide these services.  
CDC is in the process of implementing PEMS.  Currently, 0 directly-funded agencies 
are using PEMS to collect data on their services, target populations, and budgets.  Over 
time, more providers are expected to use the system as CDC directly funded agencies 
provide their contract agencies (indirectly funded) access to PEMS.  The system will 
be used to collect information on individual clients to help understand the quality and 
outcome of services.  When it is fully implemented in a couple of years, it will provide 
valuable data to service providers for improving services and to policy makers to better 
guide programs and direct resources. 
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WORKING DRAFT
CDC’s Goals and Objectives for HIV Prevention
Strategic Plan Activities and Progress Made
Overarching National Goal
Reduce the number of new HIV infections in the United States from  
an estimated 40,000 to 20,000 per year by 2005, focusing particularly 
on eliminating racial and ethnic disparities in new HIV infections.
.   By 005, decrease by at least 50% the number of persons in the United States at 
high risk for acquiring or transmitting HIV infection by delivering targeted, sustained 
and evidence-based HIV prevention interventions.
.   By 005, through voluntary counseling and testing, increase from the current 
estimated 70% to 95% the proportion of HIV-infected people in the United States 
who know they are infected.
3.   By 005, increase from the current estimated 50% to 80% the proportion of HIV-
infected people in the United States who are linked to appropriate prevention, care 
and treatment services.
4.   By 005, strengthen the capacity nationwide to monitor the epidemic, develop and 
implement effective HIV prevention interventions and evaluate prevention programs.
Goal 1
By 2005, decrease by at least 50% the number of persons in  
the United States at high risk for acquiring or transmitting 
HIV infection by delivering targeted, sustained and evidence- 
based HIV prevention interventions.
Objective :  Among people living with HIV, increase the proportion who consistently 
engage in behaviors that reduce risk for HIV transmission or acquisition.
Objective :  Among men who have sex with men (MSM), increase the proportion who 
consistently engage in behaviors that reduce risk for HIV acquisition or transmission.
 Objective 3:  Among adolescents, increase the proportion who consistently engage in 
behaviors that reduce risk for HIV acquisition or transmission.
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Objective 4:  Among injecting drug users (IDUs), increase the proportion who abstain 
from drug use or, for those who do not abstain, use harm reduction strategies to reduce 
risk for HIV acquisition or transmission.
Objective 5:  Among at risk sexually active woman (including women who have sex with 
other women), and at-risk heterosexual men, increase the proportion who consistently 
engage in behaviors that reduce risk for HIV acquisition or transmission.
Objective 6:  Increase the proportion of people at highest risk for HIV who are tested for 
STDs and treated appropriately.
Objective 7:  Increase the proportion of HIV-infected pregnant women who routinely 
receive HIV counseling, accept HIV testing and choose to take antiretroviral medication 
to interrupt perinatal transmission of HIV.
Objective 8:  Support HIV vaccine research.
Objective 9:  Reduce the number of workers who are occupationally exposed to and 
infected with HIV.
Objective 0:  Continue to monitor and support the safety of blood, tissue and organ 
supplies in the United States.
Goal 2
By 2005, through voluntary counseling and testing, increase from  
the current estimated 70% to 95% the proportion of HIV-infected 
people in the United States who know they are infected.
Objective :  Increase the motivation of at-risk individuals to know their infection status 
and decrease real and perceived barriers to HIV testing.
Objective :  Improve access to voluntary, client-centered counseling and testing (VCT) 
in high seroprevalence communities and populations at risk, focusing particularly on 
populations with high rates of undiagnosed infection.
Objective 3:  Increase the number of providers who routinely provide VCT in health care 
settings (e.g., STD clinics, substance abuse treatment programs, family planning clinics, 
emergency rooms, community health centers), as well as in nonclinical venues (e.g., 
social venues, public assistance programs, street outreach).




By 2005, increase from the current estimated 50% to 80%  
the proportion of HIV-infected people in the United States who are 
linked to appropriate prevention, care and treatment services.
Objective :  Reduce the disparities in access to prevention and care services that are 
experienced by communities of color, women and special-needs populations.
Objective :  Integrate prevention services, including adherence to treatment, for 
persons diagnosed with HIV and AIDS into the delivery of patient care in both public and 
private sectors.
Objective 3:  Increase the proportion of persons who have been diagnosed with HIV 
who are successfully linked to culturally competent, science-based prevention services.
Objective 4:  Promote the optimal level of medical services for patients diagnosed with 
HIV to benefit individual health and reduce the likelihood of further transmission of HIV.
Objective 5:  Increase the proportion of persons diagnosed with HIV who are 
successfully linked to medical care no later than 3 months after learning their HIV status 
or re-identified as being HIV-infected but out of care.
Objective 6:  Increase the proportion of correctional facility detainees (incarcerated for 
at least 30 days) identified as HIV-infected who are provided HIV prevention, treatment 
and care services and who, upon release, are successfully linked to those services in 
the communities to which they return.
Objective 7:  Increase the proportion of HIV care providers offering routine, periodic 
STD screening and treatment to HIV-infected clients.
Objective 8:  Increase the proportion of HIV care providers offering routine, periodic TB 
screening and treatment to HIV-infected clients.
Objective 9:  Increase the proportion of persons diagnosed with HIV, including pregnant 
women, and needing substance abuse treatment services who are successfully linked 
to those services.
Objective 0:  Increase the proportion of persons diagnosed with HIV and needing 
social and mental health services who are successfully linked to those services.
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Goal 4
By 2005, strengthen the capacity nationwide to monitor  
the epidemic, develop, and implement effective HIV prevention 
interventions and evaluate prevention programs.
Objective :  Develop an integrated surveillance system to measure incidence of new 
infections, to track the prevalence of disease, to monitor behaviors that place people at 
risk for HIV infection and to provide locally relevant data for community planning.
Objective : Increase the number of evidence-based interventions and the proportion of 
prevention providers funded by CDC who successfully provide demonstrably effective 
HIV prevention interventions.
Objective 3:  Support realistic and feasible evaluation efforts to ensure the delivery of 
interventions of the highest possible quality.
List of HIV Prevention Strategic Plan Performance Indicators
. Estimated number of HIV/AIDS cases diagnosed among persons 3-4 years of 
age in 30 areas with longstanding HIV reporting.
. Rate of gonorrhea cases reported each year.
3. Rate of primary and secondary syphilis cases reported each year.
4. Estimated number of new perinatally acquired AIDS cases diagnosed each year.
5. The percentage of students in 9th through th grade who reported safer sexual 
behaviors defined as:  a) never having engaged in sexual intercourse, b) not 
sexually active in the past 3 months, or, c) if sexually active in the past 3 months, 
used condoms.  
6. Among persons diagnosed with HIV infection for > months and interviewed in 
the Supplement to HIV/AIDS Surveillance project, the percentage who did not use 
a condom at last vaginal/anal sex when the status of the partner was unknown.
7. Among persons diagnosed with HIV infection for > months and interviewed in 
the Supplement to HIV/AIDS Surveillance project, the percent of injection drug 
users (IDUs) who shared a needle or syringe with someone in the past  months.
8. The percentage of HIV-positive test results from publicly-funded counseling and 
testing sites with post-test counseling sessions.
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9. Percentage of HIV cases diagnosed before progression to AIDS.
0. Percentage of HIV/AIDS cases in care within three months of diagnosis.
11. Number of states and territories with integrated, confidential, name-based HIV/
AIDS case surveillance systems for adults and adolescents.
